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ABSTRACT 
The skeleton, a favored organ for prostate cancer is organized by a mineralized 
connective tissue, and a rich marrow where hematopoiesis replenishes a variety of 
blood cells and gives rise to many cell populations.  Thus, when tumors metastasize to 
bones they encounter many cells, once considered bystanders such as hematopoietic 
stem cells and macrophages, which play key roles in tumor growth progression and 
metastasis.  Macrophages are implicated in both skeletal homeostasis and 
tumorigenesis; yet their role in skeletal metastasis is unclear. Macrophage phagocytosis 
of apoptotic cells is referred to as efferocytosis, and is an integral process by which 
harmful by-products of dead and dying cells are removed to create a pro-resolving 
environment. The purpose of this study was to determine the role of macrophages and 
efferocytosis in prostate cancer skeletal metastasis.  In vivo experimental approaches 
resulting in macrophage ablation showed significant reduction in tumor growth in tibiae 
after intratibial tumor inoculations.  Efferocytosis of apoptotic tumor cells increased 
MFG-E8 expression and promoted macrophage polarization into the M2 macrophage 
phenotype.  Conversely, efferocytosis inhibition with neutralizing MFG-E8 antibody 
resulted in reduced M2 polarization, suggesting that efferocytosis is important for 
macrophage polarization into tumor promoting M2 cells. The involvement of the 
STAT3/SOCS3 activation pathway in macrophage polarization was observed.  
Increased MFG-E8 levels when bone marrow macrophages were co-cultured with 
apoptotic cells was accompanied by SOCS3 downregulation. Inhibition of STAT3 
phosphorylation resulted in decreased efferocytosis and M2 macrophage polarization 
with an associated increase in SOCS3 protein expression.  This suggests that SOCS3 
and phospho-STAT3 act in an inversely dependent manner when stimulated by MFG-
E8 and efferocytosis. Therefore we report a novel mechanism by which MFG-E8, by 
mediating efferocytosis of prostate cancer cells, can support tumor growth through 
facilitation of M2 macrophage polarization and regulation of SOCS3/STAT3 activation.  
xiii 
 
In conclusion, the bone microenvironment provides a dynamic and rich soil for  tumors 
to thrive. Continued investigation on the role of bone marrow cells will provide a better 
understanding of the metastatic bone environment and aid in the advancement of new 
targets for the treatment and prevention of skeletal metastasis.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
PROSTATE CANCER AND SKELETAL METASTASIS 
 
Prostate cancer is the most common non-dermatologic cancer and the second 
leading cause of cancer death in American men.  According to the American Cancer 
Society, it is estimated that about 30,000 men will die of prostate cancer and 233,000 
new cases will be diagnosed in the United States for 2014 (Siegel et al., 2014).  
Advanced stage prostate carcinoma has a high tropism to bones, and an estimated 
90% of patients with metastatic disease have bone lesions at postmortem analyses 
(Bubendorf et al., 2000).  There is a high morbidity associated with skeletal metastasis 
with increased pain and decreased quality of life and survival (Coleman, 2006).   
When tumors reach the bone they interact with the resident bone and bone 
marrow cells disrupting normal skeletal homeostasis.  This interaction results in the 
release of many osteogenic and osteolytic factors that stimulate the uncontrolled 
production (osteoblastic) or resorption (osteolytic) of bone, driving its destruction 
(Mundy, 1997;Weilbaecher et al., 2011a).  Tumor cells secrete factors such as PTHrP, 
tumor necrosis factor-TNF-), interleukin-1, interleukin-6, interleukin-8, and 
interleukin-11 that stimulate bone cells (Chirgwin and Guise, 2007).  Activated 
osteoblasts and osteoclasts in turn, secrete other factors that promote tumor growth, 
feeding a destructive cascade of metastatic growth (Chirgwin and Guise, 2007).  
Therefore, skeletal metastasis depends on both priming the seed (tumor cells) as well 
as nurturing the soil (bone). Bone metastasis can be characterized according to the 
radiographic and pathologic appearances as osteolytic, osteosclerotic or mixed 
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(Weilbaecher et al., 2011a). Prostate cancer metastatic lesions are predominantly 
osteoblastic.  Tumor-derived factors such as Wnt family ligands, bone morphogenetic 
proteins (BMPs), platelet-derived growth factor (PDGF) and endothelin-1 activate 
osteoblast bone formation contributing to skeletal metastasis (Weilbaecher et al., 
2011b). Despite that prostate cancer skeletal lesions are predominantly osteoblastic, 
osteoclast activities are also increased and osteolytic lesions are commonly found in 
bone lesions (Keller and Brown, 2004;Coleman, 2006).  Skeletal related events (SREs) 
are complications that afflicted patients endure when tumors metastasize to bones as 
consequences of the abnormal bone response (Weilbaecher et al., 2011a).  Patients 
can present with ineffective hematopoiesis, hypercalcemia, pathologic fracture, and 
spinal cord or nerve root compressions (Weilbaecher et al., 2011a).  Treatment utilizing 
osteoclast-target agents have shown to reduce the skeletal complications and 
ameliorate the morbidity associated with skeletal metastasis (Gartrell and Saad, 2014).  
Bisphosphonates are a commonly used therapy to improve patients’ outcomes and 
reduce the morbidity associated with skeletal metastasis.  They not only reduce bone 
resorption but also directly affect tumor cells and cells of the microenvironment including 
macrophages (Rogers and Holen, 2011).  Zoledronic acid (ZA) is a potent third 
generation bisphosphonate utilized for treatment of metabolic bone diseases such as 
osteoporosis, Paget’s disease and cancer-related bone diseases.  The high affinity for 
hydroxyapatite results in accumulation in bone.  Bisphosphonates are internalized by 
osteoclasts during bone resorption, inducing apoptosis through inhibition of the 
mevalonate pathway (Rodan and Fleisch, 1996;Winter and Coleman, 2009).  Despite 
that randomized clinical trials showed that adjuvant ZA did not reduce the incidence of 
skeletal metastasis (Wirth et al., 2014), its effective role in the reduction of skeletal 
related events facilitated the approval of this drug for patients with prostate bone 
metastases (Gartrell and Saad, 2014).  
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PTHRP IN SKELETAL METASTASIS 
 
Tumor derived parathyroid hormone-related protein (PTHrP) is a key osteolytic 
factor in bone metastasis.  This peptide that was initially identified during the elucidation 
of mediators of malignancy-induced hypercalcemia plays various roles in normal 
physiology as well as pathological conditions.  In cancers with high bone tropism such 
as prostate and breast tumors, PTHrP can act in priming the seed, participating in cell 
autonomous processes such as tumor cell proliferation, apoptosis, survival and anoikis, 
qualities that enhance the capability of tumor growth, dissemination and metastasis 
(Soki et al., 2012;McCauley and Martin, 2012b).  PTHrP also has endocrine or 
paracrine roles in modulating bone responses and cellular aspects of the bone 
microenvironment, thus contributing to the formation of a conducive environment for 
cancer establishment in bone.  When osteolytic tumors metastasize to bone, they 
promote a destructive cascade of events also known as the “vicious cycle” (Yin et al., 
1999).  Tumor derived PTHrP binds to and stimulates the PTH/PTHrP receptor present 
in osteoblasts and osteocytes to express receptor activator of nuclear factor kappa B 
ligand (RANKL) leading to osteoclast differentiation and bone loss.  As a result of bone 
resorption, factors such as calcium, TGF-, insulin-like growth factor 1 (IGF-1) and 
fibroblast growth factors (FGFs) are released to the environment, contributing to tumor 
proliferation and augmenting PTHrP production.  In addition, PTHrP can also induce 
expression of chemokine (C-C motif) ligand 2 (CCL2 or MCP-1) thus contributing to 
tumor growth (Li et al., 2009).  CCL2 directly stimulates tumor cell migration, 
proliferation and survival and indirectly establishes a niche for growth eliciting 
angiogenesis and macrophage recruitment and polarization to the M2 type (pro-
tumorigenic macrophages) (Rozel et al., 2009;Mizutani et al., 2009).  CCL2 also 
participates in skeletal metastasis, promoting increased osteoclastic numbers and 
activity, which are important for tumor growth in bone (Loberg et al., 2007a).  A review 
of the role of PTHrP in skeletal metastasis and cancer will be discussed in Chapter 2.  
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THE BONE MICROENVIRONMENT: MORE THAN JUST BONE 
 
Bone is a complex organ, organized by a mineralized connective tissue, which 
gives support and protection to various organs.  Bone is a dynamic tissue under the 
control of local and systemic factors and is constantly remodeling itself (Mundy, 2002a).  
This tightly regulated balance between bone formation by osteoblasts, and bone 
resorption by osteoclasts controls this dynamic tissue.  In addition to bone cells, the 
bone microenvironment is comprised of a rich marrow where hematopoiesis replenishes 
a variety of blood cells and gives rise to many cell populations.  Thus, when tumors 
metastasize to bones they encounter many cell populations that can mediate critical 
roles in tumor growth and progression (Park et al., 2011b).  Cells present in the bone 
marrow that were once considered only bystanders such as hematopoietic stem cells 
and macrophages play key roles in tumor growth progression and metastasis of 
different types of cancer. 
Hematopoietic stem cells are found in close association with the endosteal 
interface of bone and bone marrow, and perivascular sinusoidal blood vessels, also 
known as stem cell niches that maintain and regulate these cells (Adams et al., 
2006;Kiel et al., 2005). The hematopoietic niche is necessary to balance the expansion 
and mobilization of HSCs to the peripheral blood as well as the regulation of self-
renewal capacity and hematopoietic commitment to differentiation.  Cells that constitute 
this tightly regulated niche, including osteoblasts, osteoclasts, endothelial cells, 
adipocytes and stromal cells, participate in the regulation and maintenance of HSCs 
(Bianco, 2011).  Hematopoietic stem cells and stromal cells actively participate in tumor 
growth mediated through effects in angiogenesis, competing with the metastatic tumor 
cells for the osteoblastic niches (Muller et al., 2001;Taichman et al., 2002;Jung et al., 
2007;Shiozawa et al., 2008;Sun et al., 2010).  Osteoclast targeted therapies with 
bisphosphonates in clinical settings are applied not only in osteoporosis, but also as 
adjuvant therapy for the skeletal related events in bone metastases.  Modifications of 
the bone microenvironment may affect HSC niches that were shown to be important for 
tumor cell adhesion and colonization to the bones.  Therefore, to determine the effects 
of the potent osteoclast inhibitor zoledronic acid in the HSC niche will bring a better 
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understanding of the mechanisms that osteoclasts orchestrate in the bone 
microenvironment and subsequently how this affects tumor metastasis to bone.  The 
effects of zoledronic acid in the bone and vasculature support of hematopoietic stem 
cell niches will be discussed in chapter 3.  
In addition to hematopoietic stem cells, emerging data on the role of other cell 
types including myeloid and bone marrow macrophages support their involvement in the 
growth, progression and metastasis of various tumors. 
Macrophages are myeloid phagocytic cells recruited in response to infection, 
inflammation and tissue injury, therefore, having a role in the innate and adaptive 
immune response (Pollard, 2009).  They also have important roles in tissue 
development such branching morphogenesis, neuronal patterning, angiogenesis, bone 
morphogenesis and adipogenesis (Pollard, 2009).  In bone, osteoclasts are considered 
specialized resident macrophages.  Indeed, osteoclast participation in tumor growth and 
progression of skeletal metastasis has been extensively studied and these cells 
identified as key contributors for the vicious and destructive cycle of bone metastasis 
(Mundy, 1997;Keller and Brown, 2004).  Resident macrophages other than osteoclasts 
have been identified in close association to the endosteal bone and termed as 
‘osteomacs’ or osteal macrophages.  Osteal macrophages constitute one sixth of the 
total cells and differ from osteoclasts, by expressing specific surface markers:  F4/80 
and CD68 (Austyn and Gordon, 1981;Chang et al., 2008). Interestingly, resident 
macrophages are found in close association with osteoblasts and play key roles in bone 
remodeling, bone healing and hematopoietic niche maintenance, skeletal homeostasis 
and PTH anabolic actions on bone remodeling (Chang et al., 2008;Cho et al., 
2014;Winkler et al., 2010a;Alexander et al., 2011a).   
Macrophages are activated differentially according to the stimuli provided:  M1 
anti-tumorigenic macrophages are classically activated and M2 pro-tumorigenic 
macrophages (also known as tumor associated macrophages, TAMs) are alternatively 
activated (5,6).  TAMs are prominently found and involved with cancer initiation, 
progression and metastasis, facilitating angiogenesis, matrix breakdown and tumor cell-
motility (Pollard, 2004;Colotta et al., 2009). Modification of the myeloid cells in bone has 
demonstrated influence in tumor metastasis to bone.  A single dose of 
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cyclophosphamide, a bone marrow–suppressive chemotherapeutic drug, administration 
prior to intracardiac tumor inoculation increased prostate cancer cell localization and 
growth in bone (Park et al., 2012a).  This was associated with a transient expansion of 
myeloid cells and increased cytokines with myelogenic potential such as C-C 
chemokine ligand 2 (CCL2), interleukin-6 (IL-6), and VEGF-A that primed the 
environment for tumor growth.  Moreover, the chemokine CCL2 known to attract and 
differentiate macrophages towards TAMS and osteoclasts has been shown to increase 
prostate cancer growth and bone metastasis (Mizutani et al., 2009;Loberg et al., 
2007b;Loberg et al., 2007a;Roca et al., 2009;Rozel et al., 2009). Therefore, 
macrophages play important roles in cancer growth as well as in the bone niche. 
However, their role in bone pathologies such as bone metastasis remains elusive. Their 
involvement in the modulation of the bone microenvironment during skeletal metastasis 
was explored in Chapter 4.  
 
MACROPHAGES AND EFFEROCYTOSIS 
 
A key function that macrophages exert in normal physiology is their involvement 
in the later stages of inflammation.  Macrophages are important phagocytic cells that 
actively participate in the cell clearance process, also known as efferocytosis, 
phagocytizing apoptotic cells to control and regulate the inflammatory response 
(Gregory and Pound, 2011a).  Efferocytosis elicits changes in immune responses and 
can result in immunosuppression of anti-tumor defenses (Reiter et al., 1999a;Savill et 
al., 2002a), production of anti-inflammatory mediators including transforming growth 
factor–  (TGF-) and interleukin-10 (IL-10), and inhibition of pro-inflammatory tumor 
necrosis factor (TNF) (Savill et al., 2002a;Michlewska et al., 2009).  MFG-E8 mediated 
efferocytosis can also promote an anti-inflammatory status in LPS stimulated cells, by 
down-regulating nuclear factor–B (NF-B) and MAP kinase signaling pathways (Miksa 
et al., 2008).  Remarkably, NF-B inhibition is also linked with TAM polarization (Biswas 
et al., 2006;Saccani et al., 2006). Interestingly, even though tumors present high 
apoptosis rates concomitantly with their high proliferation rates, the presence of 
apoptotic cells is under appreciated due to rapid cell clearance performed by 
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macrophages and other phagocytic cells.  Despite its important function in normal 
physiology, efferocytosis in cancer is an under explored field.  Not much is known 
regarding the interactions of apoptotic tumor cells with macrophages, and subsequently, 
how this affects the remaining viable tumor cells in skeletal metastasis.   
The phagocytosis process can be divided into 4 different stages (Savill et al., 
2002b;Gregory and Pound, 2011a).  The first stage consists of “find-me” signals that are 
released by apoptotic cells to facilitate the attraction and recruitment of the phagocytic 
cells within the damaged tissue.  The second stage depends on “eat –me” signals that 
are externalized on the apoptotic cell surface for their recognition by phagocytic cells 
and subsequent internalization of the body.  Sequentially, the internalized cargo 
undergoes degradation in the third stage, leading to the fourth stage of post- 
engulfment, when the phagocytic cells secrete anti-inflammatory cytokines and other 
factors, thus preventing further damage resolving the inflammatory response.   
Milk fat globule-EGF factor 8 (MFG-E8) is a protein known as a phagocytosis 
“eat me” signal secreted by numerous cells including macrophages (Hanayama et al., 
2002;Hanayama et al., 2004).  MFG-E8 facilitates efferocytosis, functioning as a bridge 
between macrophage and apoptotic cells binding to both phosphatidylserine (PS) 
externalized on apoptotic cells and the v3/ v5 integrin expressed on macrophages 
(Hanayama et al., 2004).  The role in efferocytosis was confirmed in MFG-E8 deficient 
mice that presented apoptotic cell accumulation.  The deficiency also implicated in 
autoimmunity and inflammatory related diseases (Miksa et al., 2008;Asano et al., 
2004;Thorp and Tabas, 2009).   
Interestingly, phagocytic cell activation through MFG-E8 results in similar anti-
inflammatory and tumor promoting properties, as seen in M2 TAMs (Lewis and Pollard, 
2006;Gregory and Pound, 2011b;Pollard, 2009).  Despite these suggestive links, 
efferocytosis via MFG-E8 and its role in tumor efferocytosis and M2 polarization has not 
been investigated in the context of prostate cancer or skeletal metastasis. The impact of 
efferocytosis mediated by MFG-E8 on macrophage polarization into M2 TAMs and the 
underlying mechanisms was investigated and discussed in Chapter 5.  
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CHAPTER 2 
 
THE MULTI-FACETED ACTIONS OF PARATHYROID HORMONE RELATED 
PROTEIN IN SKELETAL METASTASIS 
 
 
 
ABSTRACT 
 
Parathyroid hormone-related protein (PTHrP), identified during the elucidation of 
mediators of malignancy-induced hypercalcemia, plays numerous roles in normal 
physiology as well as pathological conditions.  Recent data support direct functions of 
PTHrP in metastasis, particularly from tumors with strong bone-tropism.  Bone provides 
a unique metastatic environment because of mineralization and diverse constituting cell 
populations in the bone marrow.  PTHrP is a key regulator of tumor-bone interactions 
and regulates cells in the bone microenvironment, through proliferative and pro-survival 
activities that prime the “seed” and the “soil” of the metastatic lesion.  This review 
highlights recent findings of the role of PTHrP in skeletal metastasis, including direct 
actions in tumor cells as well as alterations in the bone microenvironment and future 
perspectives involving potential roles of PTHrP in the premetastatic niche and tumor 
dormancy 
 
 
INTRODUCTION 
 
Parathyroid hormone related protein (PTHrP) was first discovered as an 
etiological factor of humoral hypercalcemia of malignancy (HHM), commonly found in 
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patients with certain types of advanced stage cancers such as breast, lung, renal, 
ovarian, pancreatic carcinomas, and myeloma (Mundy, 2002b;McCauley and Martin, 
2012a).  An association between hypercalcemia and malignancy was first postulated in 
1920s with the development of the calcium assay (Kramer and Tisdall, 1921) which 
allowed calcium measurement in patients with cancer.  In 1941, Albright raised a 
hypothesis that ectopic parathyroid hormone (PTH) could be the tumor-derived factor 
responsible for HHM (Albright F, 1941), due to its important role in calcium 
homeostasis, which is a tightly regulated process involving coordination of bone, kidney, 
gut and parathyroid glands (Clines and Guise, 2005).  PTH, is an 84 amino acid 
hormone secreted by the parathyroid glands, and plays an essential role in regulating 
phosphate, vitamin D, extracellular fluids and calcium balance.  Albright’s hypothesis 
that PTH was the etiological factor in HHM was true from the functional standpoint but 
did not prove true clinically (Manring and Calhoun, 2011).  It was only in 1987, that three 
independent groups identified a protein with similar biological activities and structure to 
PTH, hence named parathyroid hormone-related protein (PTHrP).  Moseley et al. 
isolated an 18kDa protein from a human lung cancer cell line with biological activities 
and high homology to the amino terminal region of PTH in which 8 residues in positions 
1-13 were identical to the human PTH (Suva et al., 1987).  Interestingly, two other 
independent groups also isolated and purified the same PTH like factor from  human 
renal carcinoma cells (Strewler et al., 1987) and from human breast cancer cells (Burtis 
et al., 1987;Stewart et al., 1987).   
Subsequently, PTHrP was found to be expressed in numerous types of cancer 
and its role in HHM was elucidated, with activation of the PTH/PTHrP receptor (PPR)  in 
the skeleton to evoke calcium release via bone resorption, and activation of the PPR in 
the kidney to decrease calcium excretion (Clines and Guise, 2005).  Indeed, the main 
causes of hypercalcemia, primary hyperparathyroidism and HHM, show as-yet 
unexplained clinical differences, even though PTH and PTHrP have similar biological 
activities.  For example HHM patients present lower levels of the active form of vitamin 
D (calcitriol), metabolic alkalosis and uncoupling responses of bone resorption and 
formation in contrast to what is observed with primary hyperthyroidism (Schilling et al., 
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1993;Nakayama et al., 1996;Clines and Guise, 2005). Other potential mediators of HHM 
are tumor-associated factors with systemic or local actions.  Systemic factors such as 
calcitriol 1,25-(OH)2D3  that are increased in lymphomas,  acts on organs responsible for 
calcium homeostasis (kidney and intestine) resulting in elevated calcium levels 
(Seymour and Gagel, 1993).  Tumor-secreted factors with local actions that stimulate 
bone resorption such as interleukin-1 (IL-1), interleukin-6 (IL-6), transforming growth 
factor alpha (TGF-α), tumor necrosis factor (TNF) and granulocyte colony-stimulating 
factor (G-CSF) also promote increased calcium (Clines and Guise, 2005) .  In addition 
to its role in hypercalcemia, further investigation demonstrated that PTHrP also plays 
important roles in tumor progression and metastasis, which is the main topic of this 
review article. 
PTHrP resembles PTH sharing 8 out of the 13 initial amino acids at the N-
terminus and binds to the PTH receptor type 1 known as the PPR.  The PTHrP gene 
PTHLH, located on chromosome 12, expands more than 15 kb including 9 exons and at 
least 3 promoters.  Alternative splicing gives rise to three isoforms: 139, 141, and 173 
amino acids (Martin et al., 1991).  Furthermore, the PTHrP protein has several 
functional domains comprised of an N-terminal domain, a mid-region domain and a 
carboxyl-terminal domain.  The N-terminal domain (amino acids 1-36) has the binding 
site to activate the PPR receptor, acting in autocrine, paracrine and endocrine manners 
and leading to different biological effects and cell autonomous functions (Figure 2.1).  
The mid-region (amino acids 37-106) includes a nuclear localization sequence (NLS) 
important for intracrine signaling of PTHrP in the nucleus and cytoplasm, regulating cell 
proliferation, survival and apoptosis. Lastly, the carboxyl-terminal domain (amino acids 
107-139), also known as osteostatin,  is associated with inhibition of osteoclastic bone 
resorption and anabolic effects in bone (Martin et al., 1991;de Castro et al., 2012).   
Along with tumorigenic functions, PTHrP also participates in normal physiology, 
acting as a hormone in calcium transportation in the fetus, late pregnancy and lactation 
(McCauley and Martin, 2012a).  PTHrP is also highly expressed in human tissues and 
plays an important role in the developmental stages of mammary glands, hair follicles 
and teeth (McCauley and Martin, 2012a).  The biological function of PTHrP is very 
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important in development during endochrondral bone formation.  Deletion of PTHrP in 
mice results in chondrodysplasia and early death and heterozygous Pthlh +/- mice have 
an early osteoporotic phenotype with reductions in trabecular volume (Karaplis et al., 
1994;Amizuka et al., 1994;Amizuka et al., 1996).  Altogether, these studies demonstrate 
the key role that PTHrP plays in normal physiology and developmental biology. 
 
Figure 2.1. Multiple actions of PTHrP in tumor growth in bone. 
Tumor-derived PTHrP acts by different modes in order to enhance tumor growth, progression 
and metastasis. PTHrP acts in an intracrine manner, increasing cell survival, apoptosis 
resistance and anoikis evasion. There are two potential pathways for nuclear localization of 
PTHrP: (A) translocation of PTHrP through the NPC in which the PTHrP nuclear localization 
sequence interacts with β1 and is then transported to the nucleus; and (B) internalization of the 
parathyroid hormone/PTHrP receptor–PTHrP complex by an endocytosis-dependent pathway to 
the cytosol and rapid transport into the nucleus. Moreover, tumor cells also express the 
parathyroid hormone/PTHrP receptor facilitating the autocrine actions of PTHrP and contributing 
to cell proliferation and apoptosis resistance and growth. When tumors metastasize to bone, 
PTHrP acts in a paracrine manner, secreting PTHrP in the bone microenvironment, activating 
osteoblasts and inducing a destructive cascade with release of numerous growth factors that 
contribute to tumor growth and enhanced PTHrP expression. Therefore, PTHrP participates in 
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all steps of the metastatic processes, from tumor growth, progression, invasion, migration and 
survival to bone modulation in order to support metastases. Permission for figure from Future 
Medicine   
β1: Importin β1; ER: Endoplasmic reticulum; NPC: Nuclear pore complex.   
The PPR is a class II G-protein coupled receptor comprised of seven 
transmembrane spanning domains.  The gene that encodes the PPR is highly 
conserved and homologous in rat, mouse and human and the multiple exons that 
encode the gene are subjected to alternative splicing (Kong et al., 1994).  PTH and 
PTHrP amino-terminal regions bind to and activate the PPR, which is expressed in the 
main target cells of PTH and PTHrP: osteoblasts in bone and renal tubular cells in the 
kidney.  Remarkably, PPR was also found to be expressed in many tumor types such 
as prostate, breast, and many other cancers (Downey et al., 1997;Asadi et al., 1996) 
regulating tumor cell autonomous processes and contributing to tumor progression and 
growth.  Consequently, PTHrP supports dual roles in skeletal metastasis:  1) modulating 
the bone and priming the metastatic microenvironment, and 2) promoting tumor cell 
autonomous function contributing to growth and progression.  In bone, the PPR is 
primarily expressed in osteoblasts, osteocytes, and bone marrow stromal cells such as 
osteoblast precursor cells.  Osteoclasts do not express the PPR evidenced by the lack 
of response to PTH (Fuller et al., 1998).  The actions of PTH and PTHrP in osteoclasts 
are mediated by osteoblasts and osteocytes responsible for secretion of factors that 
activate osteoclasts.  The PTH and PTHrP amino terminals interact with the J-domain 
functional portion of the PPR in osteoblasts stimulating multiple signaling cascades 
including adenylate cyclase-protein kinase A (AC/PKA), phospholipase C-protein kinase 
C (PC/PKC), and mitogen- activated protein kinases (MAPKs) pathways leading to 
different anabolic and catabolic responses in bone (Datta and Abou-Samra, 2009).  
Tumor-derived PTHrP can act in different ways to modulate tumor growth, 
progression and metastasis.  For example, in HHM, PTHrP is secreted from primary 
tumors and acts in an endocrine manner inducing bone resorption.  When tumors 
metastasize to bone, PTHrP acts in a paracrine manner secreting PTHrP in the bone 
microenvironment, activating osteoblasts, and inducing bone remodeling.  In addition, 
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tumor cells also express the PPR facilitating autocrine actions of PTHrP and 
contributing to cell proliferation and growth.  Lastly, PTHrP also acts in an intracrine 
manner, increasing cell survival and apoptosis resistance (Fiaschi-Taesch and Stewart, 
2003).  Although PTHrP plays multifunctional roles in skeletal metastasis, most 
investigations have focused on PTHrP function as a tumor promoting factor.  However, 
emerging evidence supports that PTHrP also alters the tumor microenvironment 
potentially contributing to metastasis development.    
 
 
ROLES OF PTHrP IN SKELETAL METASTASIS OF CANCER 
 
According to Stephen Paget’s “seed and soil” hypothesis, disseminated tumor 
cells (“the seed”) can produce metastases only when the tumor cells are seeded in the 
correct “soil” (Fidler, 2003;Paget, 1889).  Therefore metastasis is a multistep process 
that requires coordination of 2 different subsets: tumor cells and the metastatic organ.  
The tumor cells must acquire the ability to invade the surrounding tissue, gain access to 
the circulation by the lymphatic or blood circulation, survive, and extravasate into a 
secondary site (Steeg, 2006).  The second subset is the metastatic compartment that 
has to enable tumor invasion, colonization and growth.  In other words, the metastatic 
organ is the fertile soil that favors tumor cell growth.  PTHrP in skeletal metastases has 
the capacity to act on both parts of the story, nurturing the seed (tumor cells) and 
priming the soil (bone microenvironment). 
PTHrP expression is commonly found in many types of cancer and increased 
expression is observed with tumor progression with the highest expression being found 
in metastatic lesions (Southby et al., 1990;Powell et al., 1991;Malakouti et al., 
1996;Shen et al., 2007b;Guise et al., 1996;Iwamura et al., 1993).  However, the use of 
tumor-produced PTHrP as a prognostic factor is still controversial.  Clinical studies in 
breast and lung cancers have implicated PTHrP expression in primary tumors as a good 
prognostic factor (Montgrain et al., 2011;Henderson et al., 2006).  In a recent clinical 
study in non-small-cell lung carcinoma, PTHrP expression was associated with 
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increased survival in females with both early or advanced stages of disease (Montgrain 
et al., 2011).  Henderson et al demonstrated in a prospective study of 526 patients with 
breast cancer followed for a 10 year period that positive PTHrP expression in the 
primary tumors was correlated with improved survival and reduced development of 
bone metastases (Henderson et al., 2006).  They concluded that PTHrP expression in 
the primary tumors conferred a less invasive phenotype that is distinct from its known 
osteolytic roles which support skeletal metastasis.   
By contrast, clinical studies in invasive human breast tumors indicated that 
PTHrP was detected in 60% of the tumors but not in the normal breast tissues and 
expression was greater in bone metastases, with PTHrP expression detected in 
approximately 90% (Southby et al., 1990;Powell et al., 1991).  A recent and exciting 
study identified the gene for PTHrP (PTHLH) as a breast cancer risk loci.  In this large 
investigation that included two independent genome-wide associations (GWAS) from 41 
case-control studies and 9 breast cancer GWAS, three new breast cancer loci were 
identified including PTHLH (p12p11). These data delineate the most convincing 
evidence implicating PTHrP in breast cancer pathogenesis. Still the genes identified 
must be proven to be the causal genes responsible for cancer pathogenesis and the 
mechanisms need to be explored (Ghoussaini et al., 2012). PTHrP is also expressed in 
more than 90% of colon cancer patients (Malakouti et al., 1996).  Extensive 
investigation of PTHrP function in prostate tumors demonstrated that expression 
contributes to tumor growth and progression (Dougherty et al., 1999).  Studies in human 
prostate cancer observed that PTHrP was differentially expressed depending on the 
cancer stage.  PTHrP was expressed in 33% of benign prostate hyperplasia, 87% in 
well differentiated prostate cancer and 100% in poorly differentiated and metastatic 
tumors (Asadi et al., 1996;Iwamura et al., 1993).   
The widespread thought is that PTHrP is a supportive factor for cancer growth 
and progression. Differences in its prognostic applicability may reflect temporal aspects 
and/or downstream events that have been difficult to elucidate in the context of cancer. 
Moreover, the fact that PTHrP is a polyhormone witth multiple biological active domains 
may explain the variability seen in cancer prognosis and the necessity to further 
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elucidate PTHrP actions in cancer.  Alternative splicing and post translational 
proteolysis generate different PTHrP isoforms and fragments that can elicit various 
cellular responses.  The variety of PTHrP fragments and different actions (autocrine, 
paracrine, endocrine and intracrine) may justify the complexity of PTHrP induced 
responses.  The role of the different PTHrP fragments and the cell biological responses 
PTHrP generates are still not fully clarified. 
PTHrP has been extensively investigated as an important bone factor in cancers 
that have significant bone tropism, especially in prostate and breast cancers.  Indeed 
bone is a common site for tumor metastases and skeletal metastasis is the leading 
cause for mortality and morbidity among breast, prostate and lung cancer patients 
(Coleman, 2006).  Postmortem examination demonstrated that around 70% of patients 
dying with breast cancer and approximately 90% of prostate cancer patients had 
evidence of bone metastases (Bubendorf et al., 2000;Coleman, 2006).  Other cancers 
that also metastasize to the skeleton include renal tumors, melanoma and multiple 
myeloma (Chiang and Massague, 2008;Coleman, 2006).  
Radiographic manifestation of bone metastases show different characteristics; 
osteoblastic lesions demonstrate exacerbated activity of osteoblasts evidenced by 
abnormal bone formation whereas osteolytic lesions show intensified osteoclast activity 
evidenced by abnormal bone resorption (Weilbaecher et al., 2011b;Loberg et al., 2005).  
However, most of the tumors present mixed lesions, with the presence of both osteolytic 
and osteoblastic aspects (Coleman, 2006).  Osteolytic lesions are associated with bone 
fractures and HHM, a common finding with advanced bone destruction.  They are most 
common in breast, multiple myeloma, melanoma, lung, thyroid, renal, and 
gastrointestinal malignancies.  On the contrary, prostate cancer metastatic lesions are 
predominantly osteoblastic.  Tumor-derived factors such as Wnt family ligands, bone 
morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF) and endothelin-1 
activate osteoblast bone formation contributing to skeletal metastasis (Weilbaecher et 
al., 2011b).  
The interplay of tumor cells with the bone microenvironment results in tumor 
growth and bone remodeling in skeletal metastasis (Loberg et al., 2005).  Tumor cells 
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secrete factors such as PTHrP, tumor necrosis factor-TNF-), interleukin-1, 
interleukin-6, interleukin-8, and interleukin-11 that stimulate bone cells (Chirgwin and 
Guise, 2007).  Activated osteoblasts and osteoclasts in turn, secrete other factors that 
promote tumor growth, feeding a destructive cascade of metastatic growth (Chirgwin 
and Guise, 2007).  Therefore, skeletal metastasis depends on both priming the seed 
(tumor cells) as well as nurturing the soil (bone).  PTHrP is a pivotal tumor-derived 
factor playing a role in both steps.  For instance, it can act in priming the seed, 
participating in cell autonomous processes such as tumor cell proliferation, apoptosis, 
survival and anoikis, qualities that enhance the capability of tumor growth, 
dissemination and metastasis.  Importantly, PTHrP can act as an endocrine or paracrine 
factor modulating bone responses and cellular aspects of the bone microenvironment, 
thus contributing to the formation of a conducive environment for cancer establishment 
in bone. 
 
 
TUMOR CELL AUTONOMOUS FUNCTIONS OF PTHRP 
 
Tumor-derived PTHrP can act in different ways to modulate tumor growth and 
progression in a cell autonomous manner.  PTHrP can act by paracrine, autocrine and 
intracrine modes to modulate diverse cell processes (Figure 2.1). The paracrine and 
autocrine actions of PTHrP derive from PPR activation through binding of amino 
terminal PTHrP but are not the only mechanism.  Post translation protease cleavage 
generates biological active mid-region and carboxyl terminal PTHrP fragments that can 
act via paracrine and autocrine fashion through activation of presumably novel cell 
surface receptors.  The C-terminal fragment also known as osteostatin has a role in 
osteoclast inhibition and bone anabolic actions suggesting an important role in skeletal 
metastasis although their function in cell autonomous processes in cancer cells are not 
well defined (de Castro et al., 2012).  The intracrine action of PTHrP depends on its 
nuclear localization sequence (NLS) within the 87-107 amino acid region and regulates 
cell apoptosis, proliferation and cell cycle.  The PTHrP NLS is required and interacts 
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with importin independently of importin  transporting the protein 
through the nuclear pore complex dependent of microtubule integrity (Lam et al., 2002).  
Another pathway is through internalization of PPR-PTHrP complex by an endocytosis-
dependent pathway to the cytosol and rapid transport into the nucleus (Watson et al., 
2000b;Watson et al., 2000a). PPR-PTHrP complexes were reported to be found in the 
nucleus of osteoblasts in bone and cells in other organs such as kidney, liver, gut and 
ovary, although the functional mechanisms of PPR-PTHrP complexes are still not fully 
understood (Watson et al., 2000a;Watson et al., 2000b).  In addition,  proteins smaller 
than 40 kDa may be translocated through the nuclear pore complex through 
mechanisms that are,as yet, unknown owing to the difficulty of visualizing and 
quantifying the transport (Nardozzi et al., 2010) The  possibility of PTHrP peptides (<40 
kDa) without the NLS interaction with importin proteins translocating directly through the 
nuclear pore complex cannot be ruled out, owing to the small size of the molecule, 
though this would likely be at much slower rates (Nardozzi et al., 2010). Nuclear PTHrP 
localization can then exert differential cellular responses than what is seen by paracrine 
and autocrine PTHrP highlighting the great diversity of PTHrP actions.  Additional 
information on intracrine mechanisms of PTHrP can be found in detailed reviews 
(Nguyen and Karaplis, 1998;Fiaschi-Taesch and Stewart, 2003). Altogether, PTHrP 
differential actions can promote proliferation, evasion of apoptosis and survival, invasion 
and migration, and evasion of anoikis, contributing to tumor growth and progression. 
 
Proliferation 
 
PTHrP stimulates tumor cell proliferation in different types of cancer.  Recently, a 
study in breast cancer demonstrated that PTHrP is involved with tumor initiation, growth 
and metastasis (Li et al., 2011a).  In a spontaneous breast cancer model, PTHLH gene 
deletion significantly delayed tumor initiation and tumor growth.  Reduced PTHrP 
expression resulted in reduced proliferation demonstrated by lower Ki67 and cyclin D1 
staining as well as cell cycle arrest suggesting an important PTHrP role for breast tumor 
proliferation (Li et al., 2011a).  In prostate cancer, PTHrP also promotes proliferation.  
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Prostate cancer cells that overexpressed PTHrP had enhanced tumor growth and tumor 
size in bone (Dougherty et al., 1999).  Another study demonstrated that transfected cells 
that overexpressed PTHrP (1-87) stimulated cell proliferation and the intracrine 
production of IL-8, a known growth promoting and angiogenic factor (Gujral et al., 
2001).  The contribution of PTHrP to proliferation is also evident in renal carcinoma. 
Burton et al. demonstrated that autocrine PTHrP induced renal carcinoma cell 
proliferation and tumor growth, whereas antiserum and antagonists to PTHrP inhibited 
tumor growth in vitro (Burton et al., 1990).  Therefore, PTHrP contributes to tumor cell 
proliferation promoting tumor growth, an important step for subsequent tumor 
progression and metastasis. 
 
Evasion of Apoptosis and/or Promotion of Survival 
 
PTHrP intracrine actions have been under investigation for their roles in 
intracellular biology, especially cell survival, growth and apoptosis.  In prostate cancer, 
PTHrP and its nuclear localization sequence was found to be protective against cell 
apoptosis (Dougherty et al., 1999).  Prostate cancer cells that overexpressed PTHrP 
had enhanced tumor growth and tumor size in bone.  In addition, cells with deletion of 
the NLS were more susceptible to undergo apoptosis than full length PTHrP -
transfected cells or controls.  These findings indicated a role of PTHrP in prostate 
cancer cell survival via an intracrine manner.  Similar results were also observed in a 
breast cancer cell line, demonstrating a critical role for nuclear targeting in the anti-
apoptotic and cell cycle regulatory effects of PTHrP (Tovar Sepulveda et al., 2002).  
MCF-7 breast cancer cells that overexpressed PTHrP with the NLS sequence were 
protected from apoptosis induced by serum starvation and presented cells in G2-M 
stage of the cell cycle compared with cells overexpressing NLS-mutated PTHrP, 
indicating an intracrine role for PTHrP in cell apoptosis and cycle regulation.  The role of 
PTHrP autocrine/paracrine actions in cell growth and cell death in vivo was 
demonstrated in renal carcinoma cells, where anti-PTHrP antibody treatment reduced 
tumor growth by inducing cell death (Massfelder et al., 2004). Neutralizing antibody for 
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PTHrP was also used against different renal carcinoma cell lines and strategies 
blocking both the PPR and PTHrP signaling decreased tumor growth by inducing cell 
apoptosis (Talon et al., 2006). These studies highlight PTHrP as an important growth 
factor and a survival signal that contributes to tumor growth. Moreover, acquiring 
apoptosis resistance is an important quality for the survival of cells that eventually enter 
the circulation and colonize different organs, therefore establishing a metastatic foci.  
 
Invasion and Migration 
 
Intracrine PTHrP signaling is also thought to influence tumor invasion and 
metastasis.  In a prostate cancer study, PC-3 cells that overexpressed intact PTHrP 
upregulated the expression of the α1, α 5, α 6, and 4  integrin subunits (Shen and 
Falzon, 2003).  The presence of NLS signaling was necessary for the increase in 
integrin expression known to facilitate cancer cell adhesion, migration and invasion, 
requirements necessary for cancer cell colonization in skeletal metastasis (Shen and 
Falzon, 2003).  Interestingly, integrin 6 and 4 levels are also increased in colon 
cancer, suggesting a role of PTHrP in integrin expression in different types of cancers 
(Shen et al., 2007b).  PTHrP also positively regulates LoVo (human colon cancer cells) 
proliferation, migration and invasion in vitro (Shen et al., 2007a).  Overexpression of 
PTHrP augmented xenograft growth and expression of integrins 6 and 4, and 
phosphatidylinositol 3-kinase (PI3-K) pathway components.  PTHrP mediates 
upregulation of integrin α6β4 expression, activating the PI3-K/AKT pathway (Shen et al., 
2007a).  A recent study investigated the link between PTHrP expression and Rac1, a 
GTPase.  They demonstrated the PTHrP positive effect on Rac-1 activity was via 
guanine nucleotide exchange factor Tiam1. Interestingly, the effects of PTHrP 
expression were mediated by integrin α6β4 activation of PI3-K pathway that regulates 
both Rac1 and Tiam1 activity (Mula et al., 2010).  Therefore, PTHrP expression in 
prostate and colon cancer is associated with tumor growth, migration and invasion.  In 
addition PTHrP also influenced the expression of the chemokine receptor CXCR4, an 
adhesion factor expressed in breast cancer that binds to stromal cell-derived factor-1 
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(SDF-1 or CXCL12) present in bone (Li et al., 2011a).  In this study, PTHrP was co-
expressed with CXCR4 and was crucial for the metastatic spread.  The role of PTHrP 
facilitating cell invasion and migration consequently contributes to the metastatic 
spread, by increasing cell motility, enabling cell invasion to the surrounding tissue and 
facilitating the access of tumor cells to the blood.  Tumor cells can then intravasate into 
the bloodstream and disseminate into different organs where adhesion molecules would 
facilitate tumor cell adhesion and colonization into the metastatic organ. 
 
Evasion of Anoikis 
 
Anoikis is a phenomenon of cell apoptosis resulting from detachment with loss of 
cell-matrix interactions.  Evasion of anoikis is an essential step in the metastatic process 
so that the cells can survive and colonize a distant organ (Sakamoto and Kyprianou, 
2010).  The PTHrP intracrine pathway plays an important role in tumor apoptosis 
evasion, however little is known regarding the role in anoikis. Recent studies, suggest 
that PTHrP could be important for anoikis.  Bhatia et al. demonstrated in an in vitro 
study that the PTHrP intracrine pathway protected prostate cancer cell lines PC-3 and 
C4-2 from doxorubicin-induced apoptosis and promoted anchorage-independent cell 
growth (Bhatia et al., 2009).  The intracrine effects of PTHrP were mediated via integrin 
α6β4-mediated activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, since 
knockdown of integrin α6β4 decreased the PTHrP-mediated activation of the PI3K/Akt 
pathway.  PTHrP also increased nuclear factor-kappaB (NFkB) activity via a PI3K-
dependent pathway.  This study suggested a role of PTHrP in anoikis and activation of 
survival pathways.  
Most recently, Park et al. investigated the participation of PTHrP and its NLS in 
the anoikis of prostate cancer (Park and McCauley, 2012)  Here, downregulation of 
PTHrP in PC-3 cells conferred increased apoptosis of cells cultured in suspension.  On 
the other hand, overexpression of the gene resulted in protection from anoikis.  LNCap 
cells that expressed full length PTHrP or nuclear localization localization signal 
defective cells were generated and cultured under an anoikis challenge.  Interestingly, 
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only full length PTHrP expression was able to rescue cells from anoikis. Investigation of 
an apoptosis-related gene array demonstrated that gene expression of tumor necrosis 
factor- alpha (TNF-α), a pro-apoptotic protein, is increased when PTHrP is 
downregulated and decreased with PTHrP overexpression, but not in NLS-defective 
PTHrP overexpressing cells. This suggests that the PTHrP-mediated reduction in pro-
apoptotic TNF-α is dependent on full length PTHrP to confer anoikis resistance.  
Moreover, in vivo low-PTHrP expressing cells resulted in fewer metastatic lesions 
compared with cells overexpressing PTHrP, suggesting an anoikis role due to loss of 
intracrine PTHrP activity. These findings suggest that PTHrP nuclear localization 
confers resistance to anoikis and  delineates a new mechanism associated with 
prostate cancer metastasis (Park and McCauley, 2012).  Tumor cells can survive after 
detachment from the primary tumor, and overcome the physical endurances of not 
having a protective matrix and neighboring cell interactions as well as surviving in the 
bloodstream, essential steps for metastasis onset. 
 
PTHrP-dependent Expression of Growth Factors 
 
When osteolytic tumors metastasize to bone, they promote a destructive cascade 
of events also known as “vicious cycle”.  PTHrP secreted by tumor cells increases bone 
resorption and induces bone matrix release of calcium and numerous growth factors 
such as transforming growth factor- beta (TGF-, promoting tumor growth in bone.  
TGF- signaling is a very important aspect of PTHrP osteolytic actions in bone. 
Mutation of TGF- type II receptor in MDA-MB-231 cells resulted in less bone 
destruction, decreased osteoclasts and prolonged survival in mice (Yin et al., 1999).  
Conversely, constitutively active TGF- type II receptor breast cancer cells increased 
PTHrP production in tumors and enhanced osteolytic bone metastasis (Yin et al., 1999).  
In this context, a destructive cascade of tumor and bone interactions is established 
where PTHrP binds to and stimulates the PPR present in osteoblasts and osteocytes to 
express receptor activator of nuclear factor kappa B ligand (RANKL) leading  to 
osteoclast differentiation and bone loss.  Osteoclast-mediated bone resorption then 
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releases factors such as calcium, TGF-, insulin-like growth factor 1 (IGF-1) and 
fibroblast growth factors (FGFs) that favor tumor proliferation and augment PTHrP 
production.  In addition, PTHrP can also induce expression of chemokine (C-C motif) 
ligand 2 (CCL2 or MCP-1) thus contributing to tumor growth.  Li et al.  demonstrated in 
vitro and in vivo that prostate cancer–derived PTHrP induced osteoblastic secretion of 
CCL2 in bone and PTHrP antagonist treatment inhibited the secretion of CCL2 (Li et al., 
2009).  CCL2 then, supports tumor growth, progression and metastasis by different 
means.  It can directly stimulate tumor cell migration, proliferation and survival or 
indirectly establish an appropriate niche for growth eliciting angiogenesis and 
macrophage recruitment and polarization to the M2 type (pro-tumorigenic 
macrophages) (Rozel et al., 2009;Mizutani et al., 2009).  CCL2 also participates in 
skeletal metastasis, promoting increased osteoclastic numbers and activity, which are 
important for tumor growth in bone(Loberg et al., 2007a).  These studies provided 
evidence that PTHrP in bone metastasis is an important modulator for the release and 
secretion of growth factors such as TGF- and CCL2, which will further support tumor 
growth and skeletal metastasis progression.  
Overall, PTHrP is a tumor promoting factor involved in each step of metastasis.  
First, PTHrP contributes to tumor growth in the primary tumor site, promoting cell 
proliferation, survival and evading apoptosis.  Subsequently, PTHrP participates in cell 
invasion and migration required to penetrate the surrounding tissue and gain access to 
the circulation.  Next, PTHrP participates in anoikis evasion, so that tumor cells can 
survive and extravasate into a secondary site where they can establish a metastatic 
growth.  Finally, when tumors metastasize to bones, PTHrP still acts on the bone 
microenvironment to induce a destructive cascade with release of numerous growth 
factors that contribute to tumor growth and enhanced PTHrP expression.  Hence, 
PTHrP participates in all steps of the metastatic processes, from tumor growth, 
progression, invasion, migration and survival to bone modulation to support tumor 
growth as summarized in figure 2.1.  
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ROLE OF PTHrP IN THE METASTATIC MICROENVIRONMENT 
 
PTHrP actions in skeletal metastasis are not only restricted to the tumor cell 
autonomous functions but also in the modulation of the bone marrow microenvironment.  
Extensive evidence demonstrates that PTHrP is a tumor promoting factor.  However, 
emerging evidence supports that PTHrP can also modulate the bone microenvironment, 
providing a congenial “soil” for tumor metastasis.  Evidence is emerging that PTHrP 
nurtures the “soil” to house and subsequently “feed” the disseminated cells, leading to 
metastatic onset and growth.  Evolving PTHrP participation in the modulation of the 
bone metastatic environment includes modulation of the cellular contents and promotion 
of angiogenesis, all of which are known to contribute to metastasis (Figure 2.2). In this 
section, recent findings in PTHrP actions in the bone microenvironment will be 
discussed.  
 
PTHrP Actions in Bone: Direct and Indirect Effects 
 
PTHrP binds to PPRs primarily expressed in osteoblasts, osteocytes, and bone 
marrow stromal cells such as osteoblast precursor cells.  However, the net effects of 
PTH/PTHRP on bone (i.e. anabolic or catabolic) are dependent on the duration and 
exposure.  For example, intermittent administration of PTH in vivo results in bone 
formation while continual infusion of PTH causes significant bone loss (Datta and Abou-
Samra, 2009).  In a recent study, Horwitz et al. investigated the effect of continuous 
infusion of human PTH (1-34) or human PTHrP (1-36) at low doses (2 and 4 pmol/kg/h, 
respectively) in healthy adult volunteers for 7 days (Horwitz et al., 2011).  Continuous 
infusion induced hypercalcemia and hypercalciuria and rapidly increased bone 
resorption.  Interestingly, bone formation was suppressed by 30 to 40% causing 
sustained arrest in the osteoblast maturation program.  Indeed PTHrP has a direct 
effect on osteoblast cell cycle that is dependent on the developmental stage (Datta et 
al., 2005;Datta et al., 2007).  Differentiated osteoblast treated with PTH/PTHrP had 
upregulated JunB expression with reduction in cyclin D1 and G1 cell cycle arrest (Datta 
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et al., 2005).  Such findings suggest that PTHrP may influence the life span and activity 
of osteoblasts in bone. 
 
 
 
 
Figure 2.2. PTHrP actions in the modulation of bone microenvironment and a potential role for a 
premetastatic niche formation. 
Tumor-derived PTHrP endocrine actions in bone are an inadequately studied area. An evolving 
model suggests PTHrP modulates the bone microenvironment by inducing osteoblast and 
potentially osteocyte secretion of CCL2 (MCP-1) and/or IL-6, which in turn mediates expansion 
of myeloid cells, such as macrophages and myeloid-derived suppressor cells, which are 
recruited to the tumor site, contributing to tumor growth, angiogenesis and progression. 
Moreover, growing evidence demonstrates that PTHrP is a potential candidate for premetastatic 
niche formation in bone with the expansion of these myeloid cells, forming a convivial niche for 
metastatic growth in bone. Permission for figure from Future Medicine  (Soki et al., 2012) 
Solid lines: Known pathways; Dashed lines: Potential pathways. 
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Osteoblasts are not the only cell responsible for RANKL production and bone 
remodeling.  Osteocytes are cells located within bone matrix embedded and surrounded 
by mineral tissue and are the major cells present in bone, comprising 90-95% of all 
bone cells in adults.  They are also the longest lived bone cells being able to survive up 
to decades (Bonewald, 2011).  In the past 10 years much attention has been placed on 
osteocyte functions, shifting from only bystander cells into key players of the bone 
microenvironment.  Recently, two independent groups investigated the role of 
osteocytes in vivo and found an important role in bone remodeling, being the main 
source of RANKL for osteoclastogenesis (Xiong et al., 2011;Nakashima et al., 2011).  
These studies challenged the dogma in bone biology, that osteoblasts are the key cells 
that modulate bone remodeling and bone coupling.  For example, PTH and PTHrP 
actions were believed to be mediated in great part, if not exclusively, by osteoblast 
activation.  However, osteocytes also express PPRs, therefore suggesting a significant 
role in the actions of both peptides.  In a recent study, specific osteocyte deletion of 
PPR resulted in mild osteopenia, increased sclerostin expression and impaired 
homeostatic calcemic response demonstrating a significant role of PTH/PTHrP signaling 
in bone remodeling and homeostasis (Powell, Jr. et al., 2011).  Since bone metastasis 
requires interactions of tumor cells and bone cells, the osteocytes as potential PTHrP 
responsive cells could be playing a role in modulation of the microenvironment with the 
secretion of different growth factors mediating not only the tumor growth but the bone 
microenvironment.  These events would favor metastatic growth and progression, yet, 
such a role of PTHrP in osteocytes has not been delineated. 
PTHrP actions are restricted not only to direct effects on bone cells such as 
osteoblasts and osteocytes; through the activation of these cells, PTHrP induces the 
release of a variety of growth factors and cytokines derived from activated cells as well 
as the bone matrix with the effect of modulating other cellular components, such as 
stromal cells and immune cells, which could be playing important roles in the metastatic 
‘soil’   Emerging evidence suggests that PTHrP may also play a role in inflammatory 
responses associated with HHM.  Studies demonstrated that PTHrP concomitant 
expression of inflammatory cytokines such as TNFinterleukin-1 alpha (IL-1) and IL-6 
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augment bone resorption activity (Sato et al., 1989;Uy et al., 1997;de la Mata et al., 
1995).  More evidence is necessary to delineate the regulation of PTHrP and cytokine 
expression in a cancer context.  However, substantial advances have linked PTHrP 
actions in inflammatory responses and diseases (Funk, 2001)  highlighting a possible 
role in cancer, since it is considered a “wound that never heals” and an inflammatory 
aspect has been strongly implied in its progression.  Further studies are needed to 
explore PTHrP function in the cellular milieu of the bone microenvironment, the growth 
factors and cytokines expressed and how these may contribute in tumor growth and 
metastasis. 
 
Angiogenesis 
 
Angiogenesis is a well-studied process supporting tumor growth and progression.  
Growing evidence proposes that PTHrP can impact skeletal metastasis progression via 
stimulation of angiogenesis.  Akino et al. first described a direct effect of tumor-derived 
PTHrP in angiogenesis, after observation that a metastatic pituitary tumor cell line 
(GH3) that expressed high levels of PTHrP had increased vascularity in xenografts.  
Using in vitro studies they demonstrated that PTHrP did not affect endothelial cell 
proliferation and migration but dose-dependently stimulated capillary tube formation 
(Akino et al., 2000).  Although a contradictory study argued that PTHrP was an 
angiogenesis inhibitor functioning by activation of protein kinase A (PKA), little evidence 
exists to support this hypothesis (Bakre et al., 2002).  In fact, a recent study in a 
spontaneous breast cancer mouse model with specific PTHLH gene deletion, 
demonstrated that PTHrP expression not only affected tumor initiation, progression and 
metastasis but also influenced tumor angiogenesis.  PTHrP ablation resulted in reduced 
angiogenesis (Li et al., 2011a).  In addition, Gujral et al. investigated the role of PTHrP 
in IL-8 production in prostate cancer cells, a known contributing factor for tumor 
angiogenesis and growth.  Transfected cells that overexpressed PTHrP (1-87) and (1-
173) stimulated cell proliferation and the production of IL-8, but not VEGF, suggesting a 
specific IL-8 response.  Surprisingly, the PTHrP (65-87) region was required for PTHrP 
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1-87 to robustly stimulate IL-8 in prostate cancer cells.  Since exogenous PTHrP (1-36 
and 1-87) did not affect IL-8 expression they concluded that PTHrP (1-87) was required 
for intracrine IL-8 enhanced production by PTHrP (Gujral et al., 2001).  A PTHrP 
paracrine effect in angiogenesis in bone metastasis has been also investigated.  Liao et 
al. showed in in vitro studies that the PTHrP pro-angiogenic effect was dependent on 
the presence of bone marrow stromal cells (Liao et al., 2008).  A potential mechanism 
could be through PTHrP mediated osteoblastic secretion of CCL2, a known angiogenic 
factor (Zhang et al., 2010;Roca et al., 2009;Li et al., 2009).  Indeed recent data 
demonstrate that the PTHrP angiogenic effect is dependent on osteoclast activity and 
MMP9 production (Cackowski et al., 2010).  Further studies are necessary to elucidate 
the PTHrP role in tumor angiogenesis especially in bone metastasis. 
In summary PTHrP activates cells in the bone microenvironment promoting 
angiogenesis thus priming the bone microenvironment for a conducive metastatic onset 
and growth in bone.  There is convincing evidence that PTHrP participates in 
angiogenesis in bone, yet the precise role of angiogenesis in skeletal metastasis needs 
further elucidation. 
 
PTHrP as a therapeutic target. 
 
Given the multiple roles PTHrP have in hypercalcemia of malignancy and in 
cancer autonomous and metastatic setting in bone, PTHrP is a potential therapeutic 
target. Strategies utilizing neutralizing antibody, small molecular inhibitors or targeting 
the signaling pathways PTHrP elicits are promising to inhibit PTHrP actions. 
Neutralizing antibodies demonstrated positive responses in animal models, reducing 
skeletal metastasis, bone lesions and also hypercalcemia (Guise et al., 2002;Onuma et 
al., 2005). However, human clinical evidence is lacking.   
In addition to direct inhibition of PTHrP actions, chemotherapeutic drugs can also 
result in suppression of PTHrP production. Furugaki et al demonstrated that erlotinib, an 
EGF receptor tyrosine kinase inhibitor, reduced osteolytic bone resorption induced by 
lung cancer cells through its effect in the RANKL production by osteoblasts/stromal cells 
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(Furugaki et al., 2011). Interestingly, erlotinib also suppressed the production of 
osteolytic factors including PTHrP production.  Lorch et al. also demonstrated the role of 
EGF receptor in two different squamous lung carcinoma xenografts that had reduced 
PTHrP expression after treatment with EGF receptor tyrosine kinase inhibitor PD153035 
and gefitinib (Lorch et al., 2007).  Moreover, targeting cells that release the growth 
factors and cytokines known to stimulate PTHrP production such as TGF may also 
contribute for the decrease expression of PTHrP (Yin et al., 1999).   
Concurrently with the need to develop new strategies to inhibit PTHrP actions is 
the need to fully define PTHrP roles in the different stages of cancer.  The controversial 
results seen on cancer prognosis depending on the cancer stage as protective to 
destructive raises concerns on the right time PTHrP therapy should be applied. 
Moreover, the variety of PTHrP isoforms and fragments generated by posttranslational 
proteolysis highlight the different potential roles PTHrP can have in multiple cell types.  
Still, many answers are needed to safely test potential therapies against PTHrP. 
 
PTHrP, the premetastatic niche and tumor dormancy 
 
PTHrP is a potent and efficient tumor promoting factor, acting in two different 
compartments: the tumor and the bone microenvironment.  This dual role makes PTHrP 
an outstanding therapeutic target, especially for tumors with high bone tropism such as 
breast and prostate cancer.  Although extensive studies investigated the actions of 
PTHrP in cellular autonomous tumor function, PTHrP involvement in modulating the 
metastatic microenvironment warrants extensive further investigation.  For instance, 
PTHrP when functioning as an endocrine factor secreted by primary tumors, regulating 
the bone microenvironment at a distance could be an important premetastatic niche 
factor in skeletal metastasis.  
This paradigm proposes the existence of a premetastatic niche that provides a 
permissive microenvironment for the recruitment of tumor cells leading to 
micrometastasis initiation and establishment (Kaplan et al., 2006).  Studies in lung 
metastasis demonstrated participation of bone marrow derived cells in the formation of 
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the premetastatic niche before the arrival of tumor cells in the lungs (Kaplan et al., 
2005;Hiratsuka et al., 2008;Hiratsuka et al., 2006). Hematopoietic progenitor cells 
expressing VEGFR1 and fibronectin clustered in tumor-specific metastatic sites, 
suggesting the formation of a premetastatic niche that contributes to disseminating 
tumor cell engraftment in the lungs (Kaplan et al., 2005).  In addition, conditioned media 
from distinct tumor types with different patterns of metastatic dissemination redirected 
the formation of these clusters and transformed the metastatic profile, therefore 
dictating organ-specific tumor metastasis.  In addition to hematopoietic progenitor cells, 
macrophage recruitment has also been implicated in premetastatic niche formation 
(Hiratsuka et al., 2006;Hiratsuka et al., 2008).  In 2006 Hiratsuka et al demonstrated, in 
a lung premetastatic and metastatic phase, that factors released by subcutaneous 
tumors induced expression of inflammatory proteins S100A8 and S100A9 in lungs 
which triggered macrophage recruitment to the site (Hiratsuka et al., 2006).  Antibodies 
targeting S100A8 and S100A9 resulted in 80-90% reduction of colonized tumor cells to 
lungs.  Later they demonstrated that Serum amyloid A3(SAA3) by acting through Toll-
Like receptor 4 (TLR4) on macrophages and tumor cells , mediated S100A8 and 
S100A9 expression specifically in the lung (Hiratsuka et al., 2008).  
In bone, the formation of a premetastatic niche is not well defined. The lack of 
spontaneous skeletal metastasis models challenges advances in this area.  However, 
most evidence is focused mainly in the context of endocrine-like actions that modulate 
the bone microenvironment.  Factors other than PTHrP that are secreted by tumors and 
that can modulate the bone microenvironment from a distance provide evidence of 
potential premetastatic niche formation in skeletal metastasis.  For example, 
heparanase is an enzyme produced by breast cancer cells that cleaves heparan sulfate 
to produce syndecan-1.  Tumor-derived syndecan-1 shed in the primary tumor acts in 
bone, increasing osteoclastogenesis and contributing to osteolysis (Kelly et al., 
2005;Kelly et al., 2010). Other factors such as, osteopontin (OPN) and  matrix 
metalloproteinase (MMP) may also play a role in promoting tumor growth and skeletal 
metastasis (Anborgh et al., 2010;Lynch et al., 2005).  
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Indeed, PTHrP is also an attractive potential factor for the premetastatic niche 
formation in bone.  For instance, PTHrP can modulate the production of CCL2 in bone 
by osteoblasts, inducing macrophage recruitment, activation into M2 tumor-promoting 
cell and also stimulating osteoclastogenesis that will altogether enhance tumor growth 
and progression (Mizutani et al., 2009;Li et al., 2009;Rozel et al., 2009;Loberg et al., 
2007a).  This suggests a potential mechanism for a premetastatic niche formation in the 
bones, where tumor derived–PTHrP induces CCL2 expression in osteoblasts 
contributing to modulation of the bone microenvironment into a conducive niche.  In 
conclusion, although the premetastatic niche formation is not yet defined in bone 
metastasis, PTHrP is a potential candidate for the endocrine actions in bone modulation 
and premetastatic niche formation (Figure 2.2) 
Bone consists of an assorted cellular profile and PTHrP actions in this context 
are under explored.  For example, myeloid cells such as macrophages have been 
associated with tumor progression and metastasis of different types of cancer as well as 
contributing to premetastatic niche formation (Pollard, 2004;Hiratsuka et al., 
2008;Hiratsuka et al., 2006).  Since macrophages share the same precursors as 
osteoclasts, PTHrP may indirectly regulate the myeloid population in bone and skeletal 
metastasis.  A possible mechanism would be by PTHrP mediated osteoblastic secretion 
of CCL2 (Li et al., 2009). Another population likely involved in tumor progression and 
metastasis is myeloid derived suppressor cells (MDSCs) that are immature myeloid 
cells involved in immune suppression and tumor escape from host control, as well as 
angiogenesis and tumor growth (Younos et al., 2011).  MDSCs are identified by the 
expression of myeloid cell (CD11b) and granulocyte (Gr-1) markers and are increased 
in bone marrow, spleen and peripheral blood in tumor-bearing hosts (Younos et al., 
2011).  Unfortunately, their role in skeletal metastasis is not yet defined, but possible 
roles have been suggested as a potential source for angiogenesis and 
osteoclastogenesis, contributing to the development of osteolytic lesions and the 
progression of metastasis (Yang et al., 2010).  Tumor-derived PTHrP is involved in the 
expansion and potentiation of MDSCs in the bone marrow that are recruited to the 
tumor tissue contributing to tumor angiogenesis and growth (Park et al., 2011a).  
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Myeloid derived cells such as macrophages and MDSCs have been implicated in tumor 
growth, angiogenesis, immunosuppression, as well as mechanistic aspects for the 
formation of a premetastatic niche.  PTHrP modulation of these cells in bone and how 
they can contribute to skeletal metastasis is an understudied area with future potential. 
Another evolving area of study is tumor dormancy.  Tumor cell dormancy is one 
of the biggest problems in skeletal metastasis and believed to be associated with tumor 
relapse (Gao et al., 1999).  Metastasis is a very inefficient process where less than 
0.01% of the tumor cells that achieve the circulation form metastatic foci (Fidler, 
2003;Langley and Fidler, 2011).  The skeleton is a very complex environment with 
constant bone remodeling, hematopoiesis and a very rich milieu with growth factors and 
mineral components being continually released.  Therefore, the fact the bone is one of 
the common site of metastasis is not surprising.  It is thought that tumor dissemination is 
a process that occurs earlier, but in this process most of the cells fail to overcome the 
challenges imposed by entering the circulation (Fidler, 2003). However, it has also been 
proposed that when cells circumvent this challenge and find a distant organ to colonize, 
they can stay dormant for decades (Nguyen et al., 2009).  This may be the reason why 
patients with solid tumors that were completely excised present with bone metastasis 
decades later, even if the primary tumors were not present any longer.  Another 
problem of cell dormancy is that their detection is not conceivable.  Most of skeletal 
metastases diagnoses are made only when tumors are visible and in advanced stages.  
Cell quiescence is also a big challenge in cell dormancy since most anti-cancer 
therapies target the high and fast proliferative cells.  Detection of circulating tumor cells 
in the bone marrow has raised the awareness that bone could also be a potential tumor 
cell housing place (Gao et al., 1999).  In this case, bone could offer a shelter where 
tumor cells attach and stay quiescent until they can be recruited to the other sites or 
even go back to their place of origin.  PTHrP makes an interesting candidate for 
abetting cell dormancy because it not only acts via intracrine and autocrine modes to 
modulate gene expression and cellular responses in tumors, but also has paracrine 
modulation of the bone microenvironment.  The action of the PTHrP in the regulation of 
cell cycle and expression of integrins, could be useful for the tumors to attach to the 
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bone and acquire quiescence, until they get activated to proliferate and form detectable 
metastasis.  As little is known about PTHrP in cell dormancy, this is an area of potential 
promise for elucidation and therapeutic targeting.   
 
 
CONCLUSION 
 
PTHrP is an important protein not only for normal physiological processes such 
as in bone and mammary development, but also as an important player in different 
cancers and skeletal metastasis. PTHrP is a key regulator of tumor-bone interactions 
and regulates cells in the bone microenvironment, through proliferative and pro-survival 
activities that prime the “seed” and the “soil” of the metastatic lesion. In summary, 
PTHrP multi-faceted actions as an endocrine, paracrine, autocrine and intracrine 
peptide display the variety of biological functions it can regulate at the cell level.  
 
 
FUTURE PERSPECTIVES 
 
Advances in the area of bone biology, such as the identification of osteocytes as 
potential key players in bone regulation bring novel concepts and expand the influence 
that PTHrP may cause in bone.  In fact, understanding of PTHrP actions in bone is a 
crucial step to dissect the mechanisms for tumor cell growth and bone metastasis. 
Moreover, novel concepts in cancer research need to be applied and tested for PTHrP 
functions.  For example, the fact that PTHrP exerts an endocrine function in bone in the 
case of hypercalcemia of malignancy suggests that PTHrP could also modulate different 
organs via an endocrine mode.  Therefore, in bone, PTHrP is a potential premetastatic 
niche factor and further investigations in this area are needed to dissect the earlier 
steps of cancer metastasis.  Another area that is under investigated is tumor cell 
dormancy and how this affects the onset of metastasis.  Improved animal models and 
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specific molecular markers are needed to investigate these novel theories and 
concepts.  Understanding the earlier steps of tumor progression and metastasis is 
necessary for the development of new therapeutic targets to overcome cancer.  
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CHAPTER 3 
 
THE EFFECTS OF ZOLEDRONIC ACID IN THE BONE AND VASCULATURE 
SUPPORT OF HEMATOPOIETIC STEM CELL NICHES 
 
 
ABSTRACT 
 
Hematopoietic stem cells (HSC) are maintained in a tightly regulated bone 
microenvironment constituted by a rich milieu of cells.  Bone cells such as osteoblasts 
are associated with niche maintenance as regulators of the endosteal 
microenvironment.  Bone remodeling also plays a role in HSC mobilization although it is 
poorly defined.  The effects of zoledronic acid (ZA), a potent bisphosphonate that 
inhibits bone resorption, were investigated on bone marrow cell populations focusing on 
HSCs, and the endosteal and vascular niches in bone.  ZA treatment significantly 
increased bone volume and HSCs in both young and adult mice (4 week and 4 month 
old, respectively). ZA increased vessel numbers with no overall change in vascular 
volume in bones of young and had no effect on vasculature in adult mice.  Since both 
young and adult mice had increased HSCs and bone mass with differing vasculature 
responses , this suggests that ZA indirectly supports HSCs via the osteoblastic niche 
and not the vascular niche.  Additionally, gene expression in Lin- cells demonstrated 
increased expression of self-renewal-related genes Bmi1 and Ink4a suggesting a role of 
ZA in the modulation of cell commitment and differentiation toward a long-term self-
renewing cell. Genes that support the osteoblastic niche, BMP2 and BMP6 were also 
augmented in ZA treated mice. In conclusion, ZA-induced HSC expansion occurs 
independent of the vascular niche via indirect modulation of the osteoblastic niche.  
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INTRODUCTION 
 
Bone is an important hematopoietic organ tightly regulated by the diverse cellular 
components that constitute its microenvironment.  This unique microenvironment, also 
known as the stem cell niche, maintains and regulates hematopoietic stem cells 
(HSCs).  HSCs are found in close association with the endosteal interface of bone and 
bone marrow, and perivascular sinusoidal blood vessels (Adams et al., 2006;Kiel et al., 
2005).  Osteoblasts, endothelial cells, adipocytes and stromal cells are key cells that 
constitute the niche and participate in the regulation and maintenance of HSCs (Bianco, 
2011). The hematopoietic niche is necessary to balance the expansion and mobilization 
of HSCs to the peripheral blood as well as the regulation of self-renewal capacity and 
hematopoietic commitment to differentiation.  Moreover, the bone microenvironment 
plays an important role in this regulation. For instance, studies have demonstrated that 
increased osteoblast number augments HSC numbers in bone marrow (Zhang et al., 
2003;Calvi et al., 2003) whereas, osteoblast depletion leads to a reduction in HSC 
numbers (Visnjic et al., 2004). It not well defined whether enrichment of bone structures 
such as vasculature or the endosteum can alter the HSC pool in bone marrow.  In this 
context, therapies that involve modulation of bone formation or remodeling may affect 
HSC expansion and mobilization.  
Osteoclasts are believed to play a role in the bone microenvironment and 
consequently affect the HSC microenvironment.  For instance, osteoclast- induced bone 
resorption is responsible for the release of various growth factors, proteins and bone 
mineral such as calcium, all of which are known to influence in the hematopoietic cells 
and niche maintenance and mobilization (Adams et al., 2006;Kollet et al., 2006).  Still, 
the precise role of osteoclasts in HSC niche maintenance and mobilization is ill defined 
and controversial.  Although augmented osteoclast activation results in increased 
stress-induced mobilization of HSCs (Cho et al., 2010), osteopetrotic animal models 
and pharmacological strategies of osteoclast inhibition resulted in increased 
mobilization of HSCs in response to G-CSF stimulation (Miyamoto et al., 2011). 
Pharmacologic strategies such as bisphosphonates inhibit osteoclast-mediated 
bone resorption.  Zoledronic acid (ZA) is a potent third generation bisphosphonate 
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utilized for treatment of metabolic bone diseases such as osteoporosis, Paget’s disease 
and cancer-related bone diseases.  The high affinity for hydroxyapatite results in 
accumulation in bone that when it is resorbed by osteoclasts inhibition of the 
mevalonate pathway and apoptotic cell death occurs (Rodan and Fleisch, 1996;Winter 
and Coleman, 2009).  However, the mechanisms of which osteoclast inhibition affects 
the HSC niche and progenitor cells expansion are yet unclear. 
It was hypothesized that osteoclasts may play an important role in hematopoiesis 
in the bone marrow.  In this study, mice were treated with ZA, and HSCs in bone 
analyzed.  Altogether, the treatment differential response in the different hematopoietic 
progenitor and stem cells suggests that osteoclast inhibition and changes in the bone 
microstructure may play a role in the increased hematopoietic stem cells in the bone 
marrow.   
 
 
MATERIALS AND METHODS 
 
Treatment with zoledronic acid (ZA) 
All animals were maintained in accordance with institutional animal care and use 
guidelines and experimental protocols approved by the Institutional Animal Care and 
Use Committee of the University of Michigan. Male C57BL/6J mice at 4-or 16-wks of 
age were obtained from the Jackson Laboratory (Bar Harbor, ME).  Intraperitoneal 
injections were performed twice/week with 200 μg/kg of  ZA (Zometa, Novartis, Stein, 
Switzerland) or vehicle (saline) for up to 4 weeks.  At sacrifice, blood and hind limbs 
were collected for analyses. 
 
Flow cytometry analysis (FACS) 
One femur and one tibia were collected and flushed with FACS buffer (PBS, 
1%FBS, 2nM EDTA).  The enriched central bone marrow cells were filtered through a 
100m cell strainer and cells were enumerated and resuspended to a total of 5 million 
cells/ 500 L.  Lin cocktail (APC), Sca-1 (E13-161.7, PE), c-kit (2B8, FITC) antibodies 
were used to quantify the Lin- Sca1+ c-Kit+ cells. To evaluate the SLAM population 
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(CD48- CD41- CD150+ Sca1+ c-kit+) cells were incubated with the antibodies Sca-1 
(E13-161.7,biotin), c-kit (2B8, APC), CD48 (HM48-1,FITC) and CD41 (MWReg30, 
FITC), CD150(TC15-12F12.2, PE-Biolegend). For the long term reconstitution assay 
analysis, peripheral blood cells were stained with CD3, CD5, B220 (Ra3-6B2, PE). 
Endothelial progenitor cells (EPC) were identified as CD11b- (M1/70, APC) CD34+( 
RAM34, FITC-eBioscience) and flt1+( Avas12a1, PE-eBioscience) cells. After antibody 
incubation cells were washed twice with PBS and evaluated with a FACs Calibur (BD 
Bioscience, San Jose, CA, USA). All other antibodies used for flow cytometry were 
purchased from BD Bioscience.  
 
Long- Term Competitive Reconstitution Assays 
For in vivo enumeration of HSCs, 300,000 CD45.2 bone marrow cells were 
isolated from ZA-treated and untreated C57BL/6 mice and were mixed with 300,000 
CD45.1 cells from CD45.1 congenic mice. Cells were then intravenously injected into 
CD 45.2/CD45.1 recipient mice that had been lethally irradiated with 850 cGy of 
irradiation. Four weeks after transplantation, the frequency of the different cell 
populations were determined in the peripheral blood (PB) by fluorescence-activated cell 
sorting (FACS) using PE-CD45.1 and FITC-CD45.2 antibodies (BD Pharmingen) over a 
3 month period.  
 
Histology and immunohistochemistry 
After 4 weeks of treatment, mice were sacrificed and tibiae were collected and 
fixed in 10% formalin. Decalcification was performed in 10% EDTA for 14 days prior to 
paraffin embedding. Paraffin-embedded specimens were sectioned at 5 μm and stained 
with hematoxylin and eosin (H&E), or tartrate-resistant acid phosphatase (TRAP) to 
detect osteoclasts (Acid Phosphatase, Leukocyte Kit, Sigma, St. Louis, MO) or with Von 
Willebrand factor (vWF) to identify vascular spaces.  For microvessel density (MVD) 
analysis, after vWF staining, four random areas were selected. Any single or cluster of 
positively stained endothelial cells that was clearly separated from adjacent micro- 
vessels was considered as one countable microvessel. The average MVD was 
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determined for each specimen. Mayer's hematoxylin (Sigma) was used for 
counterstaining.  
 
RNA isolation and Quantitative PCR assay 
One tibia and femur were flushed with PBS and cells were sorted into Lin -, Lin+ 
using magnetic cell sorting microbeads (MACS). After sorting, cells were pelleted and 
RNA was isolated with  Tri reagent (Sigma) following the manufacturer’s protocols. One 
microgram of total RNA was reverse transcribed in a 20-L reaction volume containing 
random hexamers using a reverse-transcription assay system (Applied Biosystems, 
Foster City, CA, USA).  Quantitative reverse transcription-PCR (RT-PCR) was 
performed using the ABI PRISM 7700 with a ready-to-use mix of primers and FAM-
labeled probe assay system (Applied Biosystems). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as a reference and the delta delta CT method were 
used to calculate the data. 
 
Serum TRAP5b and calcium measurement 
Serum TRAP5b activity was measured by ELISA (Immunodiagnostic Systems, 
Inc.) following the manufacturer's instructions. A quantitative colorimetric assay with 
Calcium Reagent Set (Pointe Scientific, Inc., Canton, MI) was used to measure the total 
calcium levels in serum and bone marrow supernatants. 
 
Mirofil and Micro CT analyses 
A perfusion technique using the radiopaque silicone rubber injection agent 
Microfil ™ followed by microCT analysis was utilized as previously described (Park et 
al., 2012b;Guldberg et al., 2008).  Briefly, mice treated with vehicle or zoledronic acid 
for 4 weeks were anesthetized and perfused with lactated Ringer’s solution containing 
heparin, followed by 10% neutral buffered formalin, and then with a Microfil™ 
compound of 1.04 specific gravity mixed 4:1 with a 0.92 specific gravity diluent.  
Femora, tibiae and spleens were dissected, and bones were fixed and decalcified.  
Samples were scanned in air at a 7um voxel size by microcomputed tomography 
(eXplore Locus SP (GE Healthcare Pre-Clinical Imaging, London, ON, Canada). 
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Regions of interest were defined for both central bone vascularity and vascular regions 
near the growth plate, and quantitative differences in vessel numbers and sizes were 
determined using the stereology package of commercially available software 
(MicroView v2.2, GE Healthcare Pre-Clinical Imaging, London, ON, Canada).. 
 
Statistical analysis 
The GraphPad Instat 3 software program (GraphPad Software, San Diego, CA) 
was used to analyze the differences by one-way ANOVA or Student's t-test for 
independent analysis. The value p<0.05 was considered statistically significant. All 
assays were repeated at least twice with similar results. 
 
 
RESULTS 
 
ZA treatment increased bone area and osteoclast activity in young mice 
To elucidate the role of osteoclasts in the bone microenvironment, 4 week old 
mice were treated with vehicle (saline) or zoledronic acid (ZA) twice a week for 4 weeks.  
As expected, ZA treated mice had increased bone volume, increased trabecular 
thickness and number and decreased trabecular spacing (Fig.3.1 A-D). Serum tartrate-
resistant acid phosphatase 5b (TRACP 5b) serum levels were decreased (Fig3.1E) as 
well as osteoclast numbers in marrow following ZA treatment (Fig. 3.1F). ZA treatment 
decreased the calcium levels in the bone marrow (Fig. 3.1G) but did not alter serum 
calcium levels (Fig. 3.1H)  as previously reported (Li et al., 2011b).  Altogether, the 
inhibition of osteoclasts by ZA resulted in increased bone mass.  
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Figure 3.1.  ZA treatment effects on bone area and osteoclast activity. 
Four-week-old C57BL/6J male mice were treated with 200 µg/kg of ZA twice/week for 4 weeks. 
A–D: ZA treatment increased bone area. (A–D) Histomorphometric analysis of tibiae shows an 
increase of bone volume (BV/TV %), trabecular thickness (Tb Th, mm) and number(Tb number 
mm−1), and decreased trabecular spacing (Tb Sp,) in tibiae from ZA treated mice versus vehicle 
(VEH); E: blood serum TRAP5b levels were reduced with ZA treatment; F: representative TRAP 
staining of tibia; G–H: bone marrow calcium levels were decreased and serum calcium levels 
were not changed; Calcium levels were measured in the bone marrow (G) and serum (H) of 
mice treated with ZA or vehicle for up to 4 weeks; (T/C) Treatment/control (*P < 0.05; **P < 0.01; 
***P < 0.005 versus vehicle [VEH]). Data are presented as mean ± SEM, n = 8/gp (A–E, G–H). 
Permission for figure from J Cell Biochem (Soki et al., 2013).  
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Hematopoietic progenitor cells were increased after ZA treatment. 
To investigate the effects of osteoclast inhibition on hematopoiesis, mice were 
treated with ZA or vehicle for 4 weeks and the bone marrow cells were analyzed by 
FACS at different time points. Hematopoietic progenitor cells (Lin-Sca-1+c-kit+ referred 
to as LSK) were significantly increased when compared to the vehicle treated mice (Fig. 
3.2A).  Since hematopoietic progenitor cells were increased the long term reconstitution 
hematopoietic stem cells were also analyzed using the SLAM markers (CD48-CD41-
CD150+Sca1+c-Kit+) as previously described (Kiel et al., 2005).  As was observed with 
the number of LSK cells following ZA treatment, a trend of increased SLAM cells was 
observed with ZA treatment although it did not reach statistical significance (P=0.056) 
(Fig. 3.2B). 
 
 
 
Figure 3.2.  ZA treatment increased LSK population but not long-term hematopoietic stem cells. 
Mice were treated with 200 µg/kg of ZA twice/week for 4 weeks and bone marrow cells were 
analyzed by flow cytometry. A: ZA treatment increased bone marrow Lin−Sca1+ c-
Kit+ hematopoietic progenitor cells after 4 weeks of treatment versus vehicle (VEH) control. B: 
ZA treatment did not affect the long-term hematopoietic stem populations as identified using 
SLAM markers (CD48−CD41−CD150+Sca1+c-Kit+; *P < 0.005) T/C = treatment/control. Data are 
presented as mean ± SEM, n = 5/gp. Permission for figure from J Cell Biochem (Soki et al., 
2013) 
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Long term reconstitution of lymphoid cells was higher in ZA treated mice  
Since hematopoietic cells bearing the LSK and SLAM phenotype were increased 
in mice treated with ZA, their capacity for long term reconstitution was analyzed.  Bone 
marrow cells were collected from isogenic CD45.1 mice treated with ZA or vehicle and 
mixed with CD45.2 donor cells at equal cell numbers (Fig 3.3A).  Cells were 
transplanted into recipient mice (CD45.2) that had received lethal irradiation and 
engraftment of the CD45.1 donor cells was monitored in blood over a 3 month period.  
Lymphoid cells were increased in mice treated with ZA with higher B and T lymphocytes 
(Fig. 3.3 B,C).  There were no differences in the myeloid cell populations (Fig. 3.3D).  
Collectively the data show that HSCs are increased in the marrow following ZA 
treatment. To explore the mechanisms which could account for these data three 
potential pathways which could lead to increased HSCs were explored : 1) ZA reduced 
hematopoietic stem cell egress or mobilization from the marrow and subsequent 
retention of the cells in the bone marrow, 2) ZA increased endosteal or vascular niches 
allowing for greater localization of HPCs/ HSCs or 3) ZA altered stem cell composition 
and differentiation.  
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Figure 3.3.  Long-term HSC reconstitution was increased in ZA treated bone marrow cells.  
Donor CD45.1 mice were treated for 4 weeks with ZA or vehicle (VEH). Bone marrow cells were 
collected and mixed with rescue donor CD45.2 bone marrow cells. Mixed cells were injected 
intravenously in irradiated recipient mice, and blood cells were collected and analyzed by flow 
cytometry as indicated for CD45.1 positive and (A) B cells (B220), (B) T-cells (CD3), and (C) 
myeloid cells (Gr-1). Zoledronic acid treated mice had increased reconstitution of the B and T 
cell populations but no altered reconstitution of the myeloid Gr-1 population (**P < 0.01, 
*P < 0.05). Data are presented as mean ± SEM, n = 10. Permission for figure from J Cell 
Biochem (Soki et al., 2013) 
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Hematopoietic stem cell mobilization 
To determine the extent to which ZA alters HSC egress or mobilization from the 
marrow, peripheral blood and spleens were analyzed by FACS in mice treated with ZA 
or vehicle.  As a result of the ZA treatment, LSK numbers in the peripheral blood were 
not altered (Fig. 3.4A).  No correlation was seen between LSK numbers in bone marrow 
and peripheral blood (data not shown).  To investigate whether ZA has an effect on 
HSC mobilization or extramedullary hematopoiesis, the spleens of vehicle or ZA treated 
animals were analyzed.   Spleen weight/ body weight and LSK numbers in mice with ZA 
or vehicle were not significantly different (Fig. 3.4B,C).  Altogether this data suggests 
that increased LSKs in the bone marrow were not due to mobilization effects in mice 
treated with ZA. 
 
 
Figure3.4.  Bone marrow HSC mobilization.  
ZA did not alter the LSK population in the blood or spleen. Four-week-old C57BL/6J male mice 
were treated with 200 µg/kg of ZA twice/week for 4 weeks, and peripheral blood and spleens 
were analyzed. A: Flow cytometry analyses of LSK population in the peripheral blood; B,C: 
spleen cells were collected and LSK population was analyzed by flow cytometry (B); spleen 
weight/body weight were analyzed and no changes were observed (C). Data are presented as 
mean ± SEM, n = 10/gp (A), n = 8/gp (B,C). (T/C) Treatment/control.  Permission for figure from J 
Cell Biochem (Soki et al., 2013) 
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Endosteal and vascular niches 
The hematopoietic niche is formed in the bone marrow by hematopoietic and 
non-hematopoietic cells and localized in the endosteum (area between bone marrow 
and bone) and sinusoids.  ZA increases bone mass and thus provides an increase in 
niches to support HSCs.  Interestingly we observed in the bone sections of mice that 
augmented trabecular bone was also followed by increased small vessels number in 4 
week old mice (Fig. 3.5A).  Therefore changes in the vasculature of bone in mice 
treated with ZA or vehicle for 4 weeks were examined.  Radiopaque silicone rubber 
agent Microfil™ was perfused intravenously and micro CT analysis of vascular spaces 
was performed (Fig. 3.5 B-F).  Although the overall vessel volume fraction was not 
affected (Fig. 3.5C), ZA treated mice had reduced vessel thickness (Fig. 3.5D) and 
increased vessel numbers (Fig. 3.5E).  In addition, bone sections were stained for Von 
Willebrand factor (vWF) and vessel numbers were quantified (Fig. 3.5G). Consistent 
with the Micro CT analyses, vessel number was increased with ZA treatment.  
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Figure 3.5.  Effects of ZA on bone and vasculature.  
ZA did not alter vessel volume but increased vessel numbers in 4-week-old mice treated with 
ZA or vehicle (VEH) for 4 weeks. A: H&E staining of mice treated with vehicle or ZA shows an 
increase of vessels in the trabecular area of mice tibiae; B–F: mice were perfused with 
radiopaque silicone rubber microfil and tibiae were analyzed by micro CT; (B) Representative 
micro CT image of bones with microfil perfusion; C–F: MicroCT analysis of microfil for vessel 
volume/tissue volume (VV/TV%), thickness (V Th, mm), numbers (VN, mm−1), and spacing (VS, 
mm). ZA treatment decreased vessel thickness and increased vessel numbers; G: tibiae 
sections were stained for Von Willebrand factor (V) and vessel numbers were quantified 
(*P < 0.05, **P < 0.01, ***P < 0.005). Data are presented as mean ± SEM, n = 10/gp.Permission 
for figure from J Cell Biochem (Soki et al., 2013) 
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Hematopoietic cell composition 
The changes seen in the hematopoietic progenitor cell populations could also be 
due to changes in the hematopoietic composition of the bone marrow.  To assess 
whether ZA affected the mature hematopoietic composition, bone marrow was analyzed 
for CD41+ cells by FACS and no significant changes were observed (Fig. 3.6A).  In 
addition, peripheral blood cell count was performed and there was no alteration in the 
white and red blood cells or platelets (Fig. 3.6B). 
The other possibility could be that zoledronic acid induced changes in the bone 
could be affecting the hematopoietic stem cell differentiation into progenitor cells.  Thus, 
we decided to further investigate the constitution of the HSC population.  Stem cells are 
classified according to their repopulation capacity into long-term HSCs (LT-HSC) and 
short-term HSCs (ST-HSCs).  The LT-HSCs are stem cells that present extensive life 
long, self-renewing potential and are capable of repopulating the whole hematopoietic 
system.  In contrast, ST-HSCs have a lower self-renewing capacity but a rapid 
capability of myeloerythroid cell repopulation (Yang et al., 2005).  They can be identified 
according to the expression of cytokine polypeptide deformylase (fms)–like tyrosine 
kinase receptor 3 (flt3): long term-HSCs are LSK CD34 -flt3- and short term-HSCs (LSK 
CD34+) can be further divided into 2 subsets. ST-HSCs flt3+ for cells with great 
lymphoid reconstitution and ST-HSCs flt3- for rapid myelopoiesis.  Because increased 
LSK numbers were observed we investigated the differentiation stage of the LSK 
population.  Indeed LSK flt3+ (ST-HSCs) were increased with ZA treatment (Fig.6C)  
suggesting that cells with great lymphoid reconstitution are augmented by ZA induced 
changes in the bone microenvironment, as seen in the long term reconstitution assay 
(Fig. 3 B,C).  
To investigate whether ZA influenced bone angiogenesis we also measured 
endothelial progenitor cells (EPCs) by FACS in both bone and peripheral blood (Fig. 6D, 
E).  ZA treatment significantly decreased CD11b- CD34+ ftl1+ EPCS at 3 weeks only but 
at 4 weeks no difference was seen (Fig. 6D) in bone nor in the peripheral blood (Fig. 
6E). 
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Figure3.6.  Effects of ZA on hematopoietic cell composition.  
To investigate the effects of ZA on hematopoiesis and progenitor cells, bone marrow and blood 
cells of 4-week-old mice were analyzed; A: no alteration in the bone marrow CD41+ mature 
hematopoietic composition with ZA treatment versus vehicle (VEH) control; B: blood cell count 
of white blood cells (WBC), red blood cells (RBC), and platelets (PLT) were not altered with ZA 
treatment; C: sixteen-week-old mice were treated with ZA or vehicle (VEH) for 4 weeks and 
bone marrow cells were collected and LSK Flt3+ and Flt3− were analyzed by flow cytometry. D–
E: Endothelial progenitor cells (CD11b− CD34+ Flt3+) were analyzed over time to investigate the 
effects of ZA in bone marrow and mobilization to the peripheral blood; (D) EPCs in the bone 
marrow were significantly decreased at 3 weeks of ZA treatment but not significantly different at 
4 weeks; (E) EPCs in the peripheral blood were not altered by ZA treatment (*P < 0.05). Data 
are presented as mean ± SEM, n = 8/gp (T/C) treatment/control. Permission for figure from J 
Cell Biochem (Soki et al., 2013) 
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Gene expression analyses 
To further confirm the HSC population commitment, bone marrow cells were 
sorted into Lin- or Lin+ cells and gene expression of hematopoietic related genes were 
analyzed.  Lineage negative cells had increased expression of BMP2, BMP6, Bmi1, 
Tie2, Notch1, but no change in  Ink4a, in mice treated with ZA (Fig. 3.7A).  BMP2 and 
BMP6 are proteins known to support endosteal niche maintenance, suggesting an 
active participation of HSCs in the endosteal niche.  Bmi1, Ink4a and Tie2 genes are 
indicators of self-renewal capacity (Park et al., 2003).  Bmi1 is required for HSC self-
renewal since Bmi1-/- mice have normal HSCs in fetal liver but decreased HSC numbers 
in postnatal mice. p16Ink4a is downstream of Bmi1 and participates in the regulation of 
HSC proliferation (Smith et al., 2003).   
Because ZA may affect the calcium resource in bone due to the inhibition of bone 
resorption we also investigated calcium related genes in linage negative cells and found 
calmodulin 1(Cam1)  and calcium chloride channel (ClCa1) were decreased with ZA 
treatment (Fig. 3.7B).  
Linage positive cells had decreased gene expression for BMP6 but no significant 
changes were observed in Bmi1, Tie2, Notch1, Ink4a and flt3 (Fig. 3.7C).  Total bone 
marrow cells had decreased gene expression of osteocalcin (OCN) and vascular cell 
adhesion molecule 1 (VCAM1) genes (Fig. 3.7D).   Altogether, the increased LSK 
population may be in part due to increased self-renewal capacity and suppression of 
linage commitment towards short term hematopoietic stem cells. 
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Figure3.7.  Gene expression analyses of bone marrow sorted cells:  
Lineage negative (A,B), lineage positive (C), and unsorted total bone marrow cells (D). Bone 
marrow cells of 4-week-old mice treated with ZA for 4 weeks were sorted into Lin− and Lin+ cells 
by magnetic cell sorting beads (MACS) and gene expression analyzed by qPCR. (A) Lineage 
negative cells had increased expression of BMP2, BMP6, BMi1, Tie2, Notch1, but no alteration 
of Ink4a, in mice treated with ZA versus vehicle (VEH) control. (B) Lineage negative cells were 
also analyzed for calcium related genes. Cam1 and ClCa1 were decreased with ZA. (C) 
Lineage positive cells had decreased gene expression for BMP6 but no significant changes 
were observed in Bmi1, Tie2, Notch1, Ink4a, and Flt3. (D) Total bone marrow cells had 
decrease gene expression of OCN and VCAM1 genes (*P < 0.05, **p,0.005). Data are 
presented as mean ± SEM, n = 5/gp. Permission for figure from J Cell Biochem (Soki et al., 
2013) 
 
 
Adult model vasculature and HSCs 
Because the experiments were performed in 4 week old mice that are in an 
active phase of growth and high bone activity, adult mice were also investigated.  Four 
month old mice were treated with ZA or vehicle for 4 weeks and same analyses were 
performed. LSK numbers were again increased in ZA treated mice (Fig. 3.8A). Micro CT 
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analyses of Microfil perfused mice presented no changes in vessel volume, thickness or 
number, suggesting that increased LSK numbers in 4 month old mice were not due to 
increased vascular niches (Fig. 3.8B-G).   
 
Figure3.8.  Effects of ZA on bone and vasculature in 16-week-old mice.  
ZA did not alter vessel volume (VV/TV), thickness (V Th), or number(VN) in adult mice, but still 
increased LSK numbers. Sixteen-week-old mice were treated with ZA or vehicle (VEH) for 4 
weeks. A: Bone marrow cells were collected and LSK were analyzed by flow cytometry. B: H&E 
staining of mice treated with vehicle or ZA shows similar vessels in the trabecular area of tibiae. 
C: Representative MicroCT images of bones with microfil perfusion. D–G: MicroCT analyses of 
microfil for vessel volume/tissue volume (VV/TV%), thickness (V Th, mm), number (VN, mm−1), 
and spacing (VS, mm; **P < 0.005). Data are presented as mean ± SEM, n = 8/gp. Permission 
for figure from J Cell Biochem (Soki et al., 2013) 
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DISCUSSION 
 
In this study, treatment with ZA in both young and adult mice significantly 
increased the hematopoietic progenitor population (LSK) in the bone marrow.  The 
augmented LSK population was confirmed functionally by long term reconstitution 
assays showing increased repopulation of B and T lymphocytes in mice that received 
bone marrow stromal cells from donor mice treated with ZA.  One interesting finding 
was that reconstitution of Gr-1+ population that accounts for myeloid cells was not 
different.  A recent study demonstrated that TGF-1 can regulate the hematopoietic 
stem cell long–term differentiation.  High levels of TGF-1 resulted in stimulation of 
myeloid-biased HSCs and inhibition of lymphoid-biased HSCs (Challen et al., 2010).  
ZA is known to inhibit bone resorption and consequently reduce the release of TGF-1 
from resorbed bone (Wu et al., 2010).  Accordingly, with ZA treatment an increased 
reconstitution of lymphocyte B and T cells were observed but not the myeloid population 
suggesting that low TGF-1 could be modulating the reconstitution of these cells in the 
bone marrow.  Moreover, ZA treatment increased the LSK flt3+ population that are 
known to be short term lymphocytic reconstituting cells, confirming an effect of ZA in 
hematopoietic reconstitution. 
Since LSK cells were increased in ZA treated mice, 3 potential hypotheses were 
investigated; 1) mobilization of LSK in the bone marrow, 2) increased bone marrow 
niches supporting increased numbers of LSKs, 3) altered cell composition and stem cell 
differentiation. 
Mobilization depends on detachment of HSCs from their niches concomitantly 
with cellular migration and egress from bone marrow to the circulation.  Mobilization 
strategies have been used clinically to collect a large number of hematopoietic stem 
cells from the blood, a less invasive procedure than bone marrow aspiration for 
transplantation.  Regulation of the bone microenvironment and the niches present in the 
marrow are important to preserve HSCs and therapies that interfere in this balance can 
affect the stem cell pool.  Based on our findings, mobilization of LSKs in ZA treated 
mice was not altered since the LSK population was unchanged in the peripheral blood 
as well as the spleens.  No difference was seen in white and red blood count or in the 
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platelet numbers in peripheral blood.  Studies demonstrated that bone remodeling is 
altered when HSC mobilization is induced by granulocyte-colony stimulating factor (G-
CSF) treatment with decreased bone volume (Lee et al., 1991;Takahashi et al., 1996). 
Therefore, bone activity is closely associated with HSC commitment for mobilization and 
differentiation with egress of HSCs from the bone marrow. Interestingly ZA inhibits 
osteoclast function and subsequently results in increased bone volume, an opposite 
effect seen in G-CSF therapies.  
Since ZA treatment did not stimulate the egress of LSKs from the bone marrow 
to the circulation two other questions were addressed. First is whether ZA promotion of 
LSK increase is due to hematopoietic niche alteration and secondly, whether ZA 
regulates the factors necessary for the retention of HSCs with modulation of cell 
commitment. ZA is a bisphosphonate clinically utilized for the treatment of bone 
associated diseases such as osteosporosis and skeletal malignancies due to its 
inhibitory actions in osteoclast mediated bone resorption.  ZA actions in bone were 
confirmed by histomorphometric analyses of bone sections demonstrating a significant 
increase bone mass and decrease in osteoclast activity.  Hematopoietic niches maintain 
self-renewing and dormant HSCs in the bone marrow and although still controversial, 
HSCs are believed to reside in association with bone locals termed endosteal niches 
and surrounding sinusoids present in the marrow, known as vascular niches.  It was 
also proposed that the distinct niches have different functionalities: the endosteal niche 
homes and maintains long-term HSCs and the vascular niche is involved in the short 
term HSC maintenance, promoting the differentiation and circulation of HSCs 
(Grassinger et al., 2010).  However to fully differentiate both niches is difficult due to the 
close association of the vasculature especially in trabecular bone rich areas, locations 
where HSCs preferentially lodge (Ellis et al., 2011). An increase in the osteoblastic 
niche could account for the augmented LSK population, especially for the long-term 
LSKs that were modestly increased after ZA treatment using the SLAM markers.  
Bisphosphonates are being studied for their activities not only in the bone 
microenvironment but also putative direct effects in tumor cell proliferation, adhesion, 
invasion, apoptosis and angiogenesis (Rogers and Holen, 2011).  The anti-angiogenic 
effects of ZA have been demonstrated by its actions as a potent inhibitor of endothelial 
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cell proliferation, adhesion migration and angiogenesis.  However, ZA effects in bone 
vasculature are still poorly defined.  Bone vascular biology is an understudied area and 
the interdependency of vascular physiology and osteogenesis need to be more 
thoroughly investigated.  It is known that angiogenesis and bone formation are 
intrinsically linked during bone development (Wang et al., 2007) and repair (Wan et al., 
2008).  Osteoclasts actively participate in this process, excavating the marrow cavity, 
while sinusoids establish this unique type of bone microcirculation (Bianco, 2011).  
Although biological evidence is observed in the bone coupling with endothelial cells 
(Parfitt, 2000), the formation and modulation of the vasculature linked with bone 
modeling and the effects of stimulators (hormones, drugs and mechanical loading) that 
affect its microstructure are relatively unexplored.  Studies in mechanical loading, 
demonstrated that bone angiogenesis was accompanied with bone gain in running rats 
(Yao et al., 2004) and VEGF was the mechanism driving both effects.  Recently, an 
interest study demonstrated that intermittent parathyroid hormone (PTH) induced 
vascular endothelial growth factor (VEGF A) production that mediated PTH anabolic 
response (Prisby et al., 2011).  PTH treated mice had fewer blood vessel numbers and 
relocated existing blood vessels near to new bone formation sites. (Wood et al., 
2002;Metcalf et al., 2011).  Interestingly, ZA treatment decreased the circulating levels 
of VEGF in cancer patients with bone metastasis (Santini et al., 2003) but their effects 
on the bone vasculature were not determined. 
In this study, we observed the expected increase in bone mass, but we also 
investigated the changes that occur in the vasculature of mice treated with ZA.  To this 
end, perfusion of a radiopaque microfilm was performed to visualize and quantify 
changes in the vasculature volume and vessel numbers.  Interestingly, young mice (4 
week old) treated with ZA had no alteration in overall vessel volume but had increased 
vessel numbers that were smaller and accumulated between the augmented trabecular 
areas in the metaphysis.  This finding lead us to further investigate if the changes in the 
bone niches (both endosteal and vascular) microstructures contributed to the increased 
LSK numbers.  Because the experiments were performed in young (4week old) mice 
where bone is highly active, we also performed experiments in adult (4 month old) mice.  
Similar to the young mice, LSK cells and bone mass were significantly increased after 4 
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week treatment with ZA but surprisingly vessel numbers and volumes were not changed 
in the adult mice.  The increase in bone vessel numbers in the young model but not in 
the adult mice suggests that ZA may act differently depending on the age and bone 
activity.  Moreover, the fact that ZA is a known antiangiogenic factor, but did not 
reduced vessel number or volume in bone raises interesting questions regarding the 
mechanisms by which bone angiogenesis occurs and how important their 
interdependency is with bone modulation and activity.  Further studies are necessary to 
fully elucidate bone angiogenesis and its contribution to the bone microenvironment.  
Collectively, the findings suggest that ZA indirectly supports the osteoblastic niche and 
that the vasculature niche may not be a key player in the augmented LSK population in 
bone.  
To account for an increase of LSK in the marrow, the present study sought to 
determine whether ZA would affect other cell types in the bone marrow.  Analysis of 
hematopoietic CD41+ cells revealed similar levels between ZA and VEH.  Moreover, 
investigation of different LSK populations was performed to determine whether ZA 
inhibited cell commitment that could account for the increased population in the bone 
marrow.  Indeed short-term lymphocytic reconstituting LSK flt3+ cells were increased 
with ZA treatment.  Lymperi et al. demonstrated that inhibition of osteoclastic resorption 
with alendronate treatment resulted in expansion of hematopoietic progenitor cells 
(LSK) but with a decrease in the absolute number of LSK Flt3- HSCs and long-term 
culture-initiating cells in the bone marrow (Lymperi et al., 2011). However, alendronate 
is a second generation bisphosphonate with a lower efficacy of osteoclast inhibition than 
ZA. 
Gene expression of Lin- sorted cells demonstrated that Bmi1 and Tie2, related 
with HSC self-renewal (Rizo et al., 2008;Arai et al., 2004),  were both increased, 
suggesting that hematopoietic progenitor cells are acquiring self-renewal capacity. 
Interestingly, BMP2 and BMP6 were both augmented with ZA treatment in Lin negative 
cells.  Jung et al. demonstrated that hematopoietic stem cells participate in bone 
formation and niche activity with secretion of BMP2 and BMP6 (Jung et al., 2008). 
Later, a role of erythropoietin for BMP2 and BMP6 production was reported (Shiozawa 
et al., 2010). Indeed, the endosteal niche is expanded with ZA treatment and 
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hematopoietic progenitor cell could be actively participating in the bone formation. It is 
possible that as osteoclasts are compromised with ZA treatment their coupling factors to 
stimulate osteoblasts (e.g. ephrins) are compromised and HPCs are serving to 
compensate.  Notch 1,  a receptor for ligand Jagged 1 expressed by osteoblasts, was 
also increased and is involved in the expansion of the HSC pool in vivo (Calvi et al., 
2003)  
Altogether, accordingly with increased endosteal niches and increased LSKs, our 
data suggests that ZA indirectly supports the osteoblastic niche LSK expansion that 
occurs independent of the vascular niche. Moreover, Zoledronic acid has a differential 
response in the vasculature modulation in young and adult mice, suggesting that age 
and bone activity may be significant factors defining the vasculature modulation in bone. 
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CHAPTER 4 
 
BONE MARROW MACROPHAGES SUPPORT PROSTATE CANCER GROWTH IN 
BONE 
 
 
ABSTRACT 
 
Bone is the preferred site of prostate cancer metastasis, and advanced-stage 
patients commonly develop skeletal metastasis. Still, the mechanisms underlying bone 
metastasis remain elusive.  Resident macrophages in bone, termed “osteomacs”, play 
important roles in bone remodeling, repair and hematopoietic stem cell niche 
maintenance, yet their role in skeletal metastasis has been under investigated. The 
purpose of this study was to determine the role of macrophages in prostate cancer 
skeletal metastasis.  In vivo experimental approaches employed a chemically inducible 
macrophage ablation model (i.e. MAFIA mice) in which AP20187 (AP) injections result 
in fas-induced apoptosis of c-fms (CSF-1 receptor) positive macrophage lineage cells. A 
significant reduction in tumor growth was noted in tibiae after intratibial tumor 
inoculation when macrophages were ablated.  Similar results were observed when a 
different strategy of macrophage ablation was performed with clodronate liposomes.  
Luciferase tagged PC-3 intratibial tumors were inoculated in athymic mice and BLI 
imaging showed less growth and smaller tumors overtime in macrophage depleted 
mice. The presence of tumors was sufficient for the increase in tumor associated 
macrophages in bone marrow. Macrophage ablation in MAFIA mice also hindered 
tumor growth in osseous settings when tumors were co-implanted subcutaneously with 
vertebral bodies (vossicles) as compared to the subcutaneous tumors suggesting that 
the marrow microenvironment and the macrophages in that environment are particularly 
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vital for tumor growth. Interestingly, even though tumors were consistently smaller in 
macrophage depleted mice, paradoxical results of macrophage depletion on the bone 
were observed. Histomorphometry and CT analyses demonstrated that clodronate 
treated mice had increased bone volumes in long bones while MAFIA mice had 
significant reductions.  These results suggest that the effect of macrophage depletion on 
tumor growth was independent of its effect on bone responses and that macrophages in 
bone may be more important to tumor growth than the bone itself.  In conclusion, 
resident macrophages play a pivotal role in prostate cancer growth in bone.  
 
INTRODUCTION 
 
The skeleton is a favored organ for metastasis that results in significant morbidity 
for cancer patients.  In skeletal metastasis, the interplay of tumor cells with the bone 
microenvironment results in bone remodeling and tumor growth (Weilbaecher et al., 
2011a;Loberg et al., 2005).  Macrophages are myeloid phagocytic cells recruited in 
response to infection, inflammation and tissue injury, therefore, having a role in the 
innate and adaptive immune response (Pettit et al., 2008;Pollard, 2009).  They are 
activated differentially according to the stimuli provided:  M1 anti-tumorigenic 
macrophages are classically activated and M2 pro-tumorigenic macrophages (also 
known as tumor associated macrophages, TAMs) are alternatively activated (Pollard, 
2004;Lewis and Pollard, 2006).  TAMs are prominently found and involved with cancer 
initiation, progression and metastasis, facilitating angiogenesis, matrix breakdown and 
tumor cell-motility (Pollard, 2009;Mantovani and Sica, 2010;Mantovani, 2010;Pollard, 
2004).  Clinical studies in prostate cancer demonstrated that overexpression of colony-
stimulating factor (CSF-1) and its receptor (CSF-1R or c-fms), responsible for monocyte 
and macrophage expansion, indicated poor prognosis in primary prostate cancers and 
development of metastasis to the bone (Richardsen et al., 2008).  Modification of the 
myeloid cells in bone has demonstrated influence on tumor metastasis to bone.  
Prostate cancer cell localization and growth in bone was increased when a single dose 
of cyclophosphamide, a bone marrow–suppressive chemotherapeutic drug, was 
administered prior to intracardiac tumor inoculation (Park et al., 2012a).  This was 
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associated with a transient expansion of myeloid cells and increased cytokines with 
myelogenic potential such as C-C chemokine ligand 2 (CCL2), interleukin-6 (IL-6), and 
VEGF-A that primed the environment for tumor growth.  Moreover, the chemokine CCL2 
known to attract and differentiate macrophages towards TAMS and osteoclasts has 
been shown to increase prostate cancer growth and bone metastasis (Mizutani et al., 
2009;Loberg et al., 2007b;Loberg et al., 2007a;Roca et al., 2009;Rozel et al., 2009).  
TAMs have been implicated in tumor growth, progression and metastasis of different 
types of cancer, but little is known about their role in skeletal metastasis. 
Macrophages residing in bone, termed ‘osteomacs’ constitute one sixth of the 
total cells and differ from osteoclasts, by expressing specific surface markers:  F4/80 
and CD68 (Austyn and Gordon, 1981;Chang et al., 2008). Interestingly, depletion of 
macrophages compromised osteoblastic bone formation (Pettit et al., 2008;Chang et al., 
2008). Bone resident macrophages are found in close association with osteoblasts and 
are important in bone remodeling, bone healing and hematopoietic niche maintenance 
(Alexander et al., 2011b;Winkler et al., 2010b;Pettit et al., 2008).  Moreover, osteal 
macrophages have important roles in skeletal homeostasis and PTH anabolic actions 
on bone remodeling (Cho et al., 2014).  Differences in bone remodeling were observed 
depending on the differentiation stages of macrophages that were targeted. Depletion of 
early lineage macrophages resulted in osteopenia whereas differentiated macrophage 
depletion presented the opposite effect of an osteogenic environment and enhanced 
PTH anabolism.  Osteomacs play important roles in the bone niche. However, their role 
in pathologies such as bone metastasis remains elusive. Surprisingly, the involvement 
of macrophages and their participation in the modulation of the bone microenvironment 
during skeletal metastasis have not yet been explored.  Given the importance of 
macrophages in bone homeostasis, we hypothesized that macrophages promote 
prostate cancer metastatic growth in bone. 
 
MATERIALS AND METHODS 
 
Animal care and cell lines. 
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All animal experiments were performed with the approval of the University of 
Michigan Committee for the Use and Care of Animals. C57Bl/6 male wild-type mice and 
MAFIA mice were purchased from Jackson Laboratories (Bar Harbor, ME). Male 
athymic mice were purchased from Harlan Laboratories.   
Luciferase-labeled PC-3 cells were initially purchased from ATCC and 
established as previously described (Schneider et al., 2005).  RM-1 cells were originally 
obtained from Dr Timothy C. Thompson (Baylor College of Medicine, Houston, TX).  
 
MAFIA mouse model with intratibial RM-1 tumors.  
The macrophage Fas-induced apoptosis (MAFIA) C57BL/6-Tg mouse has a c-
fms promoter (CSF-1 receptor) specifically targeting phagocytic cells such as 
macrophages, and to a lesser extent dendritic cells. Administration of a synthetic 
dimerizer, AP20187 (Clontech Laboratories, Inc.) activates the suicide gene leading to 
Fas-mediated apoptosis in resting and cycling macrophage cells.  MAFIA mice (12-14 
wks) received daily i.p. injections of AP20187 (10 mg/kg) (or vehicle) for 3 days for 
macrophage depletion as previously described (Cho et al., 2014). Booster injections 
(1mg/kg) every 3d were administered to sustain macrophage suppression. After initial 
depletion, RM-1 mouse metastatic prostate cancer cells were inoculated via intratibial 
injection under anesthesia as previously described (Park et al., 2010).  At study end, 
bones were analyzed histomorphometrically to evaluate tumor, bone area and 
resorption indices. Serum TRAP5b was measured as an indicator of bone remodeling 
activity.  
 
RM-1 tumor measurements 
X-ray images from intratibial tumor bearing mice were analyzed for radiolucency. 
Radiolucent areas were delineated utilizing the ImageJ program for total area 
determination. Blinded measurements were performed by two different people and 
averaged for each sample.  
 
Clodronate loaded liposomes.  
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Clodronate (dichloromethylene bisphosphonate)-loaded liposomes (clodronate 
liposomes) or PBS-loaded liposomes (PBS liposomes; used as control) were purchased 
from ClodronateLiposomes.com (The Netherlands). Four-week-old male athymic or 
C57BL/6 mice were treated with clodronate liposomes (10 μl/g) for 3 consecutive 
injections, then given every third day for 2 weeks (C57BL/6) or every week at a reduced 
dosage (6 μl/g; athymic mice) for the next 3 weeks. After initial depletion, RM-1 or 
Luciferase tagged PC-3 cells were injected in the tibia of mice. In vivo bioluminescence 
(BLI) was performed every 3 days for PC-3 luciferase cell evaluation.  
 
Flow cytometric analysis.  
Immediately after sacrifice, bone marrow cells were flushed with FACS buffer 
(2% FBS, 2 mM EDTA in 1X PBS) and 1 x 106 cells were incubated with fluorescent-
conjugated antibodies (PE 10 μl; FITC 1 μl; APC 5 μl) in 500 μl of FACS buffer for 30 
min at 4°C. Antibodies for flow cytometric analyses included: anti-mouse F4/80 FITC 
(Abcam, CI:A3-1), anti-mouse CD11B APC (eBioscience, M1/70) and CD206 PE (AbD 
Serotec, MR5D3).  
 
Histology and tartrate resistant acid phosphase (TRAP) staining.  
Tibiae were fixed in 4% paraformaldehyde solutions for 24 hr and decalcified in 
10% EDTA for 21 days at 4°C. Paraffin-embedded tibial sections were stained with H&E 
and histomorphometric analyses were performed using Osteomeasure (OsteoMetrics 
Inc. Atlanta, GA). TRAP staining on bone sections was performed using a TRAP 
staining kit (Sigma-Aldrich) per manufacturer’s instructions.  
 
CT imaging.   
Fixed tibiae and femurs were analyzed by CT imaging (eXplore Locus, GE 
Healthcare, London, ON, Canada; Scanco µCT-100, Medical AG, Bruttisellen, 
Switzerland). Bones were fixed in formalin and embedded in 1% agarose.  After placing 
them in a 19 mm diameter tube, bones were scanned over their entire length using a 
CT system (µCT100 Scanco Medical, Bassersdorf, Switzerland).  Scan settings were: 
voxel size 12 µm, medium resolution, 70 kVp, 114 µA, 0.5 mm AL filter, and integration 
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time 500 ms.  Trabecular bone parameters were measured over 50 slices using a 
threshold of 28% at 15 slices distal to the growth plate; cortical bone was measured 
over 30 slices at 60% of the bone length distal to the tibio-fibular joint (TFJ) using a 28% 
threshold. 
 
Immunohistochemical F4/80 staining.   
Tibiae were fixed in 4% paraformaldehyde/PBS (4°C, 24hr), decalcified in 14% 
EDTA for 2 weeks, and embedded in paraffin. Immunohistochemical staining was 
performed, using the Cell & Tissue Staining Kit (HRP-DAB system; R&D systems) and 
the rat monoclonal anti-mouse F4/80 (1:100, Abcam, Cambridge, UK).  Percentages of 
F4/80+ cells were quantified using NIS Elements software (Nikon).  The mean area 
positive for F4/80+ cells was calculated for each tissue within 4 different areas of the 
tissue.  
 
Blood and bone marrow serum biochemical assays.  
ImmunoAssay kits obtained from IDS were used to measure serum TRAP5b 
following manufacturer’s instructions. 
 
Statistical Methods.  
Statistical analysis was performed by two-way ANOVA or unpaired t test using 
the GraphPad Instat statistical program with significance of p<0.05. Data are presented 
as mean ± SEM.  Tumor growth in the mouse models was analyzed using repeated 
measures mixed models.  Growth over time was tested between groups using an 
interaction of group and time in the model if the growth is linear. Pairwise group 
differences were explored using post-hoc tests adjusted for multiple comparisons. 
 
RESULTS 
 
Prostate cancer growth in bone of macrophage-ablated MAFIA mice 
The macrophage fas-induced apoptosis (MAFIA) mouse provides for conditional 
macrophage depletion (23).  Administration of a synthetic dimerizer, AP20187 activates 
82 
 
the suicide gene leading to Fas-mediated apoptosis in resting and cycling macrophage 
cells. In addition, bicistronic expression of the suicide gene and EGFP permit tracking of 
macrophages in all tissues of the mouse. After 3 consecutive daily injections for initial 
depletion, luciferase-labeled RM-1 mouse metastatic prostate cancer cells (Power et al., 
2009) were inoculated via intratibial injection and tumors were monitored for up to 2 
weeks (Fig. 4.1A). The efficiency of macrophage (Gr1lo, F4/80+, c-fms intermediate and 
CD11bhi) depletion was validated, before tumor inoculation, and after 3 consecutive 
daily injections (Fig. 4.1B). 
To determine the impact of macrophages on tumor growth in bone, RM-1 cells 
were injected intratibially in MAFIA mice pre-treated with vehicle or AP. After 14 days, 
tumor sizes were analyzed by radiolucent area quantification and confirmed by histology 
(Fig 4.1C).  Interestingly, macrophage depleted mice had significantly smaller tumors in 
bone compared to vehicle treated controls.   
As previously reported, macrophage depletion highlights the important roles 
macrophages play in bone formation, healing, and PTH anabolic actions (Alexander et 
al., 2011b;Cho et al., 2014) and hence likely in skeletal tumor growth.  Since 
macrophages share precursors with osteoclasts in bone, serum TRAP5b, a bone 
resorption marker, was analyzed (Fig. 4.1D).  Mice had significantly reduced levels of 
serum TRAP5b after 2 weeks of macrophage depletion compared to vehicle controls.  
Histomorphometric analyses were performed in tibiae with RM-1 tumors (Fig. 4.1E and 
F) and in tumor-free femurs.  Intratibial tumors presented no significant differences in 
total bone.  In the femurs of macrophage depleted mice, significant reductions in bone 
volume were observed confirming macrophage depletion effect in bone homeostasis as 
previously reported (Fig. 4.1F) (Cho et al., 2014). Even though serum TRAP5b levels 
were significantly reduced with macrophage depletion, osteoclast number per total 
tissue area (N.Oc/T.ar), osteoclast number per bone perimeter (N.Oc/B.Pm) and 
osteoclast surface per bone surface (Oc.S/Bs) were not significantly changed in tibiae 
or femurs with macrophage ablation.  These data suggest that macrophage ablation in 
MAFIA mice hinders tumor growth in bone and significantly decreases total bone 
volume.  
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Figure 4.1. Macrophage ablation in MAFIA mice hinders tumor growth in bone and significantly 
decreases total bone volume  
A)  Macrophage depletion regimen and intratibial tumor growth. Sixteen week old male MAFIA 
mice were treated with AP20187 (AP) (10mg/kg) or vehicle control (VEH) for 3 days (black 
arrows). RM-1 murine prostate cancer cells were injected intratibially (IT) on the fourth day 
(black triangle) and booster injections were given every third day (1mg/kg) (red arrows) for 
depletion maintenance. Fourteen days later mice were euthanized and evaluated. B) 
Representative flow cytometric analysis of the whole bone marrow cells after 3 days initial 
depletion and quantitative analyses of GR-1lo F4/80+ C-FMSint SSCint/lo CD11Bhimacrophages.  
C) Radiographic and histological analyses of intratibial RM-1 tumors in vehicle (VEH) and 
AP20187 (AP) treated mice. Tumors are highlighted in yellow and 20X images show the edges 
of tumor and bone marrow cells (BM). Radiolucent areas were quantified in radiographic images 
of intratibial tumors as shown in graph. D) Serum analyses of TRAP5b (units per liter). E) 
Histologic images (20X) in the tibia of MAFIA mice in the presence of tumors. Tumors are 
delineated in red; bone (Bn), bone marrow tumor-free areas and TRAP positive osteoclasts 
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(black arrows) are indicated. Bone histomorphometric analyses including bone volume (BV/TV), 
osteoclast numbers per total tissue area (N.Oc/T.Ar), osteoclast surface per bone surface 
(Oc.S/BS) and osteoclast numbers per bone perimeter (N.Oc/B. Pm) are shown. F) 
Histomorphometric analyses of tumor-free femurs. Data are mean ±SEM, n=6-8 per group. 
*P<0.05, *** P<0.001 
 
 
Macrophage ablation in MAFIA mice hinders prostate cancer subcutaneous 
growth in vossicle model. 
To investigate the impact of macrophages in prostate tumor growth in bone, 
murine RM-1 prostate cancer cells were injected in vertebral bodies (vossicles) (Koh et 
al., 2005) of MAFIA mice previously treated with vehicle or AP20187 for macrophage 
depletion and subcutaneously implanted in the back of MAFIA mice hosts with or 
without initial macrophage depletion. Tumors were measured every 3 days for up to 2 
weeks and booster AP or vehicle injections were given every 3 days to maintain 
macrophage ablation (Fig. 4.2A).   
Tumor sizes were significantly smaller in mice with macrophage depletion at 9 
and 12 days (Fig. 2B).  Vossicles were collected and flow cytometric analysis showed 
that tumors had decreased c-fms+F4/80+ macrophages but no significant difference in 
overall tumor weight (Fig. 4.2C and D).  Long bones from recipient mice presented 
significantly fewer macrophages in the bone marrow (c-fms+F4/80+) and decreased 
levels of both M2 (c-fms+CD206+) and M1 (c-fms+CD86+) macrophages (Fig. 4.2E).  
This suggests that macrophage ablation in MAFIA mice efficiently decreased 
macrophage levels in the vossicle model.  In the long bone marrow of the recipient mice 
treated with the AP compound, macrophage ablation was more dramatic with almost 4-
fold reduction.  Moreover, macrophage ablation decreased both M1 and M2 
macrophages in the marrow. 
To better understand the macrophage contribution in tumor growth, 
subcutaneous tumors were injected in the back of the MAFIA mice and after 2 weeks 
tumors were collected and analyzed (Fig. 4.2F).  Interestingly, no difference in size and 
weight were observed after 14 days (Fig. 4.2G), even though macrophage ablation was 
efficient in subcutaneous tumors. These data suggest that macrophage ablation in 
MAFIA mice hinders tumor growth in endogenous osseous settings as compared to the 
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subcutaneous setting. Collectively, these findings suggest the marrow 
microenvironment and the macrophages in that environment are particularly vital for 
tumor growth.  
 
Figure 4.2. Macrophage ablation in MAFIA mice hinders prostate cancer subcutaneous growth 
in vossicle model. 
A) Experimental design for vossicle model.  Sixteen week old MAFIA mice (recipients n=6) and 
7 day old mice (donors, n=10/group) were treated for 3 days with vehicle (VEH) or AP20187 
(AP) (n=6-8). Vertebrae from donor mice were collected and implanted subcutaneously with 
RM-1 prostate cancer cells (vossicles) in the back of VEH or AP treated recipient mice. Booster 
injections were given every third day (1mg/kg) for depletion maintenance and tumors were 
analyzed after 14 days. B) Vossicle tumor growth.  Tumor sizes (2 tumors /mouse) were 
measured by caliper every 3 days for up to 14 days. Tumors in macrophage ablated mice were 
significantly smaller than controls at day 9 and 12.  C) Representative vossicle-tumor H&E 
sections showing the vossicle (Vos) surrounded by the tumor cells (10X). D) Vossicles were 
analyzed by FACS for macrophage c-fms+F4/80+% of total cells.  Tumor weight (mg) was 
measured 14 days after implantation.  E) FACS analysis of macrophages in the whole bone 
marrow of tibiae shows macrophage depletion with AP treatment for macrophages c-
fms+F4/80+, M2 macrophages F4/80+CD206+  and M1 macrophages F4/80+ CD86+ cells. 
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Data are mean ± SEM n=6-8 per group. * P<0.05 , *** P<0.001.  F) Experimental design for 
subcutaneous RM-1 tumors in MAFIA mice. Sixteen week old MAFIA mice (n=8) were treated 
for 3 days with vehicle (VEH) or AP20187 (AP) for initial depletion. In the fourth day RM-1 
prostate cancer cells mixed with low growth factor matrigel were injected subcutaneously in the 
back of vehicle or AP treated mice.  Booster injections were given every third day (1mg/kg) for 
depletion maintenance and tumors were analyzed after 14 days.  G)  Subcutaneous tumors of 
VEH or AP treated mice and graphs for tumor size (mm3) and tumor weight (mg).  H) FACS 
analyses for c-fms+ F4/80+ macrophages in subcutaneous tumors.  Data are mean ± SEM, n=8 
per group. * P<0.05, *** P<0.001. 
 
 
Prostate cancer growth in bone of clodronate liposome macrophage-ablated mice 
The MAFIA mouse model targets c-fms+ immature macrophages and resulted 
not only in reduced bone volume but also decreased tumor growth.  To investigate 
whether the presence of tumors in bone would change the bone marrow population, 
macrophage populations in femurs without tumors were compared to tibiae with tumors.  
Interestingly, the presence of tumors significantly boosted the macrophage population in 
the bones when compared to tumor-free femurs (Fig. 4.3A).  Nearly a 2-fold increase in 
M2 macrophages (F4/80+CD206+), monocytes (CD11B+), and CD206+ expression in 
F4/80+CD11B+ immature macrophages was observed when tumors were present.  To 
better understand the effect of macrophage depletion at different stages of macrophage 
maturation, an alternate approach was taken utilizing clodronate loaded liposomes to 
induce apoptosis of mature phagocytic macrophages.  Clodronate liposomes were 
administered to 4 week old male mice for 3 days to initiate depletion.  RM-1 prostate 
cancer cells were injected intratibially on the fourth day and booster injections of 
clodronate were given every third day to maintain macrophage depletion for 2 weeks 
(Fig. 4.3B).  Consistent with the MAFIA mouse model, clodronate treated mice 
presented smaller intratibial tumors confirmed by histologic and radiographic analyses 
of tumor area and radiolucent area quantification (Fig. 4.2C and 4.2D).  Efficient 
macrophage ablation was confirmed by F4/80+ cell staining of tibiae sections (Fig. 
4.3E).  Figure 4.3F shows that macrophage ablation by clodronate liposome treatment 
significantly decreased M2 macrophage F4/80+CD11B+CD206+ cells in intratibial 
tumors. In summary, figure 4.3 suggests that targeting the phagocytic mature M2 
macrophages resulted in smaller tumors in bone and confirmed macrophage 
contribution to tumor growth in bone.  
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Figure 4.3. Clodronate liposome induced macrophage ablation and hindered RM-1 tumor 
growth in bone.  
A) Representative flow cytometric analysis of the intratibial tumors for M2 macrophage marker 
CD206 gated of F4/80+/CD11B+ cells over total cells.  F) FACS analyses of non-tumor femur 
versus intratibial tumors for macrophages (F4/80+), M2 macrophages (F4/80+ CD206+), 
monocytes (CD11B+) and CD206+ cells gated on F4/80+CD11B+ population (n=10).  B) 
Macrophage depletion regimen and intratibial tumor growth for 2 weeks.  Four-six week old 
C57Bl6 male mice were treated with 3 consecutive injections of clodronate loaded liposomes 
(CLOD) (10l/g) or vehicle (VEH). RM-1 murine prostate cancer cells were injected intratibially 
on the fourth day and booster injections were given every third day for depletion maintenance. 
Fourteen days later mice were euthanized and evaluated. C and D) Histological and 
radiographic analyses of intratibial RM-1 tumors in vehicle (VEH) and clodronate (CLOD) 
treated mice. C) Representative image of intratibial tumor (yellow) and tumor area/tibia area 
quantification. D) Representative X-ray image of tibia and radiolucent area (yellow) 
quantification. E) F4/80 staining (red-brown) on tibial sections (20X) and quantification. Arrows 
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show F4/80+ cells.    Data are mean ± SEM; n=18 per group, unless otherwise denoted; * 
P<0.05. 
 
Clodronate liposome macrophage ablation resulted in increased bone volume 
Both macrophage ablation strategies, the specific transgenic macrophage MAFIA 
mice, and the pharmaceutical approach targeting the more mature macrophages with 
clodronate liposome treatment, resulted in smaller tumors in bone.  To better 
understand the contribution of mature phagocytic macrophages in bone remodeling and 
how this may influence skeletal tumor growth, bone histomorphometric analyses were 
performed.  In contrast to the MAFIA model, clodronate liposome treatment resulted in 
increased total bone volume (Fig. 4.4A) even though tumors were significantly smaller 
(Fig. 4.4B).  Short term macrophage ablation for 2 weeks also resulted in decreased 
serum TRAP5b levels (Fig. 4.4C).  Osteoclast TRAP+ staining showed a significant 
reduction in the osteoclast surface per bone surface (Oc.S/BS) but no changes in 
osteoclast number per total tissue area (N.Oc/T.Ar) or bone perimeter (N.Oc/B.Pm) 
(Fig. 4.4D).   
To exclude the possibility that differences seen in bone volume could be due to 
the osteolytic nature of RM-1 murine tumor cells, CT analysis was performed in tumor-
free femurs (Fig. 4.4E).  Consistent with previous studies (Cho et al., 2014), clodronate 
liposome induced-macrophage ablation resulted in increased total bone (BV/TV), 
trabecular thickness (Tb.Th), trabecular number (Tb.N) and reduction in trabecular 
spacing (Tb.Sp).  This data shows that targeting the mature macrophage population 
results in a differential response in bone versus the MAFIA model.  Importantly, both 
macrophage ablation models presented decreased tumor sizes in bone, but had 
different responses in bone modeling, suggesting that macrophage contribution to tumor 
growth is independent of its function in bone remodeling.   
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Figure 4.4. Clodronate liposome treated mice had increased bone volume in intratibial tumor 
sections. 
A) Representative image (4X) of total bone volume (BV/TV) and quantification.  B) Total tumor 
volume (Tm V/TV) and tumor volume per bone surface (Tm V/BS) were analyzed. C) Serum 
analyses of TRAP5b (units per liter). D) Representative image (20X) of TRAP positive 
osteoclast surface per bone surface (Oc.S/BS), osteoclast numbers per total tissue area 
(N.Oc/T.Ar) (p=0.052), and osteoclast numbers per bone perimeter (N.Oc/B. Pm) were 
quantified. E) Representative 2D and 3D CT images of tumor free femurs show increased 
trabecular bone volume in clodronate treated mice. Trabecular total bone volume (BV/TV), 
trabecular thickness (Tb.Th), number (Tb.N) and spacing (Tb.Sp) were quantified.  Data are 
mean ± SEM; n=10-13 per group; * P<0.05, *** P<0.001. 
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PC-3 human prostate cancer growth in bone of clodronate liposome macrophage-
ablated mice 
A human prostate cancer model was employed to confirm the macrophage 
contribution in skeletal tumor growth using PC-3 cells in the intratibial tumor inoculation 
experiment, this time using athymic mice.  To delineate macrophage involvement in 
bone tumors,  bone marrow flush was compared between the intratibial tumors and 
tumor-free femurs of mice treated with clodronate or vehicle control, and similar results 
were observed with significantly increased M2 macrophage (F4/80+ CD206+) cells in 
the presence of tumors, suggesting the contribution of M2 macrophages in skeletal 
tumors (Fig. 4.5A)  
Three days after initial depletion with vehicle control or clodronate liposome 
treatment, luciferase tagged PC-3 cells were injected in the tibia and tumors were 
monitored by bioluminescent imaging every week for 6 weeks.  Booster injections were 
given weekly (5-8 l/g) for macrophage depletion maintenance during the 6 week period 
(Fig. 4.5B).  After 6 weeks, bioluminescent imaging showed that clodronate liposome 
treated mice presented significantly smaller tumors in the tibia compared to controls, 
confirming a role of macrophages in PC-3 tumor growth in bone (Fig. 4.5C).  Tibiae with 
tumors were collected (Fig. 4.5D) and flow cytometry confirmed significant ablation of 
M2 macrophage (F4/80+CD206+) cells (Fig. 4.5E).   
In addition, CT and histomorphometric analyses of tibiae demonstrated that 
clodronate liposome treatment increased bone volume and resulted in smaller tumors 
(Tm/TV) (Fig. 4.5F and G).  Serum TRAP5b was not changed after 6 weeks of 
macrophage ablation (Fig. 4.5H).  TRAP staining showed significant reduction in 
osteoclast surface per bone surface (Oc.S/BS), number of osteoclasts per bone 
perimeter (N.Oc/B Pm) and increased total number of osteoclasts (N.Oc/T.Ar). Similar 
to RM-1 prostate cancer cells, these data suggest that macrophages contribute to PC-3 
prostate cancer growth in bone independent of the bone response. 
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Figure 4.5. PC-3 intratibial tumors in athymic mice increased M2 macrophages that contributes 
to intraosseous tumor growth.  
A) FACS analyses of tumor-free femur whole bone marrow flush and intratibial tumors for 
macrophages (F4/80+), CD206+ cells and double positive M2 macrophages (F4/80+ CD206+) 
(n=10/group). B) Macrophage depletion regimen and intratibial PC-3 tumor growth for 6 weeks.  
Four-six week old athymic male mice were treated with 3 consecutive injections of clodronate 
loaded liposome (CLOD) (10l/g) or vehicle (VEH). PC-3 Luciferase labelled human prostate 
cancer cells were injected intratibially on the fourth day and booster clodronate or vehicle 
92 
 
injections were given every week for depletion maintenance at different doses. BLI images were 
taken every week for luciferase radiance for the next 6 weeks.  C) BLI representative images at 
42 days of intratibial PC-3 tumor growth in vehicle (VEH) and clodronate (CLOD) treated mice. 
Graph represents BLI measurements for 6 weeks. (n=15-17). D) Representative X-ray image of 
tibia and radiolucent area was delineated in yellow. E) Flow cytometric analysis of intratibial 
tumors for F4/80+/CD206+ quantification of total cells (%) and representative dot plots. F) CT 
analyses of bones in long term depleted mice with intratibial tumors (n=15-17) and 
representative 3D images shows higher total bone volume (BV/TV) in clodronate treated mice. 
G) Bone histomorphometric analyses in clodronate or vehicle treated mice in intratibial tumor 
sections of total bone volume (BV/TV), total tumor volume (TmV/TV) and tumor volume per 
bone surface (TmV/BS) (n=14-15). H) Serum analyses of TRAP5b (units per liter). I) 
Representative image (10X) of TRAP positive osteoclasts stained in red. Osteoclast surface per 
bone surface (Oc.S/BS), osteoclast number per total tissue area (N.Oc/T.Ar), and osteoclast 
number per bone perimeter (N.Oc/B.Pm) were quantified.  Data are mean ±SEM; * p<0.05, ** 
p<0.01, *** p<0.001. 
 
DISCUSSION 
 
Macrophages are heterogeneous myeloid lineage cells that comprise diverse 
functions towards the immune defenses (Mantovani and Sica, 2010;Mantovani et al., 
2004).  They can rapidly respond to signs of injury, infection and to changes in the 
environment, having a diverse differentiation and activation profile according to the 
stimuli received (Pollard, 2009).  Simplistically, macrophages can be described as 
classically activated (also known as M1) or alternatively activated (known as M2).  M1 
macrophages respond to infection and generate pro-inflammatory responses to exert 
their role as cell killers against invaders and pathogens.  On the other hand, M2 
macrophages are known to participate in wound healing, tissue repair, and as anti-
inflammatory cells to moderate inflammatory responses.  M2 macrophages are also 
known as tumor associated macrophages (TAMs) because of the similar 
immunosuppression roles they have in the context of tumors, contributing to tumor 
growth, progression and metastasis of different types of cancer (Pollard, 2004;Siveen 
and Kuttan, 2009).  In bone, ‘osteomacs’ are the resident macrophages that line the 
periosteal and endosteal tissues and have essential roles, supporting osteoblast 
maintenance and functional activity (Chang et al., 2008).  Moreover, these resident 
macrophages have been shown to impact bone healing, remodeling and hematopoietic 
stem cell maintenance (Pettit et al., 2008;Alexander et al., 2011b;Winkler et al., 
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2010b;Cho et al., 2014).  However, how resident macrophages and their impact in the 
bone microenvironment affect skeletal tumor growth is unclear.   
The present study demonstrated that targeting macrophages for depletion 
hindered tumor growth in bone.  Different strategies of macrophage depletion were 
utilized and similar results were observed.  In the transgenic MAFIA mouse, intratibial 
tumors presented smaller tumors in macrophage depleted mice compared to controls.  
Depletion of macrophages in the bone marrow was confirmed by flow cytometry looking 
at very specific macrophage markers (Gr1lo, F4/80+, c-fmsint and CD11bhi) prior to tumor 
inoculation.  When subcutaneous tumor growth was analyzed after 2 weeks of 
inoculation, no difference was observed, even though there was a significant reduction 
in macrophage c-fms+F4/80+ in both subcutaneous tumors and bone marrow.  
Interestingly, there was a significant difference in tumor size in the vossicle model at 
earlier time points in macrophage depleted mice.  We hypothesized that when tumors 
are growing within the vertebrae body, a significant reduction of macrophages have 
higher impact on the tumor growth, but when tumors outgrow the bone area this 
difference in growth is no longer the driving factor.  This suggests that macrophage 
depletion has a higher impact in the bone marrow compartment, which is rich in myeloid 
cells, and which is the case in the intratibial tumor model.  To further validate the role of 
macrophages in skeletal tumor growth, a more narrowly focused macrophage depletion 
model was introduced with clodronate liposome treatment.  Mature macrophage 
depletion was efficient, and similar to the MAFIA mouse model, there were smaller 
tumors in macrophage depleted mice.  In this model, tibiae with tumors and tumor-free 
femurs were both analyzed by FACS for macrophage markers. Interestingly, clodronate-
induced depletion significantly reduced M2 macrophages (F4/80+ CD206+) in intratibial 
tumors.  Moreover, the presence of tumors in tibiae significantly increased M2 
macrophages. Similar results were also confirmed with the human PC-3 prostate cancer 
cell line inoculated in the tibiae of athymic mice over 6 weeks.  These data not only 
confirmed the macrophage contribution for tumor growth, but also demonstrated that 
tumor development in bone marrow increased M2-like macrophages, which further 
suggests the important role of macrophage polarization in tumor progression.   
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Altering the bone microenvironment, rich in myeloid cells, prior to tumor 
inoculation affected tumor growth in bone.  Park et al demonstrated that a transient 
expansion of myeloid cells resulted from a single dose of cyclophosphamide prior to 
intracardiac tumor inoculation of prostate cancer cells increased localization and growth 
in bone (Park et al., 2012a).  Moreover, tumor derived factors such as PTHrP 
(parathyroid hormone-related protein) and CCL2 may induce direct and indirect 
changes in bone and tumor microenvironment that contribute for tumor growth 
(McCauley and Martin, 2012b;Loberg et al., 2007b;Loberg et al., 2007a;Li et al., 
2009;Roca et al., 2009;Rozel et al., 2009;Mizutani et al., 2009;Zhang et al., 
2010;Fridlender et al., 2010;Park et al., 2012a;Soki et al., 2012).  For example, PTHrP 
coming from solid prostate tumors can prime and recruit the myeloid cells, also known 
as myeloid derived suppressor cells (MDSCs) that contributed for solid tumor growth.  
CCL2 is a chemokine also known for its role in both tumor growth and myeloid cell 
modulation, a contributing factor for M2 macrophage polarization (Loberg et al., 
2007b;Loberg et al., 2007a;Li et al., 2009;Roca et al., 2009;Rozel et al., 2009;Mizutani 
et al., 2009;Zhang et al., 2010;Fridlender et al., 2010;Park et al., 2012a).  Specifically, in 
bone, CCL2 is known to be involved in a destructive cascade, being released after 
PTHrP stimulation of osteoblasts, which in turn secretes CCL2 in the bone marrow 
activating osteoclastogenesis and tumor growth (Li et al., 2009).   
Osteoclasts are key players in skeletal metastasis, and are specialized cells 
differentiated from macrophages.  Therefore, a special challenge in bone when studying 
macrophages is the effects that macrophage depletion may have on osteoclast activity.  
No difference was observed in local osteoclast numbers when tumors were present 
although systemic osteoclast TRAP5b levels were reduced after 2 weeks of 
macrophage depletion in MAFIA mice.  Clodronate liposome administration for 2 weeks 
also resulted in reduced TRAP5b levels.  A longer macrophage depletion regimen for 6 
weeks indeed resulted in decreased osteoclast number per bone perimeter and 
osteoclast surface per bone surface, but differences were not seen in TRAP5b levels.  
This may be a reflection of increased bone content while the osteoclast activity is 
stabilized as well as a differential response in the local environment versus the systemic 
circulation.  Many tumor derived factors are known to promote osteoclastogenesis such 
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as PTHrP and CCL2 (Soki et al., 2012;Park et al., 2013;Loberg et al., 2007b;Li et al., 
2009;Mizutani et al., 2009;Park et al., 2012a).  Overall, these data suggest that even 
though macrophage depletion may suppress in part osteoclast differentiation/activation, 
tumors may compensate for the suppression, driving the differentiation/activation of the 
remaining macrophage progenitors towards osteoclasts.   
An interesting finding in the present study was the fact that tumors were 
consistently smaller in macrophage depleted mice, even though paradoxical results of 
macrophage depletion on the bone were observed.  Targeting early progenitor cells 
under the c-fms promoter in the transgenic MAFIA mouse model resulted not only in 
reduced tumor growth, but also decreased bone volume in the hind limbs of 
macrophage depleted mice.  In contrast, targeting mature phagocytic macrophages with 
administration of clodronate liposome resulted in increased bone volume, while tumor 
growth was also still hindered in macrophage depleted mice in both murine RM-1 and 
human PC-3 prostate cancer cells.  These results suggest that the effect of macrophage 
depletion in tumor growth was independent of its effect on bone tissue.  We have 
previously demonstrated that osteal macrophages support bone remodeling and PTH 
anabolic actions in bone of adult murine skeletal system (Cho et al., 2014).  Clodronate 
loaded liposomes triggered an opposite effect resulting in an osteogenic 
microenvironment and augmented PTH anabolic actions.  The main difference observed 
was that the phagocytic myeloid CD68+ cells that include macrophages, dendritic cells 
and neutrophils were differential according to the depletion model.  In clodronate 
liposome treated mice there was a significant increase in CD68+ cells which led to the 
hypothesis that selective depletion of phagocytic macrophages activates a 
compensatory expansion and activation of the mononuclear phagocytic system for cell 
clearance of apoptotic cells and debris.   
Apoptotic cell clearance through phagocytosis, also known as efferocytosis, has 
been shown to contribute for tumor growth and modulation of immune responses (Reiter 
et al., 1999b;Michlewska et al., 2009;Gregory and Pound, 2011a).  For example, 
macrophage efferocytosis of apoptotic tumor cells mediated through milk fat globule 
EGF-8 (MFG-E8), a protein that facilitates this process, modulates macrophage 
polarization into M2 tumor associated macrophages (Soki et al., 2014a).  This may be a 
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potential mechanism by which macrophages may play a role not only in tumor growth 
and polarization, but also in bone responses.  How phagocytic macrophages and the 
mechanisms utilized for cell clearance may influence in tumor growth is an intriguing 
avenue of future investigation.    
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CONCLUSIONS 
 
In summary, this study shows strong evidence that resident macrophages 
contribute to prostate cancer growth in bone.  The presence of tumors was sufficient for 
the increase in tumor associated macrophages in bone marrow. Moreover, targeting 
earlier progenitor cells or mature phagocytic macrophages hinders tumor growth in 
bone with a differential effect in bone area.  The MAFIA mouse model that targets 
immature macrophage progenitors displayed reduced bone.  On the other hand, 
clodronate liposome treatment that targets mature phagocytic macrophages resulted in 
increased bone volume.  In conclusion, these data support that macrophages have 
important roles in tumor growth in bone.  Moreover, macrophage depletion hindered 
tumor growth independently of the paradoxical effect on bone content suggesting 
macrophages in bone may be more important to tumor growth than the bone itself.   
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CHAPTER 5 
 
POLARIZATION OF PROSTATE CANCER ASSOCIATED MACROPHAGES IS 
INDUCED BY MILK-FAT GLOBULE-EGF FACTOR 8 (MFG-E8) MEDIATED 
EFFEROCYTOSIS 
 
 
ABSTRACT 
 
Tumor cells secrete factors that modulate macrophage activation and 
polarization into M2 type tumor associated macrophages (TAMs), which promote tumor 
growth, progression and metastasis.  The mechanisms that mediate this polarization are 
not clear.  Macrophages are phagocytic cells that participate in the clearance of 
apoptotic cells, a process known as efferocytosis.  Milk fat globule - EGF factor 8 (MFG-
E8) is a bridge protein that facilitates efferocytosis and is associated with suppression of 
pro-inflammatory responses.  The current study investigated the hypothesis that MFG-
E8 mediated efferocytosis promotes M2 polarization.  Tissue and serum exosomes from 
prostate cancer patients presented higher levels of MFG-E8 compared to controls, a 
novel finding in human prostate cancer.  Co-culture of macrophages with apoptotic 
cancer cells increased efferocytosis, elevated MFG-E8 protein expression levels, and 
induced macrophage polarization into an alternatively activated M2 phenotype.  
Administration of antibody against MFG-E8 significantly attenuated the increase in M2 
polarization. Inhibition of STAT3 phosphorylation using the inhibitor Stattic, decreased 
efferocytosis and M2 macrophage polarization in vitro, with a correlating increase in 
SOCS3 protein expression.  Moreover, MFG-E8 knockdown tumor cells cultured with 
wild type or MFG-E8 deficient macrophages resulted in increased SOCS3 expression 
with decreased STAT3 activation.  This suggests that SOCS3 and phospho-STAT3 act 
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in an inversely dependent manner when stimulated by MFG-E8 and efferocytosis.  
These results uncover a unique role of efferocytosis via MFG-E8, as a mechanism for 
macrophage polarization into tumor promoting M2 cells. 
 
 
INTRODUCTION 
 
The skeleton is a favored organ for metastasis that results in significant morbidity 
for cancer patients (Bubendorf et al., 2000;Weilbaecher et al., 2011a).  Tumor 
associated macrophages (TAMs) have been investigated in the context of cancer (Li et 
al., 2009;Loberg et al., 2007b) yet their role in bone metastasis remains elusive (Loberg 
et al., 2005;Park et al., 2011b;Li et al., 2009).  Macrophages are activated differentially 
according to the stimuli provided: M1 anti-tumorigenic macrophages are defined as 
classically activated, and M2 pro-tumorigenic macrophages (also known as TAMs) are 
defined as alternatively activated (Pollard, 2009;Siveen and Kuttan, 2009).  TAMs are 
prominently involved with cancer initiation, progression and metastasis, facilitating 
angiogenesis, matrix breakdown, and tumor cell-motility (Pollard, 2004;Colotta et al., 
2009;Murdoch et al., 2008). While the role of TAMs in skeletal metastasis is emerging, 
the mechanisms remain to be defined. 
In addition to their high rate of cell proliferation, tumors have high apoptosis 
rates, an often forgotten but important process in tumor dynamics (Gregory and Pound, 
2011b).  The large number of apoptotic cells is under appreciated due to rapid cell 
clearance performed by macrophages and other phagocytic cells, a process known as 
efferocytosis.  Indeed, not much is known regarding the interactions of apoptotic tumor 
cells with macrophages, and subsequently, how this affects the remaining viable tumor 
cells in skeletal metastasis.  Efferocytosis elicits changes in immune responses and can 
result in immunosuppression of anti-tumor defenses (Reiter et al., 1999a;Savill et al., 
2002a), production of anti-inflammatory mediators including transforming growth factor–
  (TGF-) and interleukin-10 (IL-10), and inhibition of pro-inflammatory tumor necrosis 
factor (TNF) (Savill et al., 2002a;Michlewska et al., 2009).   
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Milk fat globule-EGF factor 8 (MFG-E8) is a protein secreted by numerous cells 
including macrophages and is known as a phagocytosis “eat me” signal (Hanayama et 
al., 2002;Hanayama et al., 2004).  MFG-E8 functions as a tether between macrophage 
and apoptotic cells via a bi-motif function, binding to both phosphatidylserine (PS) 
externalized on apoptotic cells and the v3/v5 integrin expressed on macrophages 
(Hanayama et al., 2002).  MFG-E8 mutant mice are deficient in efferocytosis, resulting 
in increased apoptotic cell accumulation, which was implicated in autoimmunity and 
inflammatory related diseases (Miksa et al., 2008;Asano et al., 2004;Thorp and Tabas, 
2009).   
Interestingly, phagocytes activated by their interaction with apoptotic cells via 
MFG-E8 share similar anti-inflammatory and tumor promoting properties as seen in M2 
TAMs (Lewis and Pollard, 2006;Gregory and Pound, 2011b;Pollard, 2009).  Pre-
treatment of LPS stimulated macrophages with rMFG-E8 results in activation of 
suppressor of cytokine signaling 3 (SOCS3), via the STAT3 pathway (Aziz et al., 
2011b).  SOCS3 proteins are known to inhibit the JAK/STAT signaling pathway, 
creating a negative feedback loop to prevent excessive activation of the pathway 
(Yoshimura et al., 2007).  This modulatory role has also been suggested as a 
mechanism for macrophage polarization. 
Despite these suggestive links, efferocytosis via MFG-E8 and its role in tumor 
efferocytosis and M2 polarization has not been investigated in the context of prostate 
cancer or skeletal metastasis.  
Given that prostate cancer has a high propensity to metastasize to the bone, 
which is rich in macrophages and anti-inflammatory factors that contribute to tumor 
growth, we hypothesized that MFG-E8-mediated efferocytosis modulates the bone 
marrow derived macrophage SOCS3/STAT3 pathway, inducing an M2 switch, and 
promoting tumor growth.  In the current study, the impact of efferocytosis mediated by 
MFG-E8 on macrophage polarization into M2 TAMs was investigated, and the 
underlying mechanisms that could be developed as potential therapeutic targets were 
delineated.  
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MATERIAL AND METHODS 
 
Primary cells and cell lines 
 All animals were maintained in accordance with institutional animal care and use 
guidelines and experimental protocols were approved by the Institutional Animal Care 
and Use Committee of the University of Michigan.  MFG-E8 mutant mice were provided 
by Kamran Atabai from the University of California, San Francisco. Briefly, MFG-E8 
mutant mice have an insertion of the pGT1-pfs gene trap-vector in intron 7 of Mfge8, 
trapping the secretory protein, resulting in fusion protein degradation in the ER (Atabai 
et al., 2005).  
Primary bone marrow cells were collected from male C57BL/6J (Jackson 
Laboratory, Bar Harbor, ME) and MFG-E8 mutant mice at 4-6wks of age for in vitro 
experiments.  Mouse bone marrow macrophages were differentiated in vitro from bone 
marrow cells cultured in -MEM media with 30 ng/ml murine M-CSF (eBioscience) for 6 
days.  At day 7, macrophages or RAW 264.7 cells were plated into 12 well plates.  Cells 
were treated with recombinant murine MFG-E8 (R&D Systems) at indicated 
concentrations.  Anti-MFG-E8 (D161-3, MBL International) and IgG control (DAKO) 
were used at 20g/ml to treat macrophages in vitro as described (Jinushi et al., 2009).   
Three prostate cancer cell lines were used in this study.  Two human bone 
metastatic prostate cancer cell lines: C42B and PC-3, were obtained from the American 
Type Culture Collection (Rockville, MD).  RM-1, a murine cell line was originally 
obtained from Dr.Timothy C.Thompson (Baylor College of Medicine, Houston, TX).  
C42B cells, originally derived from LNCaP tumors maintained in castrated and intact 
athymic male mice, are androgen-independent, metastasize to the bone, and form 
mixed osteoblastic/osteolytic lesions (Lin et al., 2001). PC-3 cells, derived from human 
vertebral prostate cancer metastasis, are androgen-independent, highly metastatic, and 
produce osteolytic lesions.  Human PC-3 cells were stably transfected to express 
dsGREEN immunofluorescence. 
Apoptosis of prostate cancer cells (RM-1, PC-3 and C42B) was induced by 
overnight serum starvation followed by 24 hour treatment with cobalt chloride (RM-1 
150M; PC-3 and C42b 200M) (Sigma-Aldrich). Cells were washed at least 3 times 
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with PBS after apoptosis induction and enumerated.  A 60-70% range of trypan blue 
positive cells was designated high apoptotic (HAP).  UV exposure of tumor cells for 20 
minutes in PBS was also utilized to induce apoptosis avoiding chemical-derived effects.  
Untreated tumor cells contained 5-10% trypan blue positive cells and were designated 
as basal apoptotic cells (BAP).  
 
Stable-shRNA constructs 
Mouse GIPZ lentiviral shRNAmir were transfected into RM-1 prostate cancer 
cells to produce MFG-E8- shRNA stable contructs. Cells were designated as RM-1 
m_08 (clone ID: V2L_277508), RM-1 m_30 (clone ID: V2LMM_39830), RM-1 m_41 
(clone ID: V3LMM_432041), RM-1 m_43 (clone ID: V3LMM_432043) RM-1 m_45 
(clone ID: V3LMM_432045) and RM-1 GIPZ scramble control (Lenti-pGipZ-scramble-
VSVG; University of Michigan Vector Core). 
 
Efferocytosis assay 
RAW 264.7 cells or primary bone marrow macrophages were plated at 50,000 
cells/cm2 and incubated at different time points with low or high apoptotic prostate 
cancer cells (RM-1, PC-3 and C42b) at a 1:3 ratio of macrophage to tumor cells, or 
fluorescent carboxyl beads (Bangs Laboratories, INC) at a 1:2 ratio.  Cells were washed 
with PBS and attached cells were collected for further analyses.  
 
Confocal microscopy 
Bone marrow macrophages, RAW 264.7 cells and prostate cancer cells were 
stained with 0.2l/ml orange or green CellTracker™ or CellTrace™ CFSE (Invitrogen)  
for 20 minutes in serum free medium followed by incubation in complete medium for 60 
minutes.  Macrophages were plated in 1.5mm cover glass chambers for confocal 
microscopy. High apoptotic cancer cells or carboxylated fluorescent beads (Bang’s 
Labs) were added at a 1:1 or 1:2 ratio to the attached macrophages for up to 24 hours 
and fixed with ice cold methanol for 20 minutes. Cells were then washed with PBS and 
covered with Vectashield® mounting medium containing DAPI (Vector Laboratories, 
Inc). Confocal microscopy images were analyzed using the Leica Inverted SP5X 
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Confocal Microscope System with 2-Photon FILM and Leica Software (Leica 
Microsystems Germany). 
 
Flow cytometry 
 Flow cytometry was performed as described (Cho et al., 2013). Briefly, cells 
were collected in FACS buffer (PBS, 2% FBS, 2mM EDTA) and 1 million cells were 
stained for 30 minutes with the following macrophage specific antibodies: F4/80 Alexa 
Fluor 647 (Abcam, CI:A3-1) and CD206 PE (AbD Serotec, MR5D3). Cells were fixed 
and permeabilized with LeucopermTM (AbD Serotec) and incubated with anti-Ym1 rabbit 
antibody (StemCell Technologies, #01404). Cells were then incubated with secondary 
antibody, Alexa Fluor® 700 Goat Anti-Rabbit IgG (Molecular Probes®) 700.  For 
confirmation of apoptosis, prostate cancer cells were stained with the FITC Annexin V 
Apoptosis Detection kit (BD PharmigenTM).  After antibody incubation, cells were 
washed twice with FACS buffer, fixed with 1% formalin and evaluated for FACS 
analyses (BD FACSAria™ III).  
 
Western blot analyses and quantification 
 For protein collection, cells were washed twice with cold PBS and lysed with 
CelLytic™ M (Sigma).  SDS-PAGE was performed in 4-20% gradient Novex Tris-
Glycine gels (Invitrogen) loaded with 50g of protein per well.  After electrophoresis, 
proteins were transferred to membranes (Duralon UV membrane; Stratagene) and 
blocked in 5% milk for 20 minutes.  The membranes were then incubated with the 
primary antibody in 5% milk overnight on a shaker at 4oC. Antibodies against actin 
(C4) 1:50,000 (Santa Cruz Biotechnology, Inc), SOCS3 1:500 dilution (Cell Signaling 
Technology), Phospho-STAT3 (3E2) and STAT3 (124H6) 1:1000 dilution (Cell Signaling 
Technology), and MFG-E8 1:500 (R&D Systems) were used.  After washing, 
membranes were incubated with secondary antibodies, washed and 
chemiluminescence (via SuperSignal West Pico Chemiluminescent Substrate, Thermo 
Scientific) imaged on X-ray film .  Protein quantification was performed using the Scion 
Image software and calculated relative to control protein expression (actin). 
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RNA extraction and quantitative RT-PCR 
RNA isolation was performed as described (Koh et al., 2011) using an RNeasy 
 Reverse Transcription Kit (Applied 
Biosystems).  Quantitative real time-PCR (qPCR) was performed using the ABI PRISM 
7700 using a ready-to-use mix of primers and FAM-labeled probe assay systems 
(Applied Biosystems) for Il10 (Mm00439614_m1),  transforming growth factor beta1 
(Tgf-β1) (Mm03024053_m1) and Ym1 (Chi3l3) (Mm00657889_mH), arginase 1 (Arg1) 
(Mm00475988_m1).  Glyceraldehyde-3-phosphate dehydrogenase (Gapdh, 
Mm99999915_g1) was used as an internal reference and the delta delta CT method 
was used to calculate the data as described (Novince et al., 2012).  
 
Immunohistochemistry 
A prostate cancer tissue microarray (TMA) was obtained through the rapid 
autopsy program at the University of Michigan Prostate Cancer Specialized Program of 
Research Excellence Tissue Core. The Institutional Review Board at the University of 
Michigan approved the use of all tissues.  A total of 30 benign (n=12) and malignant 
(n=18) paraffin embedded tissue specimens were analyzed with a Gleason score of 7-8. 
Areas of malignant and benign prostatic hyperplasia (BPH) were taken from the same 
patients (matched paired tissues).  Immunohistochemical detection of human MFG-E8 
and CD68 (KP1) was carried out in de-paraffinized and rehydrated sections using the 
HRP-AEC Cell & Tissue Staining Kit (R&D Systems) according to the manufacturer's 
protocol.  Tissue was permeabilized with 0.2% Triton-X 100 and incubated overnight at 
4°C with anti-mouse CD68 (1:200) and anti-human MFG-E8 (1:50) (Abcam).  Samples 
were counterstained with hematoxylin and mounted with paramount aqueous mounting 
medium (Dako). Negative controls were used to detect non-specific staining.  MFG-E8 
staining was quantified using NIS Elements Software (Nikon).  Briefly, the region of 
interest (ROI) tool was used to set the target area that was positively stained for MFG-
E8 over the total area (%) of the tissue.  The mean area positive for MFG-E8 was then 
calculated for each tissue within three different areas of tissue.  The proximity of CD68+ 
cells to MFG-E8 expression was determined by analyzing three tissue sections at 100x 
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magnification per specimen per TMA.  Cells overlapping or in close proximity that were 
positive for both CD68 (macrophage) and MFG-E8 expression were quantified using 
Image J software. 
 
Serum exosomes 
 Serum samples were obtained from subjects through a University of Michigan 
Institutional Review Board-approved protocol.  Serum exosome proteins were isolated 
from patients with primary (n=6), metastatic prostate cancer (n=7), or control tumor-free 
(n=3). Human serum was centrifuged at 500g for 10 min, after which the resultant 
supernatant was centrifuged at 20,000g for 20 min. Exosomes were then harvested by 
centrifugation at 100,000g for 70 min (Sorvall S100-AT5 rotor). The exosome pellet was 
resuspended in PBS, filtered through 0.2-μm nylon filters (GE) and collected by 
ultracentrifugation at 100,000g for 70 minutes. Exosomes were lysed with RIPA lysis 
buffer (Millipore, Billerica, MA) containing a complete protease inhibitor tablet (Sigma). 
Lysates were cleared by centrifugation at 14,000g for 20 min. 50g of protein were 
loaded in 4-20% gradient Novex Tris-Glycine gels and western blot analysis was 
performed as described above.  MFG-E8 protein expression was quantified using the 
Scion Image software and calculated relative to control GAPDH. 
 
Mouse inflammation antibody array 
 Bone marrow macrophages were plated into 6 well dishes (3x106 cells/well). 
After 24 hours cells were washed with PBS and 1% FBS -MEM media was added to 
the wells with or without high apoptotic RM-1 cells at a 1:1 ratio.  The supernatant was 
collected after 24 hours and proteins were analyzed using the Mouse Inflammation 
Antibody Array C1 (Cat#AAM-INF-1-8, RayBiotech, Inc) following the manufacturer’s 
instructions.  
 
Statistical Analyses 
 Statistical analysis was performed by unpaired student’s t-test to compare two 
groups with significance of p<0.05. Data are presented as mean ± SEM.   
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RESULTS 
 
MFG-E8 is highly expressed in prostate cancer 
MFG-E8 has been correlated with tumor growth and progression of different 
types of cancers such as melanoma and breast, but its expression in prostate cancer is 
still unclear.  To elucidate the pattern of MFG-E8 in prostate cancer, 
immunohistochemistry was performed on serial sections of prostate cancer patient 
derived tissue microarrays (TMAs), containing a total of 30 benign (n=12) and malignant 
(n=18) tissue specimens combined (Fig. 5.1A and B).  MFG-E8 expression was 
significantly higher in malignant (31.93% ± 1.27) compared to benign (4.89% ± 0.68) 
tissues (Fig. 5.1A).  MFG-E8 appears to be localized on the plasma membrane and the 
cytoplasm; however, invasive specimens revealed intense MFG-E8 at the leading edge 
of tumors and in the apical and basal areas of luminal epithelial cells.  The proximity of 
CD68+ cells to MFG-E8 expression was determined to be two times higher in malignant 
specimens (Fig. 5.1B).  The increased proximity of CD68+ cells in areas of high MFG-
E8 expression indicates a potential interaction between MFG-E8 and macrophages in 
prostate cancer.   
Protein expression levels were investigated in blood exosomes isolated from 
patients with prostate cancer or non-cancer controls (Fig. 5.1C).  Blood was collected 
from patients with localized primary prostate cancer or castrate resistant patients with 
metastases (Vlassov et al., 2012).  Western blot analyses revealed that MFG-E8 levels 
were significantly increased in patients that presented with primary and metastatic 
prostate cancer.  
Taken together, these data suggest MFG-E8 is a potential marker for prostate 
cancer progression. 
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Figure 5.1. MFG-E8 expression is increased in prostate cancer patients. 
A and B, immunohistochemistry was performed on serial sections of prostate cancer TMAs 
containing 30 benign (n = 12) and malignant (n = 18) matched tissue specimens combined. A, 
MFG-E8 expression in benign and malignant prostate cancer TMAs was analyzed by calculation 
of percent positive MFG-E8 expression in the region of interest. Data are mean ± S.E. **, p < 
0.0001. B, proximity of CD68-positive macrophages and MFG-E8 was determined by analyzing 
three tissue sections at ×200 magnification per specimen per TMA. Overlapping or cells in close 
proximity positive for CD68 and MFG-E8 were counted, as indicated by arrowheads. The 
number (#) of CD68+ cells in proximity to MFG-E8 was counted as indicated in the graph. The 
mean of all three images was calculated, and the overall mean was obtained for each tissue 
type. Data are mean ± S.E. *, p < 0.05. C, serum exosome proteins were isolated from patients 
with primary (n = 6) and metastatic (n = 7) prostate cancer (PCa) or control tumor-free 
individuals (n = 3). The first two controls from the top blot were also included in the bottom blot 
for standardization and relative calculation. MFG-E8 protein expression was quantified using 
Scion Image software and calculated relative to control GAPDH. Data are mean ± S.E. *, p < 
0.05. Permission for figure from J Biol Chem (Soki et al., 2014b) 
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MFG-E8 is increased in macrophages during efferocytosis of apoptotic cells  
MFG-E8 is a protein that mediates the interaction of macrophages and apoptotic 
cells, thereby facilitating efferocytosis.  To evaluate efferocytosis of apoptotic tumor 
cells by macrophages, bone marrow macrophages were cultured with tumor cells and 
efferocytosis was investigated.  RM-1 cells stained with Cell Tracker dye (CFSE+ green) 
and treated with CoCl2 to induce apoptosis, were designated as high apoptotic cells 
(HAP) (>60% apoptosis).  Untreated cells (<10% apoptosis) were designated as basal 
apoptotic cells (BAP) and used as controls.  Figure 5.2A shows representative confocal 
microscopic images of macrophages (red) co-incubated with RM-1 cells (CFSE+ green).  
Efferocytosis was quantified relative to the number of nuclei (DAPI) and was 
significantly increased when macrophages were cultured with HAP cells versus control 
BAP tumor cells (Fig. 5.2B).  Confocal microscopic images of bone marrow 
macrophages confirmed efferocytosis as shown in supplemental videos 1 and 2 (Z 
stack videos).  Increased efferocytosis of high apoptotic cells (HAP) compared to control 
(BAP) was also observed by flow cytometry quantification.  F4/80+ bone marrow 
macrophages that engulfed CFSE+ tumor cells were analyzed as shown in Figure 5.2C.   
Efferocytosis was also analyzed in unstained RAW 264.7 (RAW) macrophages 
that were co-cultured with RM-1 HAP or BAP for 5 hours.  Efferocytosis of RM-1 cells by 
macrophages was measured by flow cytometric analysis based on RAW cell engulfment 
of Cell Tracker stained RM-1 cells (Fig. 5.2D).  Efferocytosis was increased when 
macrophages were cultured with RM-1 HAP compared to control BAP tumor cells.   
MFG-E8 functions as a facilitator of efferocytosis, binding to phosphatidyl serine 
(PS) expressed on apoptotic cells and to the v3/v5 integrin expressed on 
macrophages (Hanayama et al., 2002).  To determine whether increased efferocytosis 
would affect MFG-E8 expression in macrophages, RAW cells were cultured with low or 
high apoptotic tumor cells at different time points and MFG-E8 protein expression was 
determined (Fig. 5.2E).  Western Blot analyses showed that MFG-E8 protein expression 
increased over time and was augmented when cells were cultured with HAP tumor 
cells.  Taken together, these data suggest that co-incubation of macrophages with 
apoptotic tumor cells elicits efferocytosis and increased MFG-E8 levels.  
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Figure 5.2. Efferocytosis of apoptotic tumor cells and MFG-E8 expression. 
A, representative confocal images (×63, 1. 4 oil objective) of stained macrophages (Mφ, red) 
cocultured for 5 h with CFSE-stained HAP (>60% apoptosis) and BAP (<10% apoptosis) RM-1 
prostate cancer cells (green) at a 1:1 ratio. DAPI nuclear staining is shown in blue. White 
arrowheads show colocalization suggesting efferocytosis. B, quantification of efferocytosis in 
four fields of confocal microscopic images. Macrophages were cocultured with HAP or BAP RM-
1 cells. Data are mean ± S.E. (n = 4/group). *, p < 0.05. C, flow cytometric analyses of bone 
marrow macrophages cultured with CFSE-stained RM-1 cells with basal or high apoptosis for 5 
h. A representative plot shows cells double-positive for CFSE and the macrophage marker 
F4/80 indicating efferocytosis. The graph shows collective data (mean ± S.E., n = 5/group). *, p 
< 0.05. D, flow cytometric analyses of efferocytosis. Unstained RAW 264.7 cells cocultured for 5 
h with Cell Tracker-stained HAP (>60% apoptosis) and BAP (<10% apoptosis) RM-1 cells. 
Efferocytosis was measured on the basis of unstained macrophages engulfing the RM1 Cell 
Tracker+ cells described as percent total cells ± S.E. (n = 5/group, p < 0.05). FSC, forward 
scatter. E, MFG-E8 is increased in macrophages cultured with high apoptotic RM-1 and PC-3 
cells. Shown is a Western blot analysis for MFG-E8 protein expression when RAW 264.7 cells 
were cultured with BAP or HAP for 1, 5, and 24 h of incubation. Permission for figure from J Biol 
Chem (Soki et al., 2014b) 
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MFG-E8 expression in macrophages and tumor-derived MFG-E8   
Although MFG-E8 is expressed in many tissues and cells, its expression in 
prostate cancer cell lines was unknown (Aziz et al., 2011a).  To determine whether 
MFG-E8 is expressed in prostate cancer cells, protein was collected and analyzed from 
RAW 264.7 (RAW) macrophages and three different prostate cancer cell lines: a 
prostate cancer murine-derived cell line, RM-1, and two bone metastatic human-derived 
cell lines, PC-3 and C42B (Fig. 5.3A).  MFG-E8 expression was increased in HAP 
versus BAP RM-1 cells but did not significantly change for HAP PC-3 and C42b cells 
versus BAP cells. Overall, all cell lines tested highly expressed MFG-E8.  
Since high apoptotic RM-1 cells express high levels of MFG-E8, the contribution 
of macrophage-derived MFG-E8 during efferocytosis was further investigated.  Bone 
marrow macrophages from C57BL/6J wild type (WT) or MFG-E8 mutant mice lacking 
functional secreted MFG-E8 (KO) were expanded and MFG-E8 protein levels were 
confirmed (Fig. 5.3B). To determine whether efferocytosis increased MFG-E8 
expression in macrophages without the interference of tumor derived MFG-E8, stable-
shRNA RM-1 constructs were generated using five different clones and a pGIPZ 
scramble clone as control (RM-1 GIPZ) (Fig.5.3C).  The clones with higher efficiency of 
MFG-E8 knock down, RM-1 m_08 and RM-1 m_30, were selected for further analyses.  
Bone marrow macrophages from wild type (WT) and mutant (KO) mice were co-cultured 
with basal (BAP) or high (HAP) apoptotic cells from shRNA or scramble controls for 5 
hours (Fig. 5.3C).  Interestingly, MFG-E8 protein levels were increased when wild type 
(WT) macrophages were cultured with high apoptotic cells (HAP) from control (GIPZ) 
and shRNA clones m_08 and m_30, but not detected when the KO were cultured with 
high apoptotic cells (Fig. 5.3D and E).  This suggests that even though RM-1 cancer 
cells express MFG-E8, efferocytosis elicits the production of MFG-E8 in macrophages. 
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Figure 5.3. Macrophage-derived MFG-E8 expression is increased during efferocytosis 
regardless of tumor-derived MFG-E8 expression. 
A, MFG-E8 expression in prostate cancer and macrophage cell cultures. Shown is expression of 
MFG-E8 in cells alone. RAW 264.7 macrophages (RAW), RM-1, PC-3, and C42B prostate 
cancer cells express MFG-E8. Prostate cancer cells were treated with CoCl2 for 24 h (>60% 
apoptosis) and designated as HAP. BAP cells were left untreated (<10% apoptosis). Proteins 
were analyzed by Western blotting. Expression is reported relative to corresponding β-actin 
levels. Shown is a representative blot of two independent experiments where values correspond 
to fold change relative to RAW control (for RM1) or to PC-3 (for PC-3 and C42B). Data are 
mean ± S.E. (SEM) (n = 2/group). Rel. exp., relative expression. B, MFG-E8 protein expression 
from bone marrow macrophages collected from C57Bl/6 WT or MFG-E8 KO. C, MFG-E8 stable 
knockdown in cells was generated using five different clones as described under “Experimental 
Procedures.” Protein expression indicated the greatest knockdown for MFG-E8 in clones m_08 
and m_30. D, WT or KO macrophages were cultured with BAP or HAP RM-1 cells containing 
GIPZ (negative control) or clone shRNA (m_08 and m_30) for 5 h at a 1:1 ratio. A 
representative image for Western blot analyses is shown, and MFG-E8 expression was 
determined. Experiments were repeated twice with similar results. E, quantification for MFG-E8 
expression was determined by relative expression of MFG-E8 to the control β-actin. Data are 
mean ± S.E. of two independent experiments and normalized to HAP WT GIPZ control (n = 
2/group). *, p < 0.05. Permission for figure from J Biol Chem (Soki et al., 2014b) 
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Efferocytosis of apoptotic prostate cancer cells induces M2 polarization in 
macrophages  
Since efferocytosis stimulates MFG-E8 in macrophages, and given the role of 
MFG-E8 as a potential immune modulator in macrophages, it was hypothesized that 
MFG-E8 mediated efferocytosis could be a possible mechanism for macrophage 
polarization into M2 type.  To better elucidate whether efferocytosis of tumor cells plays 
a role in M2 polarization, bone marrow macrophages were co-cultured with CFSE 
stained BAP or HAP RM-1 cells.  After 5 hours, flow cytometric analyses were 
performed to determine total efferocytosis, the population of F4/80+ macrophages that 
engulfed CFSE stained RM-1 cells (CFSE+F4/80+), and M2 polarization 
(F4/80+CD206+) (Fig. 5.4A).  Efferocytosis was significantly greater for HAP cells and 
occurred in conjunction with an increase in M2 macrophages.  Similar results were also 
observed when bone marrow macrophages were co-cultured with PC-3 cells (Fig. 
5.4B).  Although addition of rmMFG-E8 did not affect efferocytosis of tumor cells (data 
not shown), neutralizing antibody against MFG-E8 significantly inhibited efferocytosis of 
HAP cells and decreased M2 polarization of macrophages when compared to IgG 
controls (Fig. 5.4C).  In summary, flow cytometric analyses suggested that increased 
efferocytosis contributes to M2 polarization via MFG-E8.  Moreover, neutralizing MFG-
E8 antibody treatment significantly inhibited efferocytosis of HAP cells and reduced the 
HAP induced M2 polarization, suggesting a unique role for MFG-E8. 
To better determine the effect of cancer-efferocytosis in macrophage activation 
and its participation in cancer inflammation, inflammatory protein array analyses were 
performed. Bone marrow macrophages were cultured in the presence or absence of 
HAP RM-1 for 24 hours and the supernatant proteins were analyzed (Fig. 5.4D). 
Interestingly, M2 related proteins (Mantovani et al., 2004;Locati et al., 2013) such as 
interleukin-6 (IL-6), chemokine (C-C motif) ligand 2 (CCL2, also known as MCP-1), and 
chemokine (C-C motif) ligand 1 (CCL1, also known as TCA-3) were significantly 
augmented with efferocytosis.  The production of CXC-chemokine family members such 
as KC, Lix and XCL-1, as well as interleukin-13 (IL-13) and interleukin-17 (IL-17) were 
also significantly higher when macrophages were cultured with HAP RM-1 cells (data 
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not shown). However, M1 related proteins such as GM-CSF, INF-, IL-1 and , TNF-, 
and IL-12 p40/70 and IL-12P70 were not significantly changed (data not shown). 
To further validate the M2 polarization, M2 macrophage associated genes were 
investigated when macrophages were cultured with HAP RM-1 tumor cells, and at 4oC 
to block efferocytosis (Fig. 5.4E).  Expression of M2 macrophage associated genes 
such as interleukin 10 (Il10), transforming growth factor-beta 1 (Tgfb1), Ym-1 (Chi3l3) 
and arginase 1 (Arg1) were significantly decreased when efferocytosis was blocked at 
4oC. Incubation at 4oC did not alter gene expression, except arginase which was 
significantly increased (Fig. 5.4F). Collectively, these data suggest that macrophage 
alternative activation into an M2 phenotype is facilitated by efferocytosis 
 
 
Figure 5.4. Efferocytosis via MFG-E8 induces M2 polarization. 
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A and B, FACS analyses of efferocytosis in bone marrow macrophages (Mφ) cultured with BAP 
or HAP RM-1 (A) or PC-3 (B) cells. Efferocytosis was demonstrated as double-positive cells 
(CFSE+F4/80+) indicating macrophages (F4/80+) that engulfed tumor cells (CFSE+). 
Representative FACS and M2 polarization is shown as F4/80+CD206+ cells. Data are mean ± 
S.E. (n = 4/group from three independent experiments). *, p < 0.05. C, macrophages were 
treated with IgG or anti-MFG-E8 (20 μg/ml) and then cocultured with HAP RM-1 cells. FACS 
analyses of efferocytosis, reported as double-positive cells (CFSE+F4/80+) and M2 polarization 
(F4/80+CD206+) and representative FACS are shown. Data are mean ± S.E. (n = 4/group). *, p 
< 0.05 from three independent experiments. D, bone marrow macrophages were cultured for 24 
h with HAP RM-1 cells or not cultured. The supernatant was collected, and proteins were 
analyzed using a mouse inflammation antibody array. The fold increase in densitometry was 
calculated relative to the positive controls (yellow) and according to the protocol of the 
manufacturer. Shown are IL-6 (red), chemokine (C-C motif) ligand 2 (CCL2 or MCP-1, blue), 
and chemokine (C-C motif) ligand 1 (CCL1 or TCA-3, green). Data are mean ± S.E. (n = 
3/group). *, p < 0.05 from three independent experiments. E, bone marrow macrophages were 
cultured for 5 h with HAP RM-1 cells at 37 °C or at 4 °C to block efferocytosis. Gene expression 
levels were analyzed by quantitative PCR relative to Gapdh, and fold change was calculated. 
Shown are interleukin 10 (Il10), transforming growth factor β 1 (Tgfb1), Ym-1 (also known as 
chitinase 3-like protein 3, Chi3l3), and arginase1 (Arg1). Data are mean ± S.E. (n = 6/group 
from two independent experiments). *, p < 0.05; **, p < 0.001. F, bone marrow macrophages 
incubated at 4 °C did not alter gene expression. Gene expression relative to Gapdh and fold 
change was calculated for interleukin 10 (Il10), transforming growth factor β 1 (Tgfb1), Ym-
1(Chi3l3), and arginase1 (Arg1). Data are mean ± S.E. (n = 3/group). *, p < 0.05. Permission for 
figure from J Biol Chem (Soki et al., 2014b) 
 
MFG-E8 direct role in M2 macrophage polarization  
Since rmMFG-E8 is also known to modulate macrophage responses (Aziz et al., 
2011b), its direct role in macrophage polarization was investigated (Fig. 5.5).  Bone 
marrow macrophages expanded for 3 days with M-CSF were treated with different 
concentrations of rmMFG-E8 protein for 50 hours and analyzed by flow cytometry for 
the M2 markers, mannose receptor CD206 and intracellular Ym-1 (Fig. 5.5A).  
Interestingly, bone marrow macrophages showed a dose dependent increase in M2 
polarization, reaching the peak at 0.5g/ml and decreasing at 2g/ml, an MFG-E8 
concentration which has been reported to inhibit efferocytosis (Hanayama et al., 2002).  
To better clarify the direct role of MFG-E8, macrophages were treated with interleukin 4 
(IL-4) to induce M2 polarization, in the presence of anti-MFG-E8 antibody or IgG control 
(Fig. 5.5B).  M2 polarization was significantly reduced with MFG-E8 neutralization.  
These data suggest that MFG-E8 may directly activate and modulate macrophage 
polarization into an M2 type. 
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Figure 5.5. MFG-E8 has a direct role in M2 macrophage polarization. 
A, rmMFG-E8 treatment increased the M2 population in bone marrow macrophages. Bone 
marrow cells were expanded for three days with M-CSF and treated with rmMFG-E8 for 50 h at 
different concentrations (0–2 μg/ml). Shown are FACS analyses of M2 cells double-positive for 
CD206 and intracellular Ym-1. A representative FACS analysis is shown. Data are mean ± S.E. 
(n = 4/group). Two independent experiments were performed with similar results. *, p < 0.05. 
NS, not significant; Mφ, bone marrow macrophages. B, IL-4-induced bone marrow macrophage 
M2 polarization (Ym-1+ CD206+) was reduced when cells were treated with anti-MFG-E8 
antibody. Bone marrow macrophages were treated with 10 units/ml of IL-4 for 24 h in the 
presence of anti-MFG-E8 antibody (20 μg/ml) or IgG control. Data are mean ± S.E. (n = 
4/group). *, p < 0.05. Permission for figure from J Biol Chem (Soki et al., 2014b) 
 
STAT3 pathway in MFG-E8 mediated efferocytosis and M2 polarization  
MFG-E8 activates the JAK/STAT3 pathway in macrophages (Aziz et al., 2011b).  
Therefore, to determine whether the STAT3 pathway is important for MFG-E8 mediated 
efferocytosis, macrophages were treated two hours with the STAT3 inhibitor Stattic prior 
to co-culture with tumor cells (Fig. 5.6A and B).  Stattic targets the STAT3-SH2 domain 
and prevents its association with upstream kinases, inhibiting cellular phosphorylation of 
STAT3 at Tyr705 (Schust et al., 2006).  Flow cytometric analyses revealed that 
phospho-STAT3 (P-STAT3) inhibition with Stattic pre-treatment, not only inhibited 
efferocytosis of RM-1 (Fig. 5.6A) and PC-3 (Fig. 5.6B), but also decreased M2 
F4/80+CD206+ cells.  To better delineate the role of MFG-E8 in efferocytosis and 
STAT3, macrophages from mutant MFG-E8 (KO) and control (WT) were given apoptotic 
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mimicking PS-coated carboxylated beads and the STAT3 pathway was investigated 
(Fig. 5.6C-E).  Phagocytosis of PS-coated beads was significantly reduced in MFG-E8 
mutant (KO) mice as expected (Fig. 5.6C and D).  The STAT3 pathway was further 
investigated in macrophages challenged with STAT3 inhibition or vehicle, prior to 
phagocytosis with PS-coated carboxylated beads (Fig. 5.6E). Interestingly, macrophage 
phagocytosis stimulated phosphorylation of STAT3 and suppressor of cytokine 
signaling-3 (SOCS3) activation in WT compared to control non-stimulated 
macrophages.  Inhibition of STAT3 phosphorylation by pre-treatment with Stattic 
resulted in decreased STAT3 phosphorylation and further increase in SOCS3 
expression.  MFG-E8 KO macrophage P-STAT3 levels were not changed after 
phagocytosis of PS-coated beads, and even though inhibition of STAT3 was significant, 
no effect was observed in SOCS3 activation, suggesting that decreased phagocytosis in 
MFG-E8 KO blunted P-STAT3 activation and the SOCS3 response. 
Collectively, Figure 5.6 suggests that the STAT3 pathway is important for 
macrophage efferocytosis and M2 polarization.  Furthermore, efferocytosis elicits 
phosphorylation of STAT3. 
  
121 
 
 
 
 
 
Figure 5.6. Macrophage efferocytosis and activation of phospho-STAT3 signaling. 
A and B, flow cytometric analyses for efferocytosis (dual CFSE+F4/80+) and M2 polarization 
(F4/80+CD206+). Macrophages (Mφ) were pretreated with the phospho-STAT3 inhibitor Stattic 
2 h prior to culture with RM-1 (A) and PC-3 (B) HAP tumor cells at a 1:3 ratio (Mφ:HAP). Data 
are mean ± S.E. (n = 4/group). *, p < 0.05. Experiments were performed three times with similar 
results. DMSO, dimethyl sulfoxide. C, macrophages were cocultured with PS-coated 
carboxylated beads (1:2 ratio) for 1 h. Shown are representative confocal images of bone 
marrow macrophages (red) from WT or MFG-E8 mutant mice (KO) engulfing fluorescent 
carboxylated beads. DAPI (blue) was the nuclear stain. D, quantification of phagocytic index 
was calculated using the following formula: (number of engulfed beads / number of total Mφ) × 
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(Mφ that engulfed beads/number of total Mφ) × 100. Data are mean ± S.E. from two 
independent experiments, a total of n = 7/group. *, p < 0.05. E, representative Western blot 
showing two independent samples per group and the density quantification. Phospho-STAT3 
expression levels were normalized to total STAT3 (p-STAT3/STAT3, n = 4/group), and SOCS3 
(n = 2) expression levels were normalized relative to β-actin levels. Fold change was calculated 
for WT or MFG-E8 mutant mice (KO) dimethyl sulfoxide controls. Experiments were repeated 
twice, and data are mean ± S.E. *, p < 0.05. Permission for figure from J Biol Chem (Soki et al., 
2014b) 
 
MFG-E8 and efferocytosis in STAT3/SOCS3 pathway  
The STAT3/SOCS3 pathway is important for cytokine expression in 
macrophages, playing essential roles in tumorigenesis and inflammation (Hiwatashi et 
al., 2011).  SOCS3 is a negative regulator of STAT3 (Dimitriou et al., 2008).  
Interestingly, Figure 5.6E shows that STAT3 inhibition resulted in increased SOCS3 
expression.  Therefore, the relationship between P-STAT3 and SOCS3 was further 
investigated in the context of efferoctyosis of tumor cells (Fig. 5.7).  Macrophages were 
pre-treated with Cytochalasin D, a potent inhibitor of actin polymerization and 
phagocytosis, or with DMSO as a control for 2 hours prior to incubation with high 
apoptotic (HAP) PC-3 cells.  Efferocytosis inhibition with Cytochalasin D, significantly 
suppressed P-STAT3 activation in macrophages stimulated with PC-3 HAP cells (Fig. 
5.7A).  SOCS3 demonstrated an opposite response to Cytochalasin D inhibition, with 
significantly increased SOCS3 expression in both WT and KO macrophages. 
To further clarify the STAT3/SOCS3 pathway and the role of MFG-E8 in this 
process, WT and KO bone marrow macrophages were cultured with HAP RM-1 tumor 
cells expressing reduced MFG-E8 levels (GIPZ-control, versus knockdown shRNA 
m_08 or m_30 clones) (Fig. 5.7B).  The purpose of modulating tumor-derived MFG-E8 
was to determine whether paracrine MFG-E8 also played a role in the activation of 
macrophages and in the STAT3/SOCS3 pathway.  Strikingly, macrophages cultured 
with shRNA knockdown clones presented significantly reduced P-STAT3 activation and 
exacerbated SOCS3 activation, compared to cells cultured with control GIPZ RM-1 
cells, which had an opposite response.  These data suggest that tumor derived MFG-E8 
is important for macrophage activation of the STAT3 pathway and that the SOCS3 
pathway negatively regulates STAT3 activation indicating  that tumor cell efferocytosis 
impacts the STAT3/SOCS3 pathway in macrophages. 
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Collectively, the important roles of tumor cell efferocytosis in STAT3 activation 
suggest SOCS3 as a negative regulator of this pathway.  Moreover, tumor derived 
MFG-E8 may play important roles not only in efferocytosis, but may also have a 
significant paracrine effect in the regulation of the STAT3/SOCS3 pathway.   
 
 
 
 
Figure 5.7. MFG-E8 and efferocytosis in the STAT3/SOCS3 signaling pathway. 
A, WT or MFG-E8 mutant (KO) macrophages were pretreated 2 h with the efferocytosis inhibitor 
Cytochalasin D (2 μm) or control dimethyl sulfoxide. Cells were then incubated with HAP PC-3 
cells at a 1:3 ratio for 6 h. Western blot analysis was performed in two independent samples per 
group, and the relative expression to β-actin control was quantified. Phospho-STAT3 expression 
levels were normalized to total STAT3 (p-STAT3/STAT3). Data are mean ± S.E. (n = 2/group). 
*, p < 0.05. B, high apoptotic GIPZ (negative control) or MFG-E8 knockdown shRNA (m_08 and 
m_30) RM-1 cells were incubated for 5 h at a 1:1 ratio. A representative image for Western blot 
analyses is shown, and p-STAT3 and SOCS3 expression was determined. Data are mean ± 
S.E. of two independent samples per group repeated twice (total n = 4/group). *, p < 0.05. 
Permission for figure from J Biol Chem (Soki et al., 2014b) 
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DISCUSSION 
 
Efferocytosis is an important process for maintaining homeostasis, but may also 
have deleterious effects.  Its role in the context of cancer and specifically skeletal 
metastases is intriguing yet unexplored.  In normal bone, macrophages, known as 
‘osteomacs’, constitute one sixth of the total cells and express specific markers: F4/80 
and CD68 (Austyn and Gordon, 1981;Pettit et al., 2008).  Interestingly, depletion of 
macrophages influences osteoblastic bone formation, bone healing, and hematopoietic 
niche maintenance (Pettit et al., 2008;Chang et al., 2008;Winkler et al., 
2010a;Alexander et al., 2011a;Cho et al., 2014).  While there is a growing body of 
literature on tumor associated macrophages (TAMs), little attention has been given to 
the phagocytic function of TAMs in the tumor environment and the mechanisms that 
control this process.  In this study, the interactions of macrophages and tumor cells 
were investigated, with focus on efferocytosis and its effects on macrophage 
polarization via MFG-E8. 
Clearance of apoptotic cells is essential to preserve tissue integrity and prevent 
the accumulation of harmful products released from dying cells.  Deficient efferocytosis 
is associated with autoimmune diseases due to exacerbated and abnormal 
inflammatory responses (Hanayama et al., 2004;Hanayama et al., 2002). Efferocytosis 
via MFG-E8 influences phagocytic cells such as macrophages and dendritic cells to 
down regulate pro-inflammatory responses (Aziz et al., 2011b;Aziz et al., 2009). 
Furthermore, MFG-E8 has anti-inflammatory roles in homeostasis, evidenced by its 
modulation of pro-inflammatory signaling during efferocytosis, through activation of the 
v3/v5 integrin receptors expressed by macrophages (Brissette et al., 2012;Miksa 
et al., 2008;Aziz et al., 2009).  Pre-treatment of macrophages with the MFG-E8 
recombinant protein resulted in reduced pro-inflammatory responses induced by LPS 
stimulation (Aziz et al., 2011b).  Interestingly, in cancer, the pro-tumorigenic 
macrophage also known as M2 alternatively activated (or TAMs), share many 
similarities with the phagocytic macrophage.  TAMs have an anti-inflammatory role in 
the tumor microenvironment, expressing phagocytic markers such as mannose 
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receptors (CD206), and anti-inflammatory cytokines and factors, which not only 
participate in immunosuppression but also promote tumor growth (Park et al., 2011b) . 
In the present study, MFG-E8 was expressed in three different prostate cancer 
cell lines and co-culture of macrophages with cells undergoing apoptosis increased 
efferocytosis as well as MFG-E8 production.  
MFG-E8 levels were found to have a direct effect on macrophage polarization.  A 
key question in the activation of M2 TAMs is:  Which signals drive pro-tumorigenic 
polarization?  MFG-E8 also has anti-inflammatory roles, capable of modulating 
inflammatory signaling during efferocytosis (Miksa et al., 2008).  Interestingly, 
phagocytes activated by the interaction with apoptotic cells via MFG-E8 share similar 
anti-inflammatory and tumor promoting properties as seen in M2 TAMs (Gregory and 
Pound, 2011b).  Co-culture of macrophages with apoptotic cells induced macrophage 
polarization as demonstrated by both flow cytometric analyses and qPCR quantification 
of M2 related genes.  Interestingly, when efferocytosis was decreased via incubation at 
4oC, or neutralizing MFG-E8 antibody treatment, M2 polarization was also reduced, 
suggesting that efferocytosis is important for macrophage polarization into tumor 
promoting M2 cells.  When macrophages were challenged with efferocytosis, increased 
secretion of M2 related cytokines such as IL-6 and CCL-2 (MCP-1) was observed (Roca 
et al., 2009;Fernando et al., 2014;Li et al., 2009;Roca et al., 2009;Zhang et al., 2010).  
Indeed, the observation that IL-6 is dramatically increased (> 20 fold) with efferocytosis 
further supports and explains our findings of STAT3 activation in this pathway.  M1 
related proteins were not significantly changed with efferocytosis.  Furthermore, MFG-
E8 may also directly mediate macrophage responses.  Addition of rmMFG-E8 protein 
augmented macrophage polarization into an M2 macrophage and this polarization was 
significantly decreased in the presence of the neutralizing antibody against MFG-E8.  
The involvement of the STAT3/SOCS3 activation pathway in macrophage 
polarization was also investigated. The increase in MFG-E8 levels when bone marrow 
macrophages were co-cultured with apoptotic cells was accompanied by SOCS3 
downregulation.  SOCS3 deficiency in myeloid lineage cells has been shown to prolong 
activation of the JAK/STAT pathway and M1 polarization, suggesting that SOCS3 is 
required for M1 activation (Aziz et al., 2011b;Dimitriou et al., 2008;Qin et al., 2012).  
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SOCS3 downregulation in macrophages by siRNA induced M2 polarization and 
activation of STAT3 (Liu et al., 2008). In addition, myeloid cell-specific SOCS3 
conditional knockout mice (cKO) had fewer liver and lung metastatic nodules than wild 
type in a mouse melanoma metastatic model (Hiwatashi et al., 2011).  SOCS3 cKO 
myeloid cells stimulated with tumor lysates exhibited prolonged STAT3 phosphorylation 
with increased CCL8 (MCP2) production associated with the anti-tumor metastatic 
effect.   
 
Figure 5.8. Proposed model of MFG-E8-mediated efferocytosis of tumor cells and 
macrophage polarization.  
MFG-E8 is a protein that functions as a bridge binding to the αvβ3/αvβ5 integrin expressed by 
macrophages and to PS externalized on apoptotic cells. Macrophages (Mφ) interact with 
apoptotic cells, resulting in increased MFG-E8 expression, therefore mediating the efferocytosis 
of apoptotic tumor cells. This interaction activates the phosphorylation of STAT3, leading to a 
polarization of macrophages into M2 tumor-promoting macrophages with increased expression 
of M2 markers such as CD206 and Ym-1 as well as M2-related genes of cytokines and growth 
factors known to contribute to tumor promotion. Moreover, MFG-E8 and efferocytosis may 
inhibit SOCS3, a negative regulator of STAT3, therefore keeping STAT3 signaling activated and 
promoting M2 polarization. Permission for figure from J Biol Chem (Soki et al., 2014b) 
 
Here, we demonstrated that inhibition of STAT3 signaling resulted in decreased 
efferocytosis and M2 polarization.  In contrast, SOCS3 presented an opposite effect, 
with reduced expression when STAT3 was activated by efferocytosis and increased 
expression with efferocytosis and STAT3 inhibition.  Taken together, we hypothesize 
127 
 
that STAT3 participates in both efferocytosis and M2 polarization and SOCS3 functions 
as a negative regulator of this pathway (Figure 5.8).  
A notable finding in this study was the fact that tumor-derived MFG-E8 may also 
play an important role in macrophages.  The striking result of STAT3 reduction and 
SOCS3 activation in macrophages cultured with MFG-E8 knockdown cells indicates the 
importance of a paracrine effect that MFG-E8 may exert in macrophage activation and 
signaling.  Still, the data suggest that MFG-E8 could be mediating not only efferocytosis 
and cell-cell interactions, but could also be eliciting macrophage responses in an 
autocrine and paracrine manner. 
Finally, MFG-E8 is not only expressed in multiple tissues, but is also highly 
expressed in cancers such as malignant melanoma and has been associated with 
tumor progression and growth (Jinushi et al., 2008;Jinushi et al., 2009).  Jinushi, et. al., 
reported that MFG-E8 signals through Akt and Twist-dependent pathways to promote 
tumor growth and metastasis in malignant melanoma (Jinushi et al., 2008).  They 
proposed MFG-E8 blockage as a potential therapeutic strategy.  MFG-E8 antibody 
administration resulted in improved anti-tumor activities, such as radiation and 
chemotherapies, and elicited immune activation against tumor cells (Jinushi et al., 
2009). Until now, MFG-E8 expression and involvement in prostate cancer had not been 
explored.  In the present study, it was demonstrated that patients with primary and 
metastatic prostate cancer had higher MFG-E8 expression in prostate tissue and blood 
exosomes compared to control patients.  CD68+ macrophages in close proximity to 
MFG-E8 enriched areas of tumors were also augmented in malignant prostate cancer 
tissue.  BPH tissues, which present a high turnover rate of prostate epithelia, are 
associated with increased macrophages and other inflammatory cells (Wang et al., 
2012;Fujii et al., 2013).  Macrophages contribute to the high proliferation rates and 
aggravate the chronic inflammatory state (Josson et al., 2010;De et al., 2011). While 
little is known about the efferocytic macrophages present in the BPH tissue regarding 
cell clearance, it is possible that they could be active players in this process.  
Interestingly, in the present study, MFG-E8 expression was dramatically increased in 
the malignant tissues compared to BPH.  When macrophages were quantified, it was 
clear that malignant tissue presented an increased number of these cells in close 
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proximity to the MFG-E8+ epithelial cells, which suggests potential efferocytic 
interactions compared to what is observed in the BPH.  Therefore, a role for MFG-E8 in 
prostate cancer progression and growth is likely and findings from the present study 
suggest it is a potential candidate for therapeutic targeting. 
In conclusion, we report a novel mechanism by which MFG-E8, by mediating 
efferocytosis of prostate cancer cells, can support tumor growth through facilitation of 
M2 macrophage polarization and regulation of SOCS3/STAT3 activation. 
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CHAPTER 6 
 
CONCLUSIONS 
The skeleton is a favored organ for prostate cancer metastasis and one that 
results in significant morbidity for cancer patients.  The bone microenvironment provides 
a rich soil comprised of bone cells and a diverse population of cells in the bone marrow 
that interact with metastatic tumor cells.  This interaction results in the disruption of a 
tightly regulated environment, generating a conducive environment for tumors to thrive. 
Many tumor derived factors influence these events. For example, tumors secrete PTHrP 
that activates osteoblasts to secrete osteoclastogenic factors, such as RANKL, driving 
osteoclast bone resorption.  As a result, many growth factors and cytokines are then 
released to the environment, feeding the tumor cells and completing the “vicious cycle” 
present in skeletal metastasis.   
The role of PTHrP in skeletal metastasis was reviewed and extensively 
discussed in Chapter 2. Briefly, PTHrP was first identified as an etiological factor of 
hypercalcemia, but plays important roles in normal physiology, bone development and 
tumor growth, progression and metastasis. PTHrP can function in different manners: 
with endocrine, paracrine, autocrine and intracrine actions. Therefore, it plays different 
roles in various cellular processes. PTHrP is highly expressed by cancers with high 
bone tropism and associated with skeletal metastasis development and progression.  
The dual function of PTHrP applied in the “seed and soil” hypothesis is demonstrated by 
its actions in the tumor cell autonomous processes (seed) and the modulation of the 
bone microenvironment (soil), contributing for tumor growth, progression and bone 
metastasis.  Its actions in tumor cell autonomous processes include promotion of tumor 
cell proliferation, evasion of apoptosis and anoikis, survival, invasion and migration.  
Furthermore, PTHrP also plays important roles in the metastatic soil microenvironment.  
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Evolving PTHrP participation in the modulation of the bone metastatic environment 
includes regulation of the cellular content and promotion of angiogenesis.  In summary, 
PTHrP has multiple functions that contribute to tumor growth, progression and 
metastases.  Further investigation of the role of PTHrP in the modulation of the bone 
microenvironment is necessary to elucidate the earlier steps in the mechanism and 
progression of skeletal metastasis. 
The high morbidity associated with skeletal metastasis reflects the lack of 
effective anti-metastatic therapies (Rogers and Holen, 2011;Gartrell and Saad, 2014).  
Available therapies to decrease the morbidity associated with the disease are palliative 
and include bisphosphonates, with zoledronic acid being the most potent, and other 
osteoclast-targeting agents (Gartrell and Saad, 2014).  Hematopoietic stem cell niches 
such as the endosteal and vascular sites home and regulate the fate of hematopoietic 
cells for self-renewal.  Interestingly, tumor cells can mimic hematopoietic stem cell 
homing to endosteal niches through chemokine receptors (CXCR4 and CCR7,) and 
their cognate ligands (expressed in metastatic recipient tissues), thus colonizing the 
bone (Muller et al., 2001).  Other hematopoietic homing mechanisms such as 
CXCL12/SDF1 and its receptor CXCR4 and annexin II are the axis that regulates the 
prostate cancer bone tropism and homing to the endosteal niches (Taichman et al., 
2002;Jung et al., 2007;Shiozawa et al., 2008;Sun et al., 2010;Shiozawa et al., 2011).  In 
this way, hematopoietic stem cells compete with the metastatic tumor cells.  Therefore, 
therapies that modulate the bone microenvironment such as zoledronic acid, may affect 
the hematopoietic niches.  The effects of osteoclast inhibition in HSC niche and 
progenitor cell expansion are yet unclear.  Chapter 3 investigated the effects of 
zoledronic acid (ZA), a potent bisphosphonate that inhibits bone resorption, on bone 
marrow cell populations focusing on HSCs, and the endosteal and vascular niches in 
bone.  In this study, mice were treated with ZA, and HSCs in bone were analyzed.  
Increased bone volume and HSCs were both observed with ZA treatment.  Increased 
vessel numbers were observed in 4 week young mice but not in 4 month old adult mice 
suggesting that the ZA induced HSCs expansion was mediated via the osteoblastic 
niche and not the vascular niche.  Moreover, long term self-renewal and osteoblastic 
related gene expression were increased with ZA treatment suggesting a role in the 
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modulation of cell commitment and differentiation.  In summary, chapter 4 shows that 
HSCs expansion mediated by osteoclast inhibition with ZA treatment is independent of 
the vascular niche and its effect is by indirect modulation of the osteoblastic niche.  
Altogether, osteoclast inhibition and changes in the bone microstructure may play a role 
in the increased hematopoietic stem cells in the bone marrow.  Understanding the 
effects of cancer therapies in bone is of extreme relevance for tumor metastasis, since it 
may affect tumor colonization and interaction with the modified microenvironment.  
Studies demonstrated that increased bone remodeling with PTH treatment resulted in 
increased prostate cancer localization in the skeleton (Schneider et al., 2005). A 
significant reduction in prostate cancer skeletal metastasis was observed when 
concurrent administration of ZA and PTH (parathyroid hormone) were administered 
suggesting that active bone turnover offers a congenial microenvironment that facilitates 
metastatic cell colonization in bone.  However, a recent study investigated the effects of 
ZA pre-treatment in vivo in the modification of the bone microenvironment and initiation 
of tumor metastasis of breast cancer (Haider et al., 2014).  They showed that pre-
treatment did not affect overall number of tumor cells homing to bone, even though it 
appeared to induce changes in their preferential localization to osteoblasts rich areas.  
Randomized clinical trials showed that adjuvant ZA did not reduce the incidence  of 
skeletal metastasis (Wirth et al., 2014) even though it proved to be very effective in the 
reduction of skeletal related events such as pain and bone resorption (Gartrell and 
Saad, 2014). 
Macrophages actively participate in wound healing and tissue homeostasis. 
Although their protective functions in immune responses are well explored, only recently 
studies have demonstrated their participation in bone formation and wound healing. 
Moreover, since cancer has been likened to a “wound that never heals” the 
mechanisms by which these “wounds” modulate the immune responses are intriguing 
and as of yet unclear (Dvorak, 1986). Macrophages are modulated according to the 
different stimuli they receive. Exposure to tumor-derived factors polarizes macrophages 
into M2-type cells that promote tumor growth, progression and metastasis. Yet, little is 
known about their role in skeletal metastasis. In chapter 4 we investigated the role of 
macrophages in prostate cancer tumor growth in bone.  We demonstrated utilizing 
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different strategies of macrophage depletion that macrophages play important roles in 
tumor growth in bone.  Both strategies of macrophage depletion in the transgenic 
MAFIA mouse model and clodronate loaded liposome model resulted in smaller 
intratibial tumors compared to vehicle controls.  When subcutaneous tumor growth was 
analyzed in the vossicle model after 2 weeks of inoculation a significant difference in 
tumor size at earlier time points was observed in macrophage depleted mice.  We 
hypothesized that when tumors are growing within the vertebrae body, a significant 
reduction of macrophages have higher impact on the tumor growth, but when tumors 
outgrow the bone area this difference in growth is no longer the driving factor.  This 
suggests that macrophage depletion has a higher impact when the bone marrow 
compartment, rich in myeloid cells, is present, and which is the case in the intratibial 
tumor model.  
The involvement of tumor associated macrophages was also further investigated.  
Macrophage depletion significantly reduced M2 macrophages (F4/80+ CD206+) in 
intratibial tumors.  Moreover, macrophage analyzes comparing tibiae with tumors and 
tumor-free femurs showed that the presence of tumors in tibia significantly increased 
M2 (F4/80+ CD206+) macrophages in bone.  These data not only confirmed the 
macrophage contribution to tumor growth, but also demonstrated that tumor 
development in bone marrow increased M2-like macrophages, which further suggests 
the important role of macrophage polarization in tumor progression.  Because 
macrophages are progenitors for osteoclasts and given the important roles osteoclasts 
play in skeletal metastasis, osteoclast activity and numbers were analyzed.  Even 
though macrophage depletion resulted in decreased TRAP5b levels, osteoclasts were 
still observed in the histological sections, especially in areas where bones were in close 
proximity with tumors as seen in histological sections. Many tumor derived factors that 
are known to promote osteoclastogenesis such as PTHrP and CCL2 (as discussed in 
chapter 2) could act in the environment.  Therefore it is thought that even though 
macrophage depletion may suppress in part osteoclast differentiation/activation, tumors 
may compensate for the suppression, driving the differentiation/activation of the 
remaining macrophage progenitors towards the osteoclast lineage.  Even though 
tumors were consistently smaller in macrophage depleted mice paradoxical results of 
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macrophage depletion on the bone were observed.  The MAFIA mouse model had 
decreased bone volume in the hind limbs of macrophage depleted mice.  In contrast, 
clodronate liposome that targets mature phagocytic macrophages presented increased 
bone volume.  These results suggest that the effect of macrophage depletion in tumor 
growth was independent of its effect in bone responses.  Differences in the stages of 
macrophage depletion may account for the differential response in bone (Cho et al., 
2014).  It is hypothesized that clodronate liposomes selectively deplete mature 
phagocytic macrophages, resulting in a compensatory expansion of CD68+ myeloid 
cells that includes macrophages, dendritic cells and neutrophils.  The compensatory 
expansion and activation of the mononuclear phagocytic system may be a response for 
cell clearance of apoptotic cells and debris.  Apoptotic cell clearance through 
phagocytosis, could be a possible mechanism for the osteogenic response observed in 
clodronate liposome induced macrophage depletion.  In conclusion, Chapter 4 shows 
that macrophages play important roles in prostate cancer tumor growth in bone. 
Macrophage depletion hindered tumor growth independently of the paradoxical effect in 
bone content suggesting macrophages in bone may be more important to tumor growth 
than the bone itself.   
Tumors have a high rate of cells undergoing apoptosis producing a number of 
different chemokines and factors that mediate the recruitment of phagocytic cells to their 
site. In this context, macrophages actively participate as scavengers cells 
phagocytosing the apoptotic cells, an underexplored mechanism also known as 
efferocytosis.  Proteins such as milk fat globule-EGF factor 8 (MFG-E8) that recognize 
and bind to both apoptotic and phagocytic cells, are released by macrophages and 
function as a bridge protein that facilitates efferocytosis (Hanayama et al., 
2004;Hanayama et al., 2002). In addition to its role in apoptotic cell clearance, MFG-E8 
is also known for anti-inflammatory modulation in macrophages, a potential mechanism 
for cell polarization into an M2 tumor promoting macrophages (Aziz et al., 2011b;Aziz et 
al., 2009). Efferocytosis of tumor apoptotic cells and their effect in macrophages have 
not been investigated in the context of prostate cancer skeletal metastasis.  In this 
manner, the tumor is co-opting the host’s immunomodulatory mechanisms to support its 
growth.  Although this concept of co-opting the host operating system has been 
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considered, it has not been considered in the context of the bone marrow 
microenvironment.  The role of macrophages in skeletal metastasis and the 
mechanisms involved focusing on the phagocytic function in efferocytosis mediated by 
MFG-E8, and its effects on immune modulation were investigated and discussed in 
Chapter 5.   
The involvement of MFG-E8 in prostate cancer was demonstrated in tissue and 
blood exosomes of patients with primary, metastatic and BPH controls. Patients with 
primary and metastatic prostate cancer had higher MFG-E8 expression in compared to 
control patients in blood serum samples.  Moreover, MFG-E8 expression was 
dramatically increased in malignant tissues compared to BPH controls.  When CD68+ 
macrophages were quantified, it was clear that malignant tissue presented an increased 
number of these cells in close proximity to the MFG-E8+ epithelial cells, which suggests 
potential efferocytic interactions compared to what is observed in the BPH.  In vitro and 
in vivo studies also demonstrated that MFGE8 had a direct effect on macrophage 
polarization. Efferocytosis of apoptotic tumor cells via MFG-E8 increased expression 
promoted macrophage polarization into M2 phenotype.  Co-culture of macrophages with 
apoptotic cells induced macrophage polarization as demonstrated by both flow 
cytometric analyses and qPCR quantification of M2 related genes.  Efferocytosis 
inhibition with neutralizing MFG-E8 antibody resulted in reduced M2 polarization, 
suggesting that efferocytosis is important for macrophage polarization into tumor 
promoting M2 cells.  Macrophages challenged with efferocytosis had increased 
secretion of M2 related cytokines such as IL-6 and CCL-2 (MCP-1) (Roca et al., 
2009;Fernando et al., 2014;Li et al., 2009;Roca et al., 2009;Zhang et al., 2010).  MFG-
E8 can also directly induce macrophage polarization.  Addition of rmMFG-E8 protein 
augmented macrophage polarization into an M2 macrophage and this polarization was 
significantly decreased in the presence of the neutralizing antibody against MFG-E8. 
The mechanisms for macrophage activation were further delineated and the 
involvement of the STAT3/SOCS3 activation pathway in macrophage polarization was 
observed.  Increased MFG-E8 levels when bone marrow macrophages were co-
cultured with apoptotic cells was accompanied by SOCS3 downregulation. Inhibition of 
STAT3 phosphorylation, using the inhibitor Stattic, resulted in decreased efferocytosis 
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and M2 macrophage polarization with a correlating increase in SOCS3 protein 
expression.  Moreover, MFG-E8 knockdown tumor cells cultured with wild type or MFG-
E8 deficient macrophages resulted in increased SOCS3 expression with decreased 
STAT3 activation.  This suggests that SOCS3 and phospho-STAT3 act in an inversely 
dependent manner when stimulated by MFG-E8 and efferocytosis.  In conclusion, 
chapter 5 reports a novel mechanism by which MFG-E8, by mediating efferocytosis of 
prostate cancer cells, can support tumor growth through facilitation of M2 macrophage 
polarization and regulation of SOCS3/STAT3 activation 
 
 
FUTURE DIRECTIONS 
 
Skeletal metastasis is associated with the high morbidity and mortality of different 
types of cancer and the lack of effective therapies reflects our incomplete understanding 
about the mechanisms tumors utilize to colonize and thrive in the bone 
microenvironment.  The role of bone cells such as osteoblasts and osteoclasts play in 
skeletal metastasis has been extensively explored.  However, when tumors metastasize 
to bones, they encounter a diverse milieu comprised of different cell populations that 
also interacts with tumor cells.  Emerging data support the involvement of macrophages 
in tumor growth, progression and metastasis.  Interestingly most of the studies focus on 
the indirect role macrophages plays, mediated by cytokines and growth factors 
secretion that support macrophage’s contributions in tumorigenesis.  Macrophages are 
important phagocytic cells, an often underappreciated function, especially when 
studying their role in the context of tumors.  Here we demonstrated that macrophages 
play important roles in prostate cancer skeletal growth, and that the interaction of 
macrophages with tumor cells during efferocytosis mediates macrophage polarization 
into tumor promoting cells.  Identifying the mechanisms that tumors use to evade the 
immune responses are critical and relevant to the advancement of understanding 
immune cell interactions with metastatic cells and hence development of improved 
therapeutic strategies.   
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Many important questions still remain in cancer metastasis studies.  To better 
understand the earlier steps of metastasis and how the bone microenvironment 
contributes in this regard is a relevant question to be addressed.  For example, if a pre-
metastatic niche is formed before the arrival of the disseminated tumor cell to the bone.  
Which cells could be providing this conducive microenvironment for tumors to evade the 
immune surveillance and thrive?  Improved animal models and specific molecular 
markers are needed to investigate these novel theories and concepts.  Understanding 
the earlier steps of tumor progression and metastasis is necessary for the development 
of new therapeutic targets to prevent and overcome cancer.  
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